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CHAPTER I 
 
INTRODUCTION 
 
In 2008, the World Health Organization (WHO) estimated that 1.5 billion adults 
over the age of 20 were overweight (body mass index [BMI] of 25.0 - 29.9 kg/m2), and 
over 500 million men and women were obese (BMI ≥ 30.0 kg/m2). In the U.S. alone, the 
prevalence of obesity exceeds 30% in men and women across most age groups [1]. 
Strikingly, nearly 43 million children under the age of five were classified as overweight, 
as defined by a BMI greater than or equal to the 85th percentile but less than the 95th 
percentile (for children of the same age and sex) [2, 3]. Collectively, overweight and 
obesity are the most prevalent nutritionally-linked problems in the developed world [4]. 
Furthermore, type 2 diabetes is one of the most common health consequences associated 
with overweight and obesity, and is the seventh leading cause of death within the U.S. 
[5]. Current estimates from the Centers for Disease Control and Prevention indicate that 
8.3% of the U.S. population, or 25.8 million individuals, have diabetes [5]; of the 
diagnosed cases, 90% to 95% are type 2 diabetes. In 2010, there were 1.9 million newly 
diagnosed cases of diabetes within the U.S., indicating that the incidence of the disease is 
continuing to rise concomitant with the increasing prevalence of obesity [5].  
Although interaction among environmental exposures and genetic susceptibility 
ultimately determines the phenotypic characteristics of an individual, population gene 
pools shift very slowly over time and thus, are not likely to explain the rapid growth rates 
in obesity and diabetes in recent decades. In contrast, changes in lifestyle characterized 
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by excess energy consumption and decreased energy expenditure (physical activity) 
might be causally linked to the increased prevalence of obesity and type 2 diabetes [4]. 
Thus, scientists have directed substantial effort towards understanding the influence of 
environmental factors, such as the type of diet that one consumes, on the obesity and 
diabetes epidemic. Given that high-fat and high-sugar-containing, energy dense and 
nutrient deficient foods have become increasingly available and preferentially consumed 
in Westernized cultures [6-12], considerable emphasis has been placed on their respective 
contributions to the development of obesity, insulin resistance, and type 2 diabetes. 
Indeed, excessive consumption of dietary fat and fructose has been associated with 
adipose tissue accrual, ectopic lipid deposition, whole-body insulin resistance, and 
perturbations in the regulation of glucose metabolism in laboratory animals and in 
humans. Thus, studies aimed at investigating the link(s) between diet and metabolic 
diseases are warranted.  
Previous studies have indicated that the liver is particularly vulnerable to 
nutritional insults induced by consumption of a high-fat or high-fructose diet [13-23]. In 
fact, several have suggested that hepatic insulin resistance, manifested as a diminished 
ability of insulin to suppress hepatic glucose production (HGP), is the first metabolic 
consequence to emerge upon initiation of high-fat or high-fructose feeding in laboratory 
animals [16-18, 23]. This is problematic because the liver serves as one of the principal 
regulators of whole-body glucose homeostasis, given its dynamic ability to switch from 
glucose production to glucose consumption during a fasting to fed transition. Thus, 
inappropriate suppression of HGP, or inadequate activation of hepatic glucose uptake 
(HGU) in response to a meal may contribute to the development of postprandial 
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hyperglycemia, and increase the load of glucose that must be disposed of by peripheral 
tissues. Specifically, individuals with diabetes display a marked impairment not only in 
the ability of hyperinsulinemia and hyperglycemia to suppress HGP, but also in the 
ability of those postprandial stimuli to activate splanchnic (liver and gut tissues) glucose 
uptake and glycogen synthesis. As a result, diabetic individuals experience frequent bouts 
of postprandial hyperglycemia, one of the sequelae of the disease that contributes to the 
elevation of their hemoglobin A1c and many of the complications associated with 
diabetes [24, 25].  
While the effects of high dietary fat and fructose on HGP have been extensively 
studied, their chronic effects on HGU are poorly understood. This is due to both the 
complexity of its regulatory signals, and because it cannot be measured directly in 
humans or small animals [26]. On the other hand, HGU can be measured directly in the 
dog, given the accessibility of both the hepatic and portal veins. This allows for repeated 
direct measurements of HGU in the course of experimental perturbations. In addition, the 
response to glucose ingestion is very similar in dogs and humans [27]. Thus, the dog 
model is uniquely suited for the investigation of the adverse effects of high dietary fat 
and fructose consumption on HGU and glycogen synthesis in vivo.  
The goal of this dissertation was to elucidate the metabolic and hepatocellular 
consequences associated with chronic consumption of a high-fat and/or high-fructose 
diet, focusing on perturbations in the regulation of HGU and disposition by 
hyperglycemia, hyperinsulinemia, and portal vein glucose delivery – the three primary 
determinants of hepatic glucose uptake in vivo [26]. My hope is that the studies described 
herein expose in part, the metabolic and molecular underpinnings of impaired hepatic 
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glucose flux associated with diet-induced obesity and insulin resistance, thereby shedding 
light on the pathogenesis of type 2 diabetes.   
 
Dietary Fat 
   
Dietary Fat and Obesity in Humans 
As alluded to earlier, many have attributed the global surge in obesity and 
diabetes to a change in dietary consumption patterns favoring energy dense foods that are 
high in fat and sugar. These types of foods have been categorized as typical constituents 
of a Western diet. Thus, a Western dietary pattern is characterized by excess consumption 
of processed and red meat, high-fat dairy products, refined grains, french fries, and high-
sugar and fructose-containing desserts and sweets [28, 29]. Several mechanisms have 
been proposed to explain the link between high dietary fat consumption and adiposity 
accretion. For example, dietary fat imparts flavor and palatability to foods, which might 
lead to a preferential increase in the consumption of high-fat foods by virtue of their 
hedonic effects [30, 31]. In addition, the thermic effect of fat, or the increment in energy 
expended as heat after a meal, is lower than that of carbohydrate and protein, enabling 
more efficient metabolism and storage of fat calories [31, 32]. Another potential 
mechanism that has received considerable attention is the fact that fat is the most energy 
dense of all macronutrients, providing 9 kcal/g (as opposed to 4 kcal/g for protein and 
carbohydrate). Based on the First Law of Thermodynamics and the principles governing 
energy balance, an increase in dietary fat intake in the absence of an offsetting increase in 
energy expenditure should promote body weight gain and an increase in adiposity over 
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time. As such, dietary fat might play an exaggerated role in contributing to the chronic 
positive energy balance required to produce obesity simply because of its caloric density 
[33]. Indeed, an increase in the food energy supply was reported by Swinburn and 
colleagues [34] to be more than sufficient to account for weight gain in the U.S. from 
1971 – 2002. Likewise, energy density was found to be an independent predictor of 
augmented fasting insulin concentrations, obesity, and the metabolic syndrome among 
U.S. adults, suggesting that excess dietary fat consumption might contribute to the 
development of these metabolic abnormalities [35]. There also appears to be something 
unique about the consumption of high-fat and/or high-sugar-containing foods that 
perturbs the normal regulation of energy intake. For example, Bray and colleagues [36] 
analyzed food records from free-living adults over two, 7-day periods and found that the 
number of calories consumed per day was significantly and positively correlated with 
dietary fat consumption. Further clinical evidence supporting the notion that energy dense 
foods promote excess energy intake was provided by the studies of Blundell et al. [37] 
and Green et al. [38] in which subjects were given lunches differing in energy, sucrose, 
and fat content, but only those consuming lunches containing the high-fat, high-sucrose 
and/or energy dense combinations were likely to overeat at their next meal [37, 38]. 
These data are in agreement with other human studies which demonstrated an impaired 
ability to reduce energy intake at subsequent meals to compensate for food eaten earlier 
when the preceding food choices were high in fat or high in fat and sugar [38-42]. 
Altogether, these data suggest that one of the means through which a high-fat diet may 
promote the development of obesity is by perturbing the normal homeostatic mechanisms 
that govern energy intake. In such a case, decreasing one’s consumption of foods that 
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drive energy overconsumption might be an effective approach in preventing or reversing 
obesity.  
Nevertheless, the role of high dietary fat in contributing to the worldwide obesity 
epidemic is a controversial topic [10, 30]. One reason for this is because a reduction in 
the percentage of energy consumed from fat occurred during the 1990s despite explosive 
growth in the incidence of obesity [43-46]. However, it was estimated that the decrease in 
energy consumption from fat was only 3-5%, which would not necessarily be expected to 
result in a coordinate decline in body weight [10, 11]. In addition, it was postulated that 
the absolute amount of dietary fat remained elevated during this time period, whereas the 
percentage of energy intake from fat decreased as a result of an increase in energy intake 
from dietary carbohydrates [47, 48]. Despite the controversy, several epidemiological 
studies have supported the assertion that a positive relationship exists between total 
dietary fat intake and obesity prevalence. One of the most cited epidemiologic reports 
was provided by Bray and Popkin [10, 49], in which they performed a least-squares 
regression analysis to assess the relationship between an increase in the proportion of 
dietary energy intake from fat and the prevalence of overweight among adult participants 
from twenty different countries. A large significant positive association was found 
between the percentage of energy from dietary fat intake and the proportion of 
individuals in the population who were overweight [10, 49]. In addition, by use of time-
trend analysis to examine obese individuals and their preceding diet history, Sonne-Holm 
and Sorensen [50] demonstrated a significant positive association between dietary fat 
consumption and subsequent development of obesity among nearly 400,000 Danish 
military recruits. Furthermore, data acquired from research on the Western-diet 
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influenced nutrition transition in countries such as China, South Africa, and Brazil have 
also demonstrated a positive relationship between increases in dietary fat intake and 
increases in the incidence of obesity [10, 51, 52]. To ascertain whether an increase in 
energy intake from fat as opposed to other non-fat sources (e.g. protein and carbohydrate) 
had an independent effect on adiposity in the China Health and Nutrition Survey [53], 
Popkin and colleagues [54] examined the effect of fat per se after controlling for the 
effects of total energy intake, and changes in energy intake from non-fat sources (e.g. 
protein and carbohydrate). The modified regression analysis displayed an independent 
effect of dietary fat intake on body weight [10, 49, 54]. Collectively, these studies are in 
agreement with the concept that dietary fat per se might play a role in the obesity 
epidemic worldwide.  
Although useful for generating hypotheses, epidemiologic studies are often prone 
to confounding factors and are not indicative of a causal relationship. Thus, many 
randomized controlled dietary trials have been conducted to circumvent some of the 
weaknesses inherent in non-experimental studies, and to clarify the role of total dietary 
fat in obesity. Bray and Popkin [10] conducted a meta-analysis of 28 short-term, 
controlled clinical trials that studied the effects of reductions in dietary fat on weight loss. 
When fitted into a regression model, with the main explanatory variable as the change in 
percentage of energy from fat, their analysis concluded that a 10% reduction in the 
percentage of energy from fat would result in a marginally significant decline in body 
weight of 16 g/d; however, a large degree of heterogeneity existed among the studies [10, 
49].  
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One of the criticisms of short-term dietary trials is that they are not thought to be 
predictive of long-term weight control, given that the weight loss experienced during the 
first 6 to 12 months of intervention is usually regained. Indeed, based on the analysis of 
Bray and Popkin [10], one would expect a body weight reduction of 6 kg over one year if 
a 10% reduction in the percentage of energy from fat was sustained, but that did not 
occur in studies that have lasted for one year or greater [31, 55-60]. In fact, the long-term 
randomized trials of fat reduction showed little if any impact of total dietary fat on body 
weight, given that fat consumption within the range of 18% to 40% of energy had no 
significant effect on body fatness [30, 31]. Thus, considerable controversy continues to 
exist regarding the role of total dietary fat per se in the obesity epidemic.   
 
Dietary Fat, Insulin Resistance, and Type 2 Diabetes in Humans 
In addition to being a major predictor for the progression to type 2 diabetes [61], 
insulin resistance is a common pathogenic link underlying many of the metabolic 
abnormalities clustered under the term, “metabolic syndrome” [62, 63]. Thus, several 
studies have been conducted to investigate the complex relationship between 
overnutrition/obesity and insulin resistance/diabetes. The Insulin Resistance and 
Atherosclerosis Study (IRAS) found a significant inverse association between the 
percentage of energy from total fat and the degree of whole-body insulin sensitivity, as 
measured by the frequently sampled intravenous glucose tolerance test (FSIGTT); 
however, this relationship was partly attributable to the effect of dietary fat on obesity 
[64]. Likewise, Van Dam and colleagues [29] assessed the impact of dietary fat and 
processed meat, typical constituents of a Western diet, on risk of type 2 diabetes in a 
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large prospective, 12-year follow-up of U.S. men in the Health Professionals Follow-up 
Study. Their results indicated that total dietary fat, saturated fat, and frequent 
consumption of processed meats were associated with an increased risk of type 2 
diabetes, albeit not independent of BMI [29].  
On the other hand, several studies have reported a direct relationship between 
total fat intake and risk of type 2 diabetes that is independent of obesity and/or BMI. For 
example, in a large prospective study of U.S. men [28], their habitual dietary 
consumption patterns were divided into two groups: a prudent pattern, characterized by 
increased intakes of fruits, vegetables, fish, poultry, and whole grains, and a Western 
pattern, characterized by processed foods rich in total fat, saturated fat, and sugar, as 
outlined previously under Dietary Fat and Obesity in Humans. Their analysis 
demonstrated a slight reduction in the risk for type 2 diabetes in men that consumed the 
prudent diet, whereas men that consumed the Western pattern diet displayed a 
substantially higher risk for type 2 diabetes [28]. This risk was magnified when the 
Western pattern diet was coupled with low physical activity and/or obesity [28]. 
Furthermore, the association between Western diet consumption and type 2 diabetes risk 
was independent of BMI [28], suggesting that foods consumed as part of a Western diet 
may directly promote the development of insulin resistance and type 2 diabetes, 
regardless of overweight or obesity. This finding is at odds with the author’s previous 
study [29], in which the association between total dietary fat intake and type 2 diabetes 
was not independent of BMI. The disparity in their findings suggests that components of 
a Western diet other than dietary fat may be independently associated with the 
development of type 2 diabetes, such as refined grains and/or high-sugar and fructose-
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containing desserts and sweets. In addition, these data indicate that the association 
between a Western pattern diet and type 2 diabetes is stronger than the association 
between any one dietary factor and type 2 diabetes.  
Data suggestive of a link between high-fat foods and glucose abnormalities was 
provided by Gulliford and colleagues [65], in which they found that use of solid fat for 
cooking, consumption of whole milk, or use of butter and/or margarine spreads was 
associated with higher hemoglobin A1c in healthy adults, even after adjustment for BMI, 
age, waist-hip ratio, and activity. Further epidemiologic evidence supporting the 
relationship between high dietary fat and type 2 diabetes risk independent of obesity was 
provided by the San Luis Valley Diabetes Study [66], in which consumption of a very 
high-fat, low-carbohydrate diet, as assessed by 24-hour diet recalls, was associated with a 
3.4-fold increase in the risk of type 2 diabetes after adjustment for obesity. In addition, 
the percentage of energy consumed from fat was a significant predictor of conversion 
from impaired glucose tolerance to type 2 diabetes, even after adjusting for energy intake, 
obesity, and markers of glucose metabolism [67]. Collectively, these studies and others 
demonstrate that an association exists between total dietary fat intake and risk of type 2 
diabetes, although that relationship is sometimes dependent upon the effects dietary 
changes have on BMI or obesity.   
Several controlled clinical trials have been conducted to assess the impact of 
dietary fat on insulin sensitivity and glucose metabolism. Contrary to the equivocal 
findings regarding low-fat diets and weight loss, data from studies addressing the ability 
of a reduction in dietary fat to modulate insulin sensitivity independent of obesity are 
more conclusive. For example, in studies of healthy individuals, short-term consumption 
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of a low-fat diet, in which 14% to 25% of the energy was derived from fat, resulted in 
significant improvements in insulin sensitivity as measured by the FSIVGTT or 
hyperinsulinemic euglycemic clamp [68-73]. Moreover, the improvements in insulin 
sensitivity were independent of changes in body weight [68-73]. Conversely, short-term 
consumption of a high-fat diet elicits adverse metabolic consequences. In young healthy 
men, 5 days of hypercaloric (50% extra kcal/d) high-fat feeding (60% of kcal from fat) 
resulted in an increase in fasting plasma glucose levels secondary to an elevation in 
hepatic glucose production [74], whereas 11 days of high-fat feeding (83% of kcal from 
fat) attenuated the suppressive action of insulin on endogenous glucose production and 
diminished its stimulatory effects on glucose oxidation [75]. 
Swinburn and colleagues assessed the long-term effects of a reduced-fat ad- 
libitum diet in glucose intolerant individuals [76]. After five years, participants who were 
compliant with low-fat dietary recommendations maintained a significant reduction in 
fasting and 2-hour plasma glucose concentrations despite having the same body weight as 
they had five years prior [76]. Plasma triglyceride concentrations in the low-fat diet group 
were not reported. In support of the effectiveness of dietary interventions in disease 
prevention, data from the multicenter clinical research study entitled, “Diabetes 
Prevention Program (DPP),” demonstrated a 58% reduction in the development of type 2 
diabetes over a 3-year period in overweight individuals with impaired glucose tolerance 
that were assigned to an intensive lifestyle intervention group, which lost a modest 
amount of weight through dietary changes (specifically, a 6% decrease in the percentage 
of energy from fat coupled with a reduction in total energy intake) and increased physical 
activity (150 min of exercise per week) [77]. After an average 10 year follow-up period, 
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study participants that had been enrolled in the intensive lifestyle modification program 
maintained an average 34% reduction in the rate of type 2 diabetes development 
compared to the placebo group, as reported in the Diabetes Prevention Program 
Outcomes Study [78]. The Finnish Diabetes Prevention Study also reported a significant 
reduction in the development of type 2 diabetes in participants that had reduced their total 
dietary fat intake and increased their physical activity levels [79]. However, neither study 
was designed to delineate between the relative contributions of changes in diet, exercise, 
and weight loss to diabetes risk reduction. In addition, neither study classified the quality 
of the carbohydrate consumed by the participants. Altogether, these data suggest that 
changes in the constituents of the diet that one consumes, particularly with regard to 
dietary fat, can have a remarkable impact on glucose metabolism and risk of diabetes.  
 
Dietary Fat Quality and Insulin Sensitivity in Humans 
Some of the discordance in the findings regarding the role of total dietary fat in 
obesity, or the direct effects of dietary fat in the risk for type 2 diabetes might be 
explained by the fact that all dietary fats are not created equal. Thus, assessing the impact 
of total dietary fat in the absence of consideration of the quality (whether saturated, 
monounsaturated, or polyunsaturated) of dietary fat consumed might be misleading. In 
general, most epidemiologic studies have found a positive association between saturated 
fat intake and hyperinsulinemia, glucose intolerance, and type 2 diabetes that is 
independent of body fat [80-85]. In addition, Stein and et al. [86] and Dobbins et al. [87] 
demonstrated that saturated fatty acids have a greater insulinotropic potency than 
unsaturated fatty acids, suggesting that chronic consumption of Western diet rich with 
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saturated fat might contribute to hyperinsulinemia, which in and of itself can impair 
whole-body insulin action and glucose uptake, as demonstrated previously in dogs [88, 
89]. Conversely, diets rich in monounsaturated and polyunsaturated fatty acids have 
generally been shown to exert beneficial effects on insulin sensitivity [80, 90-92]. Vessby 
and colleagues [93] best exemplified this in the KANWU (Kuopio, Aarhus, Naples, 
Wollongong, and Uppsala) study, a large multicenter, controlled intervention trial. 
Healthy participants were randomly assigned to consume isocaloric quantities of either a 
saturated fat diet (17% of energy) or a monounsaturated fat diet (23% of energy), while 
the total amount of fat (37% of energy) and other dietary constituents remained constant. 
After 3 months, subjects that consumed the saturated fat diet displayed a significant 
reduction (10%) in insulin sensitivity as assessed by the FSIVGTT, whereas subjects that 
consumed the monounsaturated diet displayed no change in insulin sensitivity despite 
consuming the same percentage of total energy from fat. The difference between groups 
was most striking in subjects that consumed less than 37% of energy from fat, whereas 
the improvement in insulin sensitivity brought about by the substitution of saturated fat 
with monounsaturated fat was abolished at dietary fat intakes greater than 37% of total 
energy [80, 93]. Collectively, these data provide strong evidence that both fat quality and 
quantity play a role in modulating insulin sensitivity in humans and thus, might be 
causally linked to the diabetes epidemic in association with consumption of a Western 
diet.  
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Dietary Fat, Adiposity, and Insulin Action in Experimental Animal Models 
Given that high-fat-fed laboratory animals are useful models for investigating the 
putative effects of a Western diet in humans, numerous studies have been conducted in 
the rodent and dog in attempts to elucidate the metabolic pathogenesis of obesity and 
insulin resistance induced by a nutritional insult in the form of high dietary fat. It is 
evident from most studies that high-fat feeding impairs insulin action in experimental 
animal models; however, the duration of high-fat feeding required to elicit insulin 
resistance, and the temporal manifestation of insulin resistance in the liver, skeletal 
muscle, brain, and/or adipose tissue are issues that remain incompletely understood. 
Some studies have suggested that the initial defect in insulin action in response to a high-
fat diet occurs in the liver in a relatively short period of time. For example, Kraegen et al. 
[17] performed hyperinsulinemic euglycemic clamp experiments in male Wistar rats that 
were fed isocaloric high-fat (59% of energy from fat) or high-starch (10% of energy from 
fat) diets for three days or three weeks, in order to assess the progressive changes in 
insulin sensitivity following a nutritional challenge. Three days of high-fat feeding was 
sufficient to induce whole-body insulin resistance, as evidenced by a significant decrease 
(46%) in the glucose infusion rate required to maintain euglycemia during the clamp; 
however, this was attributable to a significant decline in the ability of insulin to suppress 
hepatic glucose production, with no difference between groups in insulin-stimulated 
whole-body glucose uptake (Rd). These data were confirmed by additional studies in 
which [3H]-2-deoxyglucose was administered during the clamp, and tissue-specific 
glucose metabolic index (Rg) was measured. Indeed, there was no difference between 
groups in Rg in any of the hindlimb muscles tested after only three days of high-fat 
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feeding. On the other hand, three weeks of high-fat feeding resulted in a further decline in 
hepatic insulin sensitivity and a significant decrease (35%) in insulin-stimulated whole-
body glucose disposal (Rd), indicative of the emergence of impaired insulin-mediated 
muscle glucose uptake. Similar studies conducted by the same group of investigators 
demonstrated that the suppressive effects of a high-fat diet on insulin-mediated peripheral 
glucose uptake after three weeks of feeding occurred predominantly in oxidative skeletal 
muscles [94, 95]. Taken together, these data suggest that hepatic insulin resistance 
develops prior to skeletal muscle insulin resistance in the context of high-fat feeding [17, 
94, 95].  
Although marked impairments in whole-body insulin sensitivity and glucose 
metabolism induced by short-term (three days or three weeks) high-fat feeding occurred 
in the absence of an increase in body weight or energy consumption relative to chow-fed 
control animals, high-fat-fed rats accumulated more white adipose tissue in association 
with a significant reduction in energy expenditure and brown adipose tissue [94, 95]. 
Other studies have also demonstrated that pair feeding of high-fat and low-fat diets to rats 
results in greater adipose tissue accretion in high-fat-fed animals despite similar body 
weights and energy consumption between groups [96, 97]. Thus, as growing rodents are 
fed a high-fat diet, the excess energy is preferentially deposited as fat, whereas feeding of 
a standard rodent chow supports the growth of the rodent by means of increasing lean 
body mass. Thus, the proportion of dietary fat consumed can affect fat deposition, insulin 
action, and whole-body glucose metabolism independent of total energy intake or 
changes in body weight.  
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Samuel et al. [23] also demonstrated liver-specific effects of short-term high-fat 
feeding in male Sprague-Dawley rats, which were fed either a high-fat diet (59% of 
energy from fat) or regular rodent chow (10% of energy from fat) for three days. In 
agreement with the findings of Kraegen and colleagues [17], insulin suppression of 
endogenous glucose production during a hyperinsulinemic-euglycemic clamp was 
significantly reduced in high-fat fed rats compared to chow-fed controls (74% vs. 8% 
suppression, respectively), whereas insulin-stimulated whole-body glucose utilization 
was similar between groups [23]. In addition, three days of high-fat feeding was 
associated with a significant reduction in hepatic glycogen synthase activity and in the 
percentage of glycogen synthesized through the direct pathway [23]. These data are 
indicative of a selective impairment in insulin regulation of hepatic glucose production 
and storage after only three days of high-fat feeding in rodents, and support the concept 
that hepatic insulin resistance precedes skeletal muscle insulin resistance.  
The temporal development of hepatic insulin resistance in relation to the 
pathogenesis of diet-induced obesity and whole-body insulin resistance was investigated 
in a canine model over a 12 week feeding period, in which the animal’s normal daily diet 
was supplemented with 2g/kg of cooked bacon grease [16]. This constituted a total 
increase in dietary fat energy of approximately 8% (from 36% to 44% of total energy 
from fat), and was termed a “moderate-fat diet” [16]. The authors reported that this 
moderate increase in dietary fat did not result in a significant change in total daily energy 
intake [16]. After twelve weeks of moderate-fat feeding, there was a two-fold increase in 
total trunk fat and fasting hyperinsulinemia, despite little change in total body weight. 
Furthermore, moderate-fat feeding was associated with a progressive decline in hepatic 
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insulin sensitivity, as indicated by a deterioration in the ability of insulin to suppress 
hepatic glucose production during a hyperinsulinemic euglycemic clamp after 6 and 12 
weeks of fat feeding [16]. Despite clear evidence of hepatic insulin resistance at week 12, 
rates of insulin-stimulated whole-body glucose uptake were not significantly reduced 
after 6 or 12 weeks of a moderate-fat diet, even after adjustment for elevations in the 
steady-state plasma insulin levels over time [16]. Altogether, these data support the 
notion that hepatic insulin resistance precedes muscle insulin resistance in the context of 
high-fat diet-induced increases in adiposity [16]. 
In contrast, other studies have suggested that peripheral insulin resistance 
precedes hepatic insulin resistance with high-fat diet-induced obesity. For example, 
Rocchini et al [98] observed a significant reduction in insulin-mediated whole body 
glucose uptake at 1 week in dogs placed on a high-fat diet (regular diet supplemented 
with 0.9 kg of cooked beef fat), whereas the ability of insulin to suppress hepatic glucose 
production was retained for the duration of the study (6 weeks). Similarly, Kim et al [99] 
reported a significant decrease in insulin-stimulated whole body glucose uptake, with 
only a tendency towards reduced suppression of hepatic glucose production by insulin in 
dogs fed a hypercaloric, high-fat diet (standard diet supplemented with 6 g/kg of cooked 
bacon grease, corresponding to 54% of total energy from fat) for 6 weeks. The 
impairment in insulin-mediated peripheral glucose uptake was attributed to nocturnal 
elevations in free fatty acid levels in dogs maintained on the high-fat diet [100]. 
Ironically, that study was conducted by the same laboratory which previously reported no 
change in insulin-stimulated peripheral glucose uptake after 6 weeks of moderate-fat 
feeding, whereas the ability of insulin to suppress endogenous glucose production was 
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markedly impaired by this time [16]. The reason for the disparities in their findings is not 
clear. Nevertheless, the literature describing the metabolic consequences of high-fat 
feeding in laboratory animals provides evidence that high dietary fat is associated with 
insulin resistance and aberrant glucose metabolism, depending on the amount and 
duration of high-fat feeding. 
One potential reason for the heterogeneity in the metabolic responses to high-fat 
feeding in animal models is that the composition of dietary fat differs among studies. For 
example, in the studies by Samuel et al. [23], Storlein et al. [94], and Kraegen et al. [17, 
95], the lipid component of the high-fat diet was safflower oil, which consists 
predominantly (over 80%) of polyunsaturated omega-6 fatty acid species in the form of 
linoleic acid. On the other hand, bacon grease was utilized in the studies of Rocchini et 
al. [98] and Kim et al. [16, 100], which consists predominantly of saturated and 
monounsaturated fatty acid species. Indeed, Storlein and colleagues [101] demonstrated 
that the fatty acid composition and the lipid environment in which they are presented in 
high-fat diets is a determinant of insulin sensitivity in rats. However, as demonstrated in 
the KANWU study [93], it is possible that a threshold of total dietary fat consumption 
exists above which differences in the quality of dietary fat might have little impact on the 
metabolic phenotype. Thus, the debate continues regarding the temporal manifestation of 
hepatic vs. peripheral insulin resistance in the pathogenesis of diet-induced obesity and 
whole-body insulin resistance. Part of the goal of Specific Aim I is to shed light on the 
temporal manifestation of glucose intolerance and whole-body insulin resistance in 
response to excess consumption of a diet high in fat and fructose.    
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Dietary Fructose  
 
Dietary Fructose Consumption in the U.S. 
Changes in food technology over the last several decades resulted in a shift in the 
sweetener composition of the food supply from predominantly cane sugar in the form of 
sucrose, to predominantly corn sugar in the form of high-fructose corn syrup [102]. 
Initially, dietary fructose was investigated as a beneficial sweetener for individuals with 
type 2 diabetes given its low glycemic index, a way of classifying carbohydrate-
containing foods based on the incremental area under the curve (AUC) for the glucose 
response they elicit; however, it became evident that chronic consumption of a high-
fructose diet leads to the development of many of the features of the metabolic syndrome 
[12].  
Between 1978 and 2004, there was a 61% increase in the per capita availability of 
high-fructose corn syrup [103]. This was associated with a 32% increase in average 
individual intakes of dietary fructose concomitant with a 41% increase in carbohydrate 
intake and an 18% increase in total energy intake, according to Nationwide Food 
Consumption Survey (1977-1978) and NHANES (1999-2004) data [103]. Much of the 
increase in sugar and carbohydrate intake within this time frame was attributed to a 
marked elevation in the consumption of high-fructose corn syrup-sweetened beverages 
[9, 104-106]. When expressed in a different way, the per capita consumption of high-
fructose corn syrup increased from approximately 0.3 kg/person/year in 1970 to 33 
kg/person/year in 2000 [9, 107]. Given that sucrose (50% glucose/50% fructose) and 
high-fructose corn syrup (either 42% fructose/58% glucose or 55% fructose/45% 
 20 
glucose) have very similar compositions in terms of their molar ratios of glucose and 
fructose, the positive associations between high-fructose corn syrup consumption, 
obesity, and risk of type 2 diabetes is most likely due to the steady overconsumption of 
total sugar, of which fructose is the major contributor. Indeed, consumption of sugar-
sweetened beverages has been associated with the development of insulin resistance 
[108], type 2 diabetes [109, 110], fatty liver [111, 112], and cardiovascular disease [46, 
113], underscoring the clinical significance of a potential link between dietary sugar 
consumption and metabolic disease. 
 
Metabolism of Dietary Fructose 
Fructose is a monosaccharide with a chemical formula identical to that of glucose 
(C6H12O6); however, the presence of a keto group on the second carbon of fructose makes 
it distinct from glucose, which contains an aldehyde group at carbon number one. The 
liver is largely responsible for the metabolism of dietary fructose given that the enzymes 
essential for its catabolism (fructokinase, aldolase B, and triokinase) are highly expressed 
in the liver, and that first pass hepatic extraction of fructose is greater than 50% [114]. 
Loss of fructose into the urine of individuals with an inherited deficiency of fructokinase 
(hereditary fructosuria) lends support to the fact that fructose is poorly metabolized in 
extrahepatic tissues [12]. Shiota et al. [115, 116] demonstrated that net hepatic fructose 
uptake (first pass and recirculated) accounted for ~80% of the fructose delivered into the 
portal vein.  
The hepatic metabolism of fructose is distinct from that of glucose at several 
steps. Although both glucose and fructose enter the hepatocyte through the bidirectional 
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glucose transporter, GLUT2 [117, 118], fructose is rapidly phosphorylated by 
fructokinase, which has a low Km for fructose [119, 120] and a high Vmax  [119, 121]. 
Glucose, on the other hand, is phosphorylated by glucokinase, which has a high Km for 
glucose [122]. The product of the fructokinase reaction, fructose-1-phosphate, is a potent 
stimulator of hepatic glucokinase translocation from the nucleus to the cytosol [123], 
thereby facilitating the uptake and storage of glucose by the liver in an acute setting. The 
six-carbon fructose-1-phosphate metabolite is further catabolized into triose phosphates 
through the enzymatic action of aldolase B and triokinase [124], thereby bypassing one of 
the main rate-determining enzymes of glycolysis, phosphofructokinase-1 (PFK-1) [13]. 
Fructose is also unique in that its metabolism is not regulated by insulin or negative 
feedback (e.g. ATP or citrate), whereas the rate-limiting enzymes involved in the 
catabolism of glucose through the glycolytic pathway (glucokinase, PFK-1, and pyruvate 
kinase) are regulated by the energy status of the cell and by insulin [12]. 
Fructose ultimately has several fates within the liver, including oxidation to CO2, 
or conversion into glucose, glycogen, lactate, or lipid, but their relative contributions to 
fructose disposal differ [124]. For example, gluconeogenically-derived glucose and 
glycogen are the predominant fates of triose phosphates produced from the hepatic 
metabolism of fructose [125, 126]. In addition, catheterization studies performed in 
humans have consistently demonstrated that administration of 13C-labeled fructose results 
in approximately 50% of the fructose load recirculating as 13C-labeled glucose, 
suggesting that glucose synthesis is quantitatively the largest pathway of hepatic fructose 
disposal [127-130]. On the other hand, in vitro studies have suggested that the 
predominant fate of lactate produced by the catabolism of fructose is lipid via de novo 
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lipogenesis [131-133]. Inhibition of pyruvate dehydrogenase kinase and subsequent 
activation of pyruvate dehydrogenase is thought to facilitate de novo lipogenesis in 
response to high-fructose feeding [131-133], resulting in an unregulated supply of carbon 
(via acetyl-CoA and glycerol-3-phosphate) for the synthesis of fatty acids through de 
novo lipogenesis [12, 124]; however, the precise mechanism through which fructose 
decreases PDK activity is not clear. Furthermore, this pathway constitutes only a minor 
portion of fructose disposal [134-136].  
 
Dietary Fructose and Obesity in Humans 
In 2004, Bray and colleagues [9] used age-standardized, nationally representative 
measures of obesity from 1960 to 1999, and data on the availability of high-fructose corn 
syrup collected annually over the same time period, to demonstrate that the rising 
prevalence of obesity was temporally associated with an increase in the consumption of 
high-fructose corn syrup, predominantly in the form of calorically sweetened beverages.  
In support of this hypothesis, Ludwig and colleagues [137] conducted a longitudinal (19 
months) study in adolescents in which they found that each additional serving of sugar-
sweetened beverage consumption was associated with an increase in BMI and in the 
frequency of obesity after adjustment for anthropometric, demographic, dietary, and 
lifestyle variables. Furthermore, baseline consumption of sugar-sweetened drinks was 
independently associated with change in BMI [137], suggesting that high-fructose corn 
syrup might contribute to obesity in adolescents as well. In another study, consumption of 
high-fructose corn syrup-sweetened soda for 3 weeks resulted in significant increases in 
total energy intake and body weight in male and female participants when compared to 
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consumption of an equivalent quantity of artificially-sweetened (aspartame) diet soda 
[138]. Likewise, middle-aged men with type 1 or type 2 diabetes reported an increase in 
body weight upon the addition of 50-60 g fructose/day into their diets for 24 weeks [139]. 
Taken together, these studies raise the possibility that a link exists between high dietary 
fructose consumption and increased body weight.  
On the other hand, a meta-analysis of intervention studies investigating the effects 
of fructose intake (less than 100 g fructose/day) on body weight found no significant 
relationship between the dose of fructose ingested and body weight [140]. In addition, the 
hypothesis proposed by Bray and colleagues [9] has been disputed by others given that a 
rise in other macronutrient intakes also occurred during the same time frame, which 
might have been linked to the increased prevalence of overweight and obesity [141]. 
Furthermore, there has been little evidence from studies conducted in humans 
demonstrating that high-fructose corn syrup acts in an exclusive manner to promote 
obesity [141]. Thus, much like the proposed association between total dietary fat and 
obesity, considerable controversy exists regarding the purported causal relationship 
between dietary fructose and obesity prevalence within the U.S.  
 
Dietary Fructose, Insulin Resistance, and Type 2 Diabetes in Humans 
In contrast to the tenuous link between increased consumption of dietary fructose 
and the obesity epidemic, numerous studies have provided clear evidence that excess 
consumption of dietary fructose is associated with the development of insulin resistance 
and an increased risk for type 2 diabetes. With regard to epidemiologic evidence, Gross et 
al. [105] compared the per capita nutrient consumption in the U.S. between 1909 and 
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1997 with data from the Centers for Disease Control and Prevention regarding the 
prevalence of type 2 diabetes. Their findings indicated that corn syrup (which largely 
consists of fructose) was positively associated with the prevalence of type 2 diabetes, 
even after adjustment for total energy intake in a multivariate nutrient-density model 
[105]. Conversely, fiber intake was negatively associated with the prevalence of type 2 
diabetes, suggesting that changes in the quality and composition of carbohydrate 
consumed during the 20th century paralleled the upward trend in the prevalence of type 2 
diabetes [105]. In addition, analysis of nearly 3000 cases over 20 years of data collection 
from the Health Professionals Follow-Up Study indicated that consumption of sugar-
sweetened beverages was associated with a significant elevation in risk of type 2 
diabetes, whereas a 17% reduction in risk was achieved by replacement of one serving of 
sugar-sweetened beverage with 1 cup of coffee [142]. In a separate study, combined 
intakes of fructose and glucose were associated with a significant increase in risk of type 
2 diabetes during a 12 year follow-up of over 4000 middle-aged men and women that 
were free of diabetes at baseline [109]. Lastly, Malik and colleagues [143] conducted a 
meta-analysis to ascertain whether consumption of sugar-sweetened beverages was 
associated with risk of type 2 diabetes and the metabolic syndrome. Their analysis 
provided abundant evidence to support the contention that the caloric and fructose 
content of sugar-sweetened beverages are associated with obesity and risk of type 2 
diabetes, gout, and heart disease [143].   
 With regard to experimental studies, Hallfrisch et al. [144] demonstrated that 
consumption of a diet containing 15% of energy from fructose for 5 weeks resulted in 
augmented fasting plasma glucose concentrations and exaggerated glycemic and 
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insulinemic responses to a sucrose load in healthy men, suggesting that a moderate 
increase in dietary fructose impairs glucose tolerance and insulin sensitivity. In addition, 
six days of eating a high-fructose diet, in which 25% of total energy was derived from 
fructose, resulted in an increase in fasting plasma glucose and triglyceride levels, and a 
significant impairment in the ability of insulin to suppress adipose tissue lipolysis and 
hepatic glucose production during a hyperinsulinemic euglycemic clamp in normal men 
[145]. Interestingly, supplementation of the high-fructose diet with fish oil normalized 
the perturbations in lipid metabolism, but not insulin sensitivity [145]. These data imply 
that high dietary fructose elicits dyslipidemia and insulin resistance through separate 
mechanisms, and that the deterioration of insulin sensitivity induced by high-fructose 
feeding might not be associated with hypertriglyceridemia or augmented lipolysis in 
normal men.  
 Recently, Stanhope and colleagues [146] conducted a well-controlled intervention 
study in older, overweight or obese subjects in which they compared the effects of 
consuming fructose-sweetened versus glucose-sweetened beverages, providing 25% of 
their energy requirements, for ten weeks. Participants were instructed to ingest the sugar-
sweetened beverages as three servings a day with meals, while continuing to consume 
their ususal diet ad libitum. At the end of the ten week study, both groups had gained 
comparable amounts of body weight (~ 1.4 kg) and body fat (~ 0.8 kg); however, 
participants consuming the fructose-sweetened beverages deposited a significantly 
greater proportion of their fat in visceral adipose tissue depots, whereas subjects 
consuming glucose-sweetened beverages preferentially accrued fat in subcutaneous 
adipose tissue depots [146]. Differential effects in glucose metabolism and insulin 
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sensitivity were also evident following consumption of glucose-sweetened versus 
fructose-sweetened beverages, in which the latter was associated with increased fasting 
glucose and insulin concentrations, impaired glucose tolerance, and decreased whole-
body glucose disposal and insulin sensitivity [146]. Furthermore, consumption of 
fructose-sweetened beverages promoted dyslipidemia in that twenty-four-hour 
postprandial plasma triglyceride levels were significantly increased in association with 
decreased lipoprotein lipase activity and an elevated rate of hepatic de novo lipogenesis 
[146]. Likewise, fasting plasma concentrations of low-density lipoprotein (LDL) 
cholesterol, apolipoprotein B, oxidized LDL, and small-dense LDL, and postprandial 
levels of remnant-like particle-triglyceride and -cholesterol were all significantly 
augmented after ten weeks of increased fructose consumption [146]. Despite similar body 
weight gain, these other changes did not occur in subjects consuming the glucose-
sweetened beverages for ten weeks, demonstrating that the adverse effects of excess 
dietary fructose were not solely attributable to weight gain [146, 147]. In fact, 
postprandial triglyceride concentrations were increased within twenty-four hours after 
consumption of fructose-sweetened versus glucose-sweetened beverages (providing 30% 
of total kcal) in short-term studies in younger adults [148], suggesting that postprandial 
hypertriglyceridemia, perhaps mediated by an increase in hepatic de novo lipogenesis, is 
one of the earliest metabolic perturbations associated with excess fructose intake [149]. 
Taken together, these data provided experimental evidence to suggest that relatively 
short-term consumption of high dietary fructose elicits adverse metabolic and 
cardiovascular effects by promoting visceral adipose tissue accretion, aberrant lipid 
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metabolism, and decreased insulin sensitivity, thereby increasing the risk for type 2 
diabetes and cardiovascular disease [146, 147].     
 
Dietary Fructose, Insulin Action, and Dyslipidemia in Experimental Animal Models 
Numerous studies have also demonstrated the capacity of dietary fructose (either 
free fructose or complexed with glucose as sucrose) to induce insulin resistance, hepatic 
lipid accumulation, and hypertriglyceridemia in experimental animal models. For 
example, Storlein and colleagues [150] compared the effects of feeding isocaloric 
quantities of a high-starch diet or high-sucrose (50% glucose, 50% fructose) diet (69% of 
total kcal as sucrose or cornstarch) on whole-body insulin action in adult male Wistar 
rats. After four weeks of feeding, the glucose infusion rate required to maintain 
euglycemia during a hyperinsulinemic euglycemic clamp was significantly lower in high-
sucrose fed rats, indicative whole-body insulin resistance. The decrease in the clamp 
glucose infusion rate was the result of a significant impairment in the ability of insulin to 
suppress endogenous glucose production, whereas insulin-mediated whole-body glucose 
uptake was only slightly reduced, corresponding to a 10% reduction in tissue-specific 
glucose metabolic index (Rg) in skeletal muscle [150]. The perturbations in glucose 
metabolism in high-sucrose-fed rats occurred in the absence of an increase in body fat. 
These data suggest that four weeks of high-sucrose feeding produced a major impairment 
in insulin action at the liver that was independent of changes in body weight or adiposity 
[150]. In a follow-up study [151], the same group of investigators assessed the 
contribution of the fructose moiety of sucrose versus that of glucose in the development 
of insulin resistance after 4 weeks of feeding a high-fructose or high-glucose diet (35% of 
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total kcal as fructose or glucose combined with another 35% of kcal as cornstarch) to 
adult male Wistar rats. Four weeks of high-fructose versus high-glucose feeding was 
associated with a significant decrease in the ability of insulin to suppress hepatic glucose 
production coupled with an equivalent decline in insulin-mediated peripheral glucose 
disposal during a hyperinsulinemic-euglycemic clamp [151]. The authors concluded that 
fructose, not glucose, was the deleterious factor associated with impaired insulin action 
after high-sucrose feeding [151].  
Pagliassotti and colleagues [19] also demonstrated that 8 weeks of high-sucrose 
feeding (68% of kcal from sucrose) in rats was sufficient to induce whole-body insulin 
resistance, as indicated by a significant reduction in the glucose infusion rate required to 
maintain euglycemia with increasing insulin concentrations, and impaired suppression of 
hepatic glucose production by hyperinsulinemia. These changes were associated with an 
increase in hepatic PEPCK activity [18, 152], increased G6Pase expression and activity 
[14, 153, 154], and lower GK activity [14]. Next, Pagliassotti et al [18] investigated 
whether the amount of sucrose consumed and the duration of dietary sucrose exposure 
influenced the temporal development of insulin resistance in a tissue-specific manner. 
Three groups of male Wistar rats were fed a low-sucrose diet (18% of total energy from 
sucrose), a high-sucrose diet, or a high-starch diet (68% of total kcal from sucrose or 
cornstarch, respectively) for 8, 16, or 30 weeks [18]. Sucrose-fed rats were pair-fed to 
their respective starch control rats. Despite no difference among diet groups in body 
weight gain or percentage of body fat, both the low-sucrose and high-sucrose diets 
induced whole-body insulin resistance; however, the time course of induction and tissue 
distribution of insulin resistance was influenced by the quantity of dietary sucrose 
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consumed [18]. For example, consumption of the high-sucrose diet resulted in hepatic 
and peripheral insulin resistance within 8 weeks, as demonstrated by a decline in the 
ability of insulin to suppress endogenous glucose production concomitant with decreased 
insulin-mediated whole-body glucose disposal [18]. On the other hand, consumption of 
the low-sucrose diet required at least 16 weeks to elicit hepatic insulin resistance, 
whereas there was no significant decline in insulin-mediated peripheral glucose disposal 
after 30 weeks of feeding [18]. In agreement with the findings of Thorburn and 
colleagues [151], Thresher et al. [155] also demonstrated that dietary fructose was the 
primary mediator of sucrose-induced impairments in insulin action and glucose 
intolerance in vivo.  
A more detailed analysis of the temporal development of insulin resistance in the 
liver versus muscle after 1, 2, 5, or 8 weeks of high-sucrose versus high-starch (68% of 
total kcal as sucrose or cornstarch, respectively) feeding demonstrated that hepatic insulin 
resistance precedes muscle insulin resistance as determined by sequential 
hyperinsulinemic euglycemic testing [156]. In addition, the reduction in hepatic insulin 
sensitivity was accompanied by increases in liver triglyceride levels in sucrose-fed 
animals, but the rate of hepatic triglyceride accumulation was dependent upon the 
quantity of dietary sucrose consumed [18]. Furthermore, rats fed a high-sucrose diet 
developed fasting hypertriglyceridemia and hyperinsulinemia, whereas those fed a low-
sucrose diet did not [18]. Nevertheless, a decrease in hepatic insulin sensitivity was 
evident in both high- and low-sucrose-fed groups, suggesting that hyperinsulinemia and 
hypertriglyceridemia per se are not causally linked to hepatic insulin resistance induced 
by an increase in dietary sucrose consumption. On the other hand, the time course of the 
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changes in fasting plasma insulin and triglyceride levels in high-sucrose-fed rats was 
consistent with the time course of the development of peripheral insulin resistance in 
those animals, suggesting that perhaps hyperinsulinemia and/or hypertriglyceridemia are 
linked to impaired insulin action in skeletal muscle following consumption of high 
dietary sucrose, and by extension [151, 155], fructose. In support of this hypothesis, there 
was a significant inverse association between fasting plasma triglyceride concentrations 
and clamp rates of whole-body glucose disposal and insulin-stimulated muscle glycogen 
synthesis [156] in high-sucrose-fed rats. All together, the aforementioned studies provide 
evidence to suggest that the liver is particularly susceptible to the adverse effects of 
dietary fructose, whether consumed in moderate or high quantities, whereas peripheral 
tissues (primarily skeletal muscle) appear to be vulnerable to the adverse effects of 
dietary fructose only when consumed in high quantities.  
 
Catalytic Quantities of Fructose and Hepatic Glucose Metabolism 
In contrast to the studies which have defined the metabolic consequences of 
chronic high dietary fructose consumption, other studies have demonstrated that the acute 
administration of small quantities of fructose actually improves postprandial glycemic 
and insulinemic responses. For example, inclusion of 7.5 g of fructose with a standard 75 
g oral glucose load substantially reduced the glycemic response during an oral glucose 
tolerance test in both normal and type 2 diabetic individuals [157, 158]. In addition, 
infusion of catalytic quantities of fructose with an intraportal or intraduodenal glucose 
load markedly enhanced net hepatic glucose uptake (NHGU) and hepatic glycogen 
synthesis (GSYN) in conscious dogs [115, 116, 159]. Augmented NHGU was attributed 
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to the ability of fructose-1-phosphate (the product of fructokinase) to stimulate the 
translocation of hepatic glucokinase from the nucleus to the cytosol, thereby facilitating 
NHGU [116, 160-162]. Indeed, low-dose fructose infusion partially restored hepatic 
glucose effectiveness in individuals with type 2 diabetes, as evidenced by a 44% decline 
in endogenous glucose production during hyperglycemia and euinsulinemia, whereas no 
further improvement in glucose effectiveness was evident in non-diabetic subjects in 
response to fructose infusion [163]. Furthermore, Petersen et al. [164] demonstrated that 
low-dose fructose infusion increased carbon flux through glycogen synthase and 
stimulated hepatic glycogen synthesis [164]. Altogether, the beneficial effects of catalytic 
quantities of fructose on hepatic glucose flux appear to be mediated by the activation of 
hepatic glucokinase and glycogen synthase [165].  
Wei and colleagues [154] proposed that the differential effects of low-dose 
fructose versus chronic high-dose fructose exposure might be mediated by its effects on 
glucose-6-phosphatase expression. For example, the gene expression of the catalytic 
subunit of glucose-6-phosphatase was reduced during a hyperinsulinemic hyperglycemic 
clamp combined with low-dose fructose infusion into the portal venous circulation, but 
significantly augmented in the presence of a high-dose fructose infusion [154]. Although 
the acute regulation of hepatic glucose uptake by low-dose intraportal fructose infusion 
cannot be explained by a decrease in glucose-6-phosphatase gene expression, it is 
possible that chronic consumption of high dietary fructose might lead to persistent 
elevations in glucose-6-phosphatase mRNA and protein, thereby antagonizing the 
balance between hepatic glucose output via glucose-6-phosphatase, and hepatic glucose 
uptake via glucokinase.  
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Cellular Mechanisms of Diet-Induced Hepatic Insulin Resistance 
 
Molecular Changes Associated with High-Fat or High-Fructose Feeding  
The cellular mechanisms by which high dietary fat or high dietary fructose confer 
metabolic abnormalities are overlapping in some respects, and distinct in others. One 
similarity amongst fat and fructose is that both nutrients in excessive amounts have 
profound effects on the liver, particularly in the early stages of feeding. In rodent models, 
high-fat and high-fructose feeding has been associated with hepatic lipid deposition, 
impaired regulation of glucokinase and glucose-6-phosphatase, decreased activation of 
insulin signaling intermediates, impaired regulation of glycogen synthase, and activation 
of stress signaling pathways. For example, the accumulation of triacylglycerol and 
diacylglycerol (DAG) in the livers of rats after three days of high-fat feeding was 
associated with a decrease in insulin-stimulated tyrosine phosphorylation of the insulin 
receptor and IRS 1/2, a reduction in the association of IRS proteins with PI-3K, a 
decrease in Akt and glycogen synthase activity, and an increase in GSK3β and JNK 
activity [23]. Impaired insulin signaling was associated with activation of PKCε 
secondary to liver lipid accumulation, whereas impaired activation of liver glycogen 
synthase was associated with a significant decrease in the incorporation of glucose into 
glycogen through the direct pathway, although the percentage of glycogen synthesized 
through the indirect pathway was slightly increased [23]. Furthermore, Oakes and 
colleagues [22] reported that three weeks of high-fat feeding in rats resulted in a 
significant impairment in the ability of insulin to suppress hepatic glucose production in 
association with impaired suppression of glucose-6-phosphatase activity, and 
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significantly reduced glucokinase activity during a hyperinsulinemic-euglycemic clamp. 
Altogether, these data indicate that high-dietary fat exerts adverse effects on the 
regulation of hepatic glucose metabolism in part by promoting liver lipid accumulation, 
by impairing the balance between glucose-6-phosphatase and glucokinase activity, and 
by attenuating the activation of insulin signaling intermediates, which translates into 
impaired activation of liver glycogen synthase.  
Consumption of a high-fructose (or sucrose) diet has also been associated with a 
decrease in insulin-stimulated tyrosine phosphorylation of the IR, a reduction in insulin 
stimulated tyrosine phosphorylation of IRS 1/2, a reduction in the association of IRS 
proteins with PI-3K, a reduction in Akt and glucokinase activity, and an increase in 
G6Pase mRNA and activity [13, 14, 18, 19, 152, 154, 155, 166-170]. These changes were 
associated with an increase in JNK1 activity, an increase in protein tyrosine phosphatase 
1b (PTP1b) and inducible nitric oxide synthase (iNOS) protein levels, an increase in 
hepatic lipid peroxidation, an increase in liver lipid and DAG concentrations, and 
activation of PKCε [168-173]. The transcriptional changes that frequently accompany 
high-fructose feeding include hepatic induction of the lipogenic transcription factors 
SREBP-1c and ChREBP [126, 174, 175]. In fact, Koo and colleagues demonstrated an 
induction of ChREBP and fructose metabolic enzymes (fructokinase and aldolase B), 
along with pyruvate kinase, fatty acid synthase, and glycerol-3-phosphate acyltransferase 
in the livers of high-fructose fed rats, suggesting that ChREBP is a mediator of the 
lipogenic effects of fructose along with SREBP1c [126]. Furthermore, high fructose diet-
induced hyperlipidemia and insulin resistance was ameliorated when the expression of 
hepatic ChREBP was knocked down in vivo [176]. On the other hand, knockdown of 
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ChREBP in high-fat-fed rodents had no beneficial metabolic effects [174]. Collectively, 
these data indicate that high-dietary fructose also exerts adverse effects on the regulation 
of hepatic glucose metabolism by promoting liver lipid accumulation, by impairing 
insulin signal transduction to Akt, and by increasing the ratio of glucose-6-phosphatase to 
glucokinase activity.  
One of the common links underlying the adverse metabolic effects of excess 
dietary fat or fructose consumption in rodents is hepatic lipid accumulation. High-fat 
diets are thought to promote hepatic lipid deposition though increased delivery of dietary 
fat to the liver that exceeds its ability to oxidize the fatty acids or export them in VLDL 
particles [177], whereas high-fructose diets are thought to promote hepatic lipid 
deposition by stimulating de novo lipogenesis [146, 149, 171]. Recently, Ren and 
colleagues [178] investigated the role of endoplasmic reticulum (ER) stress and 
inflammation in hepatic steatosis and insulin resistance during high-fat feeding (lipid 
oversupply) versus high-fructose feeding (excess de novo lipogenesis). After only three 
days of feeding, both diets resulted in an increase in hepatic triglyceride levels and in 
SREBP1c mRNA expression; however, only the high-fructose diet increased hepatic de 
novo lipogenesis and the expression of ChREBP, acetyl-CoA carboxylase, fatty acid 
synthase, and stearoyl-CoA desaturase [178]. Furthermore, high-fructose feeding was 
associated with activation of ER stress signaling pathways (PERK/eIFα and IRE/XBP-1) 
but not JNK, whereas high-fat feeding was associated with activation of JNK but not ER 
stress [178]. These data suggest that different mechanisms are involved in the 
development of hepatic insulin resistance and hepatic steatosis induced by high-fructose 
or high-fat feeding.  
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Taken together, it is clear that both nutrients in excessive amounts have profound 
effects on hepatic insulin sensitivity and glucose metabolism. However, most of the 
aforementioned clamp studies were conducted under euglycemic conditions, in which the 
liver is only a minor contributor to whole-body glucose disposal. Thus, a defect in hepatic 
glucose uptake might have gone undetected. In addition, previous studies have generally 
utilized supraphysiological quantities of fructose (e.g. ≈ 60% of kcal as fructose) to 
investigate its physiologic and cellular effects [126, 151, 171, 179]. As a result, the 
combined effects of dietary fat and fructose, in quantities that mimic a Western diet, on 
the temporal development of glucose intolerance and impaired hepatic glucose flux in 
vivo are incompletely understood. Thus, one of the overarching goals of this dissertation 
is to shed light on the pathogenesis of impaired hepatic glucose flux under conditions that 
mimic the postprandial state after chronic consumption of dietary fat and fructose in 
quantities that mimic a Western diet. 
 
Regulation of Hepatic Glucose Uptake  
The liver plays an integral role in maintaining whole-body glucose homeostasis. It 
consumes glucose in the postprandial state and stores it as glycogen, while in the post 
absorptive state it supplies glucose to the blood by breaking down glycogen and by 
converting gluconeogenic precursors into glucose. The ability of the liver to act as a 
dynamic regulator of glucose homeostasis is due in part to its proximity to the portal vein, 
the vessel into which the two main hormonal regulators of glucose metabolism, insulin 
and glucagon, are secreted. Thus, the liver is the first tissue to be exposed to secreted 
insulin and glucagon, and is extremely sensitive to subtle changes in the concentrations of 
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these hormones. Likewise, the liver is uniquely equipped with the ability to sense the 
route by which glucose is delivered to it. In contrast to intravenous glucose infusion by 
way of a peripheral vein, hepatic portal venous glucose delivery (by means of oral 
glucose ingestion or intraduodenal/portal vein glucose infusion) markedly amplifies HGU 
and GSYN in the rat [180, 181], dog [181-189], and human [190, 191]. amplifies HGU 
and glycogen synthesis (GSYN) in the rat [180, 181], dog [181-189], and human [190, 
192]. The augmentation of HGU elicited by the intraportal route of glucose delivery has 
been attributed to a unique, neurally-mediated signal generated in the presence of a 
negative arterial-portal venous glucose gradient, termed the “portal glucose signal” [26, 
182-184, 193-199]. In response to ingestion of a glucose-containing meal, the portal 
signal works in concert with increased plasma glucose and insulin to orchestrate a 
coordinated response favoring enhanced HGU and GSYN, thereby buffering 
perturbations in postprandial glycemia. Although the metabolic effects of intraportal 
glucose delivery have been studied in animal models and in the human, the molecular 
events linking the pleiotropic actions of the portal glucose signal to increased HGU and 
GSYN in vivo have not been clearly defined. 
The clinical significance of investigating the regulation of hepatic glucose flux is 
underscored by the finding that individuals with diabetes display a marked impairment 
not only in the ability of hyperinsulinemia and hyperglycemia to suppress hepatic glucose 
production, but also in the ability of those postprandial stimuli to activate HGU and 
GSYN [200-204]. As a result, diabetic individuals experience frequent bouts of 
postprandial hyperglycemia, which contributes to the elevation of their hemoglobin A1C 
and pre-disposes them to many of the complications associated with the disease. 
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However, the molecular events associated with a diminished response of the liver to 
hyperinsulinemia, hyperglycemia, and portal glucose delivery are incompletely 
understood. 
 
Regulation of NHGU by Hyperglycemia 
 Previously, Shulman et al. [205] investigated the effect of hyperglycemia per se 
on the net hepatic glucose balance independent of changes in plasma insulin and 
glucagon levels in 36-h-fasted, conscious dogs. A pancreatic clamp was performed 
during which somatostatin was infused to inhibit endogenous insulin and glucagon 
secretion. Insulin and glucagon were replaced into the portal venous circulation at basal 
rates (0.3 mU/kg/min and 1.0 ng/kg/min, respectively), while saline or glucose was 
infused into a peripheral vein at the beginning of the experimental period. In contrast to 
the saline-infused group, hyperglycemia per se induced a significant decline (56%) in net 
hepatic glucose output (NHGO) (from 2.2±0.1 to 0.9±0.1 mg/kg/min) in the presence of 
basal insulin and glucagon concentrations, but net hepatic glucose uptake (NHGU) did 
not occur during the 2 hour experimental period [205]. Similar results were reported by 
Cherrington et al. [206] in the presence of a 2-fold increase in the hepatic glucose load 
(HGL) brought about by intravenous glucose infusion during euinsulinemic and 
euglucagonemic conditions. Furthermore, hyperglycemia per se was not associated with 
an increase in terminal liver glycogen levels over those of saline-infused dogs [205], 
consistent with the lack of NHGU in the presence of basal insulin and glucagon 
concentrations [205, 206]. In accord with this, Sacca et al. [207] reported that 
hyperglycemia had an inhibitory effect on glucose production in the presence of fixed 
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basal pancreatic hormone concentrations in the overnight-fasted human. 
Interestingly, acute removal of glucagon in the presence of similar hyperglycemia 
and euinsulinemia induced a switch from just reduced NHGO to NHGU (0.9±0.2 to -
1.5±0.2 mg/kg/min, respectively), suggesting that glucagon is a powerful modulator of 
NHGB during hyperglycemia and euinsulinemia [205]. On the other hand, acute removal 
of glucagon in presence of basal glucose and insulin concentrations partially suppressed 
NHGO in dogs (approximately 35% reduction) [208], and net splanchnic glucose 
production in humans (approximately 75% reduction) [209].   
A decline in NHGO in the presence of hyperglycemia can be the consequence of a 
decrease in net hepatic gluconeogenesis, net hepatic glycogenolysis, or both. Rossetti and 
colleagues [210] investigated the mechanisms by which hyperglycemia per se regulates 
hepatic glucose production in vivo. Pancreatic clamp studies were performed in 
conscious rats during which somatostatin was infused to disable the endocrine pancreas, 
and insulin and glucose were replaced at basal and 2-fold basal rates, respectively, into 
the peripheral circulation. Consistent with previous studies [205, 206], hyperglycemia per 
se under euinsulinemic conditions was associated with a 58% decrease in hepatic glucose 
production, nearly all of which was accounted for by a decline (89%) in hepatic 
glycogenolysis [210]. These changes were accompanied by an increase in the activation 
of glycogen synthase coupled with a decrease in glycogen phosphorylase a activity, 
whereas the activities of glucose-6-phosphatase and glucokinase were unaffected by 
acute hyperglycemia [210]. However, a significant increase in the contribution of plasma-
derived glucose carbons to the hepatic glucose-6-phosphate pool and total glucose-6-
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phosphatase flux (as a reflection of glucose cycling) was indicative of a substrate-
mediated increase in glucokinase flux in response to an acute elevation of plasma glucose 
[210]. Interestingly, infusion of a glucokinase inhibitor, glucosamine, significantly 
impaired the ability of hyperglycemia per se to suppress hepatic glucose production in 
rats, suggesting that activation of glucokinase is also a key component in facilitating 
hepatic glucose effectiveness [211].  
The metabolic findings of Rossetti et al. [210]were confirmed in the conscious 
dog by Sindelar and colleagues [212], in which hyperglycemia was shown to inhibit 
glucose production through suppression of hepatic glycogenolysis. Likewise, Petersen et 
al. [213] demonstrated in humans that hyperglycemia per se suppressed net hepatic 
glycogenolysis primarily through inhibition of glycogen phosphorylase flux. Thus, in 
normal individuals, hyperglycemia alone can suppress NHGO and HGP by affecting the 
regulation of enzymes involved in glucose phosphorylation and glycogen metabolism in 
the absence of a change in glucose-6-phosphatase activity or flux. However, 
hyperglycemia alone is inadequate to stimulate HGU in the presence of basal insulin and 
glucagon levels. 
 
Regulation of NHGU by Hyperinsulinemia 
 McGuinness and colleagues [89] performed four-step hyperinsulinemic 
euglycemic clamp experiments in conscious dogs following an overnight fast. Insulin was 
infused into a peripheral (cephalic) vein at 1, 2, 10, and 15 mU/kg/min for 100 minutes 
each, which corresponded to steady state plasma insulin levels of 58±3, 120±18, 
1134±102, and 2044±293 µU/ml. In addition, glucose was infused through the saphenous 
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vein in order to maintain euglycemia throughout the study. Physiologic hyperinsulinemia 
in the presence of euglycemia and basal glucagon concentrations resulted in complete 
suppression of NHGO, with only marginal stimulation of NHGU (from 2.38±0.66 to -
0.1±0.29 or -0.55±0.26 mg/kg/min with 1 or 2 mU/kg/min of exogenous insulin infusion, 
respectively) [89]. In contrast, pharmacologic hyperinsulinemia in the presence of 
euglycemia stimulated a significant increase in NHGU (-1.83±0.13 or -2.89±0.96 
mg/kg/min with 10 or 15 mU/kg/min of exogenous insulin infusion, respectively) [89]. 
Nevertheless, supraphysiologic levels of circulating insulin were still insufficient to elicit 
peak rates of NHGU seen in response to physiologic hyperinsulinemia, hyperglycemia, 
and portal vein glucose delivery. 
 Recently, Ramnanan et al. [214] described the time course of the physiologic and 
hepatocellular changes associated with suppression of NHGO in response to an 8-fold 
elevation in hepatic sinusoidal insulin concentrations during euglycemia and 
euglucagonemia in 24-h-fasted conscious dogs. Indeed, hyperinsulinemia resulted in 
rapid suppression (within the first 30 min) of NHGO, which was attributable to a robust 
decline in net hepatic glycogenolysis and gluconeogenesis, with only a transient decrease 
in net hepatic gluconeogenic flux. Despite complete inactivation of hepatic glucose 
production, however, 4 hours of hyperinsulinemia was associated with only marginal 
stimulation of NHGU (-0.8±0.1 mg/kg/min) [214]. 
Molecular markers in the liver that changed within the first 30 min of 
hyperinsulinemia concomitant with suppression of hepatic glucose production included 
activation of insulin signaling intermediates (Akt and GSK3β), nuclear exclusion of 
FOXO1, activation of glycogen synthase, inhibition of glycogen phosphorylase, and 
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increased fructose-2,6-bisphosphate concentrations [214]. In humans, hyperinsulinemia 
per se was also shown to inhibit hepatic glycogenolysis primarily through stimulation of 
liver glycogen synthase flux [213]. Collectively, the aforementioned studies demonstrate 
that a physiologic rise in insulin in the presence of euglycemia and basal glucagon 
concentrations is inadequate to stimulate NHGU to any large extent. 
 
Regulation of NHGU by Hyperglycemia and Hyperinsulinemia 
 In 36-h-fasted dogs, Cherrington and colleagues [206] investigated whether a 
physiologic, four-fold increase in plasma insulin (from 12±1 to 36±2 µU/ml) brought 
about by intraportal infusion of the hormone would augment the response of the liver to 
hyperglycemia (from 112±12 to 244±11 mg/dl) brought about by intravenous infusion of 
glucose. Indeed, the combination of hyperglycemia and hyperinsulinemia caused a robust 
switch from NHGO (2.8±.3 mg/kg/min) to NHGU (peak rate of 3.7±1.2 mg/kg/min), but 
2 hours of hyperinsulinemia and hyperglycemia was required to elicit peak rates of 
NHGU. Consistent with the stimulation of NHGU, terminal liver glycogen levels were 
significantly greater in the hyperinsulinemic-hyperglycemic group (44.0±4.2 mg/g liver) 
compared to the euinsulinemic-hyperglycemic group (19.4±2.2 mg/g liver). Pagliassotti 
et al. [198] reported a similar time course and magnitude of change in NHGB in 42-h-
fasted dogs in the presence of a four-fold elevation in insulin and a two-fold increase in 
the hepatic glucose load brought about by intravenous (peripheral) glucose infusion, in 
which a peak rate of NHGU (approximately 3.0 mg/kg/min) was achieved after ninety 
minutes of hyperinsulinemia and hyperglycemia (approximately 35 µU/ml and 235 
mg/dl, respectively, in arterial plasma) [198]. Augmented NHGU in the presence of a 
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combined elevation in glucose and insulin was associated with rapid (30 min) activation 
of liver glycogen synthase, and a significant increase in liver glycogen levels relative to 
control animals with hyperglycemia alone [198]. Likewise, physiologic elevations of 
glucose and insulin in humans led to high rates of net hepatic glycogen synthesis 
secondary to stimulation of glycogen synthase flux and suppression of glycogen 
phosphorylase flux [213].  
Numerous other studies have also demonstrated rates of NHGU in the dog 
ranging from 1.0 to 2.9 mg/kg/min in the presence of plasma glucose concentrations of 
160 to 290 mg/dl and plasma insulin levels of 35 to 384  µU/ml [215]. In humans, 
splanchnic glucose uptake (comprising glucose disposal by the gut and liver) ranged from 
1.0 to 1.6 mg/kg/min in the presence of plasma glucose concentrations of 175 to 225 
mg/dl and plasma insulin levels of 40 to 55 µU/ml [215]. 
Altogether, the aforementioned studies indicate that physiologic changes in 
glucose, insulin, or glucagon individually are insufficient to stimulate NHGU. In 
addition, although NHGU is significantly increased in the presence of a four-fold rise in 
insulin and a two-fold increase in glucose by way of intravenous glucose infusion, these 
factors still cannot account for the peak rates of NHGU that are evident following an oral 
glucose challenge [27, 190]. Thus, factors in addition to hyperglycemia and the 
concentrations of pancreatic hormones must be involved in the regulation of NHGU in 
response to ingestion of a glucose-containing meal.  
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Regulation of NHGU by Portal Glucose Delivery 
  It has been known for some time now that in the presence of matched blood 
glucose profiles, oral glucose ingestion results in a plasma insulin response that is nearly 
double that seen in the same individuals when glucose is infused intravenously [216]. The 
unique hormonal response to oral versus intravenous glucose delivery was attributed to 
the release of insulinotropic factors by the gut in the presence of oral glucose ingestion, 
and thus termed the “incretin effect.” In addition, DeFronzo and colleagues [190] 
assessed the influence of the route of glucose administration (oral versus intravenous) on 
splanchnic (which includes the gut and liver tissues) glucose uptake in humans. During 
the first hour of their experiment, glucose was infused intravenously to elevate the plasma 
glucose concentration at 125 mg/dl above basal. Afterwards, participants ingested 1.2 g 
of glucose per kilogram of body weight, and the variable intravenous (“peripheral”) 
glucose infusion rate was adjusted to clamp the plasma glucose concentration at 125 
mg/dl above basal for the remaining 3 hours of the study. Net splanchnic glucose uptake 
during the first 60 min of intravenous glucose infusion was 1.0 mg/kg/min. In response to 
oral glucose ingestion, net splanchnic glucose uptake increased six-fold (to 
approximately 6.0 mg/kg/min) despite unchanged plasma glucose levels. Likewise, oral 
glucose ingestion was associated with a 50% increase in the mean plasma insulin 
response compared to that reached with intravenous glucose infusion alone [190]. Thus, 
the route of glucose administration had a significant impact not only on the beta cell, as 
reported previously, but also on glucose uptake by splanchnic tissues.   
 The findings of DeFronzo and colleagues [190] in humans were tested in the dog 
model in a study by Abumrad et al. [27], in which conscious dogs were administered an 
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oral glucose load of 1.63 g/kg body weight. In response to the oral glucose challenge, the 
arterial blood glucose concentration nearly doubled, while the arterial plasma insulin 
concentration increased approximately 5-fold, with minimal changes in plasma glucagon 
levels. Under these hormonal and glycemic conditions, there was a rapid switch from 
NHGO (2.0 mg/kg/min) to NHGU (approximately 4.5 mg/kg/min), demonstrating that 
the increase in glucose uptake by splanchnic tissues following oral glucose ingestion was 
predominantly attributable to augmented hepatic glucose uptake. Furthermore, the 
magnitude of the increase in splanchnic [190] or hepatic [27] glucose uptake following 
oral glucose ingestion was greater than what would have been predicted based on the 
accompanying plasma insulin and glucose levels, suggesting that the normal response of 
the liver to an oral glucose challenge requires a signal in addition to glucose and insulin 
to ensure adequate storage of glucose by the liver in the postprandial state.  
Initially, DeFronzo and colleagues [190] speculated that ingestion of glucose 
triggers the release of a gastrointestinal factor that enhances splanchnic glucose uptake, 
but other changes also accompanied oral versus intravenous glucose delivery. For 
example, there was an increase in insulin secretion, and there was a shift in the blood 
glucose gradient between the hepatic artery and the portal vein. Oral glucose delivery 
resulted in portal venous glucose concentrations that were higher that those in the arterial 
circulation (negative arterial-portal [A-P] glucose gradient), whereas arterial glucose 
concentrations were higher with intravenous (peripheral) glucose infusion (positive A-P 
glucose gradient). As a result, it was not clear how much of the enhanced response of 
splanchnic tissues to oral glucose delivery was attributable to augmented insulin 
secretion, the secretion of a gut factor, or the generation of a negative A-P gradient. Thus, 
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our laboratory carried out a series of pancreatic clamp experiments in the conscious dog 
in which NHGU was assessed during peripheral versus intraportal glucose infusion, 
thereby bypassing the gut. In addition, somatostatin was infused to inhibit endogenous 
insulin and glucagon secretion, and both hormones were replaced intraportally at a fixed 
rate. Adkins and colleagues [182] demonstrated that under conditions of basal 
insulinemia, basal glucagonemia, and hyperglycemia by way of peripheral glucose 
infusion (mean arterial and portal venous plasma glucose concentrations of 217 and 213 
mg/dl, respectively), there was no stimulation of NHGU. However, when some of that 
glucose was switched from a peripheral to an intraportal infusion (arterial and portal 
plasma glucose concentrations of 200 and 220 mg/dl, respectively), NHGU was 
significantly increased (1.4 mg/kg/min), even though the hepatic glucose load and the 
plasma insulin and glucagon concentrations were the same as those in the peripheral 
glucose infusion protocol [182]. Altogether, these data and others [186, 187] ruled out the 
involvement of a gut factor in the enhanced response of the liver to oral glucose 
ingestion, and suggested that augmented NHGU in the presence of intraportal glucose 
infusion was attributable to the generation of a “portal glucose signal.” Subsequent 
studies [183, 197, 198] demonstrated that when hyperinsulinemia (four-fold increase) 
was combined with hyperglycemia, NHGU was consistently 2.5 to 3-fold greater in the 
presence versus absence of the portal signal, suggesting that hyperinsulinemia and portal 
glucose delivery have an additive effect in augmenting NHGU. Furthermore, Holste et al. 
[217] demonstrated that a selective decrease in glucagon does not further enhance the 
response of the liver to hyperglycemia, hyperinsulinemia, and portal glucose delivery, 
whereas an increase in glucagon reduces NHGU due to impaired suppression of hepatic 
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glucose uptake. Thus, in diabetic individuals, hyperglucagonemia may antagonize 
splanchnic glucose uptake in response to a meal. 
 
Interaction between the Portal Glucose Signal, Insulin, and the Hepatic Glucose Load 
 Myers and colleagues [196, 197] further investigated the relationship between 
portal glucose delivery, the hepatic sinusoidal insulin level, and the hepatic glucose load 
in 2 separate studies using the conscious dog model. In the first study [197], the 
pancreatic clamp technique was employed to the fix plasma glucagon levels at a basal 
concentration, while insulin was infused intraportally at two-, four-, or eight-fold basal in 
two separate groups. One group received a portal glucose infusion (approximately 4-5 
mg/kg/min) in order to activate the portal glucose signal, while the other group received 
an intraportal saline infusion. In both groups, a variable peripheral glucose infusion was 
utilized to double the hepatic glucose load in both protocols. In the presence of 
hyperinsulinemia and hyperglycemia without the portal glucose signal, NHGU was 
0.6±0.3, 1.5±0.4, 3.0±0.8 mg/kg/min with a two-, four-, and eight-fold rise in insulin, 
respectively. However, infusion of a portion of that glucose into the portal vein in order 
to activate the portal signal triggered an increase in NHGU at all 3 insulin infusion rates, 
which corresponded to NHGU rates of 2.0±0.5, 3.7±0.7, and 5.5±0.9 mg/kg/min in the 3 
insulin infusion periods, respectively [197]. Thus, although insulin is a clear determinant 
of NHGU in both the absence and presence of portal glucose delivery, the effect of the 
portal glucose signal on NHGU is at least equal to the effect of insulin, even across wide 
range of insulin concentrations [26, 197]. Likewise, the effects of portal glucose delivery 
and hyperinsulinemia on hepatic glycogen accumulation are additive under physiologic 
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conditions [198], demonstrating that the two signals efficiently couple glucose uptake and 
storage by the liver in the postprandial state [208, 219]. Indeed, the permissive effect of 
insulin on the response of the liver to portal glucose delivery was exemplified in a study 
by Pagliassotti et al [218], in which acute or chronic removal of insulin by way of 
somatostatin infusion or pancreatectomy, respectively, resulted in the loss of an increase 
in NHGU in the presence of the portal glucose signal.   
 In a second study, Myers and colleagues [196] again utilized the pancreatic clamp 
to fix the glucagon concentration at a basal level while elevating the plasma insulin 
concentration four-fold. In one group, the hepatic glucose load was increased by 
approximately 65%, 140%, and 220% by means of a peripheral glucose infusion. In 
another group, glucose was infused intraportally (approximately 10 mg/kg/min), while 
the peripheral glucose infusion was adjusted as necessary to match the hepatic glucose 
loads to those of the first group. In the absence of portal glucose delivery, NHGU was 
1.2±0.4, 2.8±0.8, and 5.1±1.2 mg/kg/min, which corresponded to graded increases in the 
hepatic glucose load. However, NHGU at the three different hepatic glucose loads was 
magnified in the presence of portal glucose delivery (3.8±0.4, 4.8±0.6, and 9.6±1.4 
mg/kg/min, respectively) [196]. Thus, analogous to insulin, the hepatic glucose load is 
also a determinant of NHGU in both the absence and presence of portal glucose delivery, 
but the portal signal substantially augments NHGU across a wide range of hepatic 
glucose loads [26, 196]. Likewise, the rate of NHGU is directly related to the magnitude 
of the negative A-P gradient across the range of physiologic gradients under conditions of 
hyperglycemia and physiologic hyperinsulinemia [199]. Altogether, these data provide 
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sufficient evidence to indicate that NHGU is dependent upon the hepatic glucose load, 
the hepatic sinusoidal insulin level, and the portal glucose signal [26]. 
 
Mechanism of Portal Signaling 
 The mechanism(s) by which a negative A-P glucose gradient is sensed, a portal 
glucose signal generated, and NHGU increased has been the focus of numerous studies. 
Several lines of evidence suggest that the portal glucose signal is neurally-mediated. For 
example, Adkins-Marshall et al. [184] demonstrated in dogs that surgical denervation of 
the liver ablates its response to portal glucose delivery (NHGU was 2.1±0.5 and 2.2±0.7 
mg/kg/min during peripheral and portal glucose infusion, respectively) under conditions 
of basal glucagonemia, hyperinsulinemia (four-fold basal), and hyperglycemia (hepatic 
glucose load two-fold basal). In addition, Pagliassotti and colleagues [198] compared the 
time course of the effect of insulin and the portal glucose signal on NHGU in conscious 
dogs, the idea being that a neurally-mediated signal generated by portal glucose infusion 
should result in rapid stimulation of NHGU as opposed to peripheral glucose delivery. 
The pancreatic clamp was used to fix plasma glucagon at a basal level, and to vary the 
plasma insulin level as desired. Hyperglycemia preceded the experimental period in order 
to suppress NHGO to zero. In one group (Control), hyperglycemia via peripheral infusion 
was sustained for the duration for the study. In a second group (Portal Signal), insulin 
was fixed at a basal level while glucose was infused intraportally to activate the portal 
glucose signal, and the peripheral glucose infusion rate was adjusted as necessary to 
match the hepatic glucose load to that of the control group. In a third group (Insulin), the 
insulin level was increased four-fold in the presence of hyperglycemia, but in the absence 
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of portal glucose delivery, while in the fourth group (Insulin + Portal Signal), all stimuli 
were present (hyperglycemia, hyperinsulinemia, and portal glucose delivery). In the 
control group, NHGU was 0.4 mg/kg/min, and there was little accumulation of liver 
glycogen during the study. In the Portal Signal group, NHGU was markedly 
(approximately 3.0 mg/kg/min) and rapidly (15 min) increased despite the same 
experimental conditions as the Control group. This resulted in a robust increase in liver 
glycogen levels in association with rapid activation of liver glycogen synthase, even in 
the absence of a rise in insulin [198]. These data lend support to the notion that the portal 
signal is in part, neurally-mediated. Furthermore, when hyperglycemia and 
hyperinsulinemia were combined in the Insulin group, NHGU eventually approached the 
rate observed in the Portal Signal group alone, but it required nearly 90 min to achieve 
this rate. On the other hand, hyperglycemia, hyperinsulinemia, and portal glucose 
delivery increased NHGU to a maximum rate of approximately 4.3 mg/kg/min after only 
60 min, demonstrating that the portal signal activates the liver much more quickly than 
would otherwise be the case in its absence [208, 219]. Likewise, dissipation of the 
hepatic response to portal glucose delivery is equally as rapid (≈ 15 min) upon removal of 
the portal glucose signal [194]. 
Further evidence supporting the involvement of the nervous system in the effect 
of portal glucose delivery on NHGU was provided by Shiota and colleagues [219], in 
which they conducted a study to shed light on which branch of the autonomic nervous 
system (sympathetic or parasympathetic) was associated with the response of the liver to 
the portal glucose signal. Under conditions of hyperglycemia and hyperinsulinemia, 
pharmacologic blockade of α,β-adrenergic receptors by means of intraportal infusion of 
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phentolamine and propranolol did not result in an increase in NHGU. On the other hand, 
the combination of adrenergic blockade and cholinergic stimulation by means of 
intraportal infusion of acetylcholine resulted in an increase in NHGU of 1.8 mg/kg/min in 
the presence of hyperinsulinemia and hyperglycemia, but not portal glucose delivery 
[219]. These data imply a role for the parasympathetic nervous system in mediating the 
effects of portal glucose delivery on NHGU. However, Cardin et al. [220] and 
DiCostanzo et al. [221] later found that halting electrical transmission in the vagus nerves 
by vagal cooling had no effect on NHGU in the presence of hyperinsulinemia, 
hyperglycemia, and portal glucose delivery. Thus, the afferent limb of the vagus nerve is 
not likely to be involved in the response of the liver to portal glucose delivery. Other 
studies have highlighted a potential role for changes in nitric oxide [222-224] and 
serotonin [225-227] signaling in mediating the effects of the portal glucose signal on 
NHGU. Nevertheless, the precise mechanism(s) by which portal glucose delivery 
coordinates changes in hepatic glucose metabolism in the postprandial state are 
incompletely understood.  
 
Mechanism of Action of the Portal Glucose Signal 
Given that the metabolic response of the liver to portal glucose delivery is rapid 
(NHGU is maximally stimulated 15 min after initiation of intraportal glucose infusion), 
its biochemical mechanism of action cannot be explained by changes in gene expression. 
Pagliassotti et al. [198] demonstrated rapid activation of liver glycogen synthase in 
response to portal glucose delivery, even in the presence of basal insulin concentrations. 
Rapid stimulation of NHGU in the presence of portal glucose infusion might result in an 
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increase in hepatocellular glucose-6-phosphate concentrations, which is a potent 
allosteric activator of phosphorylated glycogen synthase. Thus, the portal signal increases 
the provision of substrate needed for glycogen synthesis, and directs a significant 
proportion of that substrate into glycogen by activating glycogen synthase, with the 
remaining carbon leaving the liver as lactate [198]. Rapid activation of liver glycogen 
synthase by portal glucose delivery might also be neurally-mediated. Afferent fibers in 
the hepatic branch of the vagus nerve can detect the glucose concentration in the hepatic 
portal vein, and previous studies have demonstrated that electrical stimulation of the 
efferent limb of the vagus nerve activates liver GS [215, 228-230]. Thus, the biochemical 
mechanism of action of the portal glucose signal might also be neurally-mediated.  
Given the magnitude of the increase in NHGU in response to portal glucose 
delivery, it is likely that other mechanisms in addition to rapid activation of glycogen 
synthase are involved. One potential target through which the portal signal might exert its 
effects is hepatic glucokinase (GK). Indeed, phosphorylation of glucose by GK is thought 
to be rate-limiting for HGU [231, 232]. Under basal conditions, GK is sequestered in the 
nucleus in a catalytically inactive, super-open conformation via binding by its regulatory 
protein, GKRP; under hyperglycemic and/or hyperinsulinemic conditions, GK dissociates 
from GKRP and translocates to the cytoplasm where it catalyzes the phosphorylation of 
glucose [122, 123, 162, 233-235]. In addition, hyperglycemia stimulates the transition of 
GK from a super-open conformation to a closed conformation, corresponding to the high 
affinity, catalytically active form of GK [122, 234-237].  Given that GLUT2 is a high 
capacity, low affinity glucose transporter that is expressed at a high level in the liver, the 
transport step for glucose into the hepatocyte is not rate-limiting [238]. As a result, 
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fluctuations in extracellular blood glucose levels are immediately followed by parallel 
changes in intracellular glucose levels, which are monitored by GK [122]. Thus, the rapid 
effects of portal glucose delivery on NHGU might also be mediated by stimulation of the 
translocation of GK from the nucleus to the cytosol secondary to a rise in the portal vein 
blood glucose level [26, 233]. In Specific Aim III, one of our goals is to identify the acute 
molecular changes associated with increased HGU and GSYN in response to portal 
glucose delivery per se in normal dogs.   
  
Impaired Regulation of Splanchnic Glucose Uptake with Diabetes 
Postprandial hyperglycemia is one of the sequelae of diabetes that contributes to 
the elevation of hemoglobin A1c associated with the disease [24, 25]. It is due in part to 
inappropriate suppression of hepatic glucose production (HGP) coupled with inadequate 
stimulation of HGU, highlighting the key role of the liver in regulating postprandial 
glucose metabolism [200, 202-204, 239-243]. Indeed, splanchnic (which comprises the 
gut and liver tissues) glucose uptake (SGU) and hepatic GSYN through the direct 
pathway were markedly diminished in type 2 diabetic subjects compared to non-diabetic 
controls despite equivalent elevations in plasma insulin and glucose during a clamp 
experiment [200, 201, 244]. Furthermore, delivery of glucose into the portal venous 
circulation (by way of enteral glucose infusion) in the presence of hyperinsulinemia was 
ineffective in normalizing the diminished rates of SGU and GSYN in diabetic subjects 
[200]. Given that type 2 diabetic subjects displayed a decrease in the contribution of 
extracellular glucose to the UDP-glucose pool, the authors [200, 201] speculated that that 
a defect in GK was linked to the aberrant hepatic response in type 2 diabetic individuals. 
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Indeed, a reduction in hepatic GK expression has been reported previously in morbidly 
obese type 2 diabetic humans [245] and in genetic rodent models of obese, type 2 
diabetes [246]. The critical role of GK in maintaining whole-body glucose homeostasis is 
exemplified in subjects with autosomal dominant mutations on one or two alleles of the 
GK gene, resulting in a moderate to severe form of diabetes, respectively, called 
maturity-onset diabetes of the young, Type 2 (MODY) [247-250]. These individuals 
display fasting hyperglycemia, and impaired glucose uptake and hepatic GSYN in 
response to hyperinsulinemia and hyperglycemia [250]. Likewise, animal models with a 
liver specific deletion of GK have mild fasting hyperglycemia, markedly impaired 
glucose tolerance, and significantly decreased hepatic GSYN under hyperglycemic 
conditions [251]. On the other hand, transgenic overexpression of hepatic GK lowers 
postprandial hyperglycemia in normal rats [252], improves hepatic glucose flux and 
fasting plasma glucose levels in 20-week-old Zucker diabetic fatty (ZDF) rats [246], and 
renders mice resistant to the development of obesity-induced type 2 diabetes when fed a 
high-fat diet [253].  
Altogether, these data indicate that the diabetic liver is resistant to the hormonal 
and glycemic cues that are characteristic of the postprandial state, and suggest that 
impaired regulation of hepatic GK might be a common pathogenic factor underlying 
disturbances in postprandial hepatic glucose flux and glycogen synthesis with diabetes. 
However, the temporal manifestation of impaired HGU along the continuum of 
worsening insulin action that occurs with type 2 diabetes is poorly understood. Likewise, 
the cellular events associated with a diminished response of the liver to hyperinsulinemia, 
hyperglycemia, and portal glucose delivery under insulin resistant conditions have not 
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been clearly defined.  
 
Specific Aims 
 
The overall objective of this body of work is to elucidate the metabolic and 
hepatocellular consequences associated with chronic consumption of a high-fat and/or 
high-fructose diet, focusing on perturbations in the regulation of hepatic glucose uptake 
and disposition by hyperglycemia, hyperinsulinemia, and portal vein glucose delivery – 
the primary determinants of hepatic glucose uptake in vivo [26]. The following Specific 
Aims were designed to investigate these issues. 
 
Specific Aim I: To determine the temporal impact of high-fat/high-fructose feeding – 
with or without partial pancreatic resection – on glucose tolerance, whole-body insulin 
sensitivity, and net hepatic glucose uptake (NHGU). 
The objective of Specific Aim I was to investigate the influence of a high-
fat/high-fructose diet (HFFD; 52% of energy from fat / 17% of energy from fructose) on, 
1) the temporal development of insulin resistance and impaired glucose tolerance in the 
presence or absence of a compromised endocrine pancreas, and 2) the ability of the liver 
to take up glucose under conditions that mimic the postprandial state (e.g. 
hyperinsulinemia, hyperglycemia, and portal vein glucose delivery). Partial 
pancreatectomies (≈ 65% resection) were carried out with the intent to develop a large 
animal model of type 2 diabetes when coupled with a HFFD, thereby mimicking the 
natural progression and metabolic characteristics of the human disease. Prior to initiation 
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of the HFFD or chow control diet (CTR), baseline metabolic assessments of glucose 
tolerance and whole-body insulin sensitivity were acquired by performing oral glucose 
tolerance tests (OGTTs) and hyperinsulinemic euglycemic (HIEG) clamps, respectively. 
The OGTTs were repeated after 4 and 8 weeks of HFFD or CTR feeding, whereas the 
HIEG clamps were repeated after 10 weeks of feeding. Finally, hyperinsulinemic 
hyperglycemic clamps with portal vein glucose delivery were performed after 13 weeks 
of HFFD or CTR feeding in order to assess NHGU and net glycogen synthesis during 
conditions that mimic the postprandial state.  Specific Aim I enabled us to characterize 
the temporal manifestation of perturbations in glucose metabolism and whole-body 
insulin sensitivity in a large animal model upon exposure to a HFFD, which mimics a 
typical Western diet. 
 
Specific Aim II: To delineate the impact of a HFFD on the response of the 
gastrointestinal tract, endocrine pancreas, liver, and peripheral tissues to an orally-
administered, liquid mixed meal. 
In Specific Aim I, the metabolic consequences associated with HFFD feeding 
were detected in response to a glucose challenge, which lacked other meal-associated 
factors that can influence the gastric emptying rate, insulin and glucagon secretion, and 
NHGU. Administration of a standard mixed meal has been proposed as a more 
physiological challenge to the system. In view of these considerations, experiments were 
conducted in the conscious dog to determine if 8 weeks of HFFD feeding, 1) impairs 
NHGU in a non-clamped, mixed meal setting, 2) impairs insulin secretion in the presence 
of other insulin secretagogues (e.g. amino and fatty acids), 3) affects the acute lipid 
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response to a mixed meal and, 4) alters gastrointestinal function and/or meal 
macronutrient absorption. Specific Aim II enabled us to expose defects in hepatic and 
extrahepatic tissues in response to a more physiological mixed meal challenge, which 
contributed to our understanding of the mechanisms responsible for impaired glucose 
tolerance after chronic consumption of a HFFD.  
 
Specific Aim III: To elucidate the physiologic and hepatocellular effects of the portal 
glucose signal per se during conditions that mimic the postprandial state, following short-
term exposure to a HFFD or chow control (CTR) diet. 
Specific Aim I revealed impaired glucose tolerance after only 4 weeks of HFFD 
feeding. Hepatic glucose uptake was not measured at 4 weeks, but was impaired when 
measured after longer-term (i.e. 13 weeks) consumption of a HFFD. Given the vital role 
of the liver in the disposition of an oral glucose load, we hypothesized that impaired 
HGU was already present at 4 weeks of HFFD feeding, and was responsible in part for 
the exaggerated glycemic response to an oral glucose challenge. Thus, one of the 
objectives of Specific Aim III was to determine if 4 weeks of HFFD feeding is sufficient 
to impair HGU under hyperinsulinemic hyperglycemic conditions. In addition, Specific 
Aim I revealed that portal glucose delivery was incapable of stimulating a switch from 
net hepatic glucose output (NHGO) to NHGU after 13 weeks of HFFD feeding. Thus, we 
hypothesized that HFFD feeding precipitated the loss of an intact portal signaling 
mechanism, but the cellular changes associated with portal glucose delivery in normal 
dogs have not been clearly defined, and the cellular changes associated with resistance to 
the stimulatory effects of hyperinsulinema, hyperglycemia, and portal glucose delivery in 
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HFFD-fed dogs are not known. Thus, another objective of Specific Aim III was to 
identify the molecular “signature” of the portal glucose signal per se in the presence of a 
physiologic rise in glucose and insulin. Furthermore, we wanted to elucidate the cellular 
explanation for the defect in HGU associated with HFFD feeding, and whether that 
cellular defect persists in the presence of the portal glucose signal after only 4 weeks of 
HFFD feeding. Specific Aim III enabled us to delineate the molecular changes associated 
with hyperinsulinemia, hyperglycemia, and portal glucose delivery per se in CTR-fed and 
HFFD-fed dogs.  
 
Specific Aim IV: To compare the physiologic and hepatocellular effects of high dietary 
fat vs. fructose on HGU and glycogen synthesis (GSYN) during conditions that mimic 
the postprandial state.  
The observation that HFFD feeding significantly impaired HGU posed the 
question of whether excess dietary fat, fructose, or both are required to elicit aberrant 
hepatic glucose flux under conditions that mimic the postprandial state. We hypothesized 
that their individual effects on hepatic glucose flux would be additive. Thus, the objective 
of Specific Aim IV was to delineate the relative contribution (when consumed 
isoenergetically) of high dietary fat vs. fructose (17% of total energy) to impaired HGU 
and GSYN after 4 weeks of feeding.  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Animal Care and Surgical Procedures 
 
Animal Care 
Experiments were conducted on 18- (Specific Aims I, III, and IV) or 24-h 
(Specific Aims I and II) fasted conscious male mongrel dogs that had been fed once daily 
a specific experimental diet (see Table 2.1). Water was available ad libitum, whereas a 
fixed quantity of food was provided each day. All facilities met the standards published 
by the American Association for the Accreditation of Laboratory Animal Care, and the 
Vanderbilt University Medical Center Animal Care and Use Committee approved all 
protocols. 
 
Surgical Procedures 
Hepatic Catheterization 
Approximately 16 days prior to the hyperinsulinemic hyperglycemic pancreatic 
clamp study, a sterile laparotomy was performed on each dog under general anesthesia. A 
surgical plane of anesthesia was induced with propofol (5.0 mg/kg, intravenous or I.V.) 
preceded 30 minutes by Glycopyrolate/Buprenex (0.01/0.02 mg/kg subcutaneous or 
S.C.). A S.C. injection of Cephazolin (10 mg/kg) was also administered to the dog pre-
operatively. Following induction, the animal was immediately intubated with an 8.5 mm 
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inner diameter (ID) endotracheal tube (Concord/Portex, Kenee, NH), and ventilated with 
a tidal volume of 400 ml at a rate of 14 breaths per minute. The plane of anesthesia was 
maintained by inhalation of 1.5-2.0% isoflurane with oxygen. A laparotomy was 
performed by making a midline incision 1.5 cm caudal to the xyphoid process through 
the skin, subcutaneous layers, and linea alba, and extending caudally 15-20 cm. A portion 
of the jejunum was exposed and a branch of a jejunal vein was selected for cannulation. 
A small section of the vessel was exposed by blunt dissection and ligated with 4-0 silk 
(Ethicon, Inc, Sommerville, NJ). A silastic infusion catheter (0.04 in ID; HelixMedical, 
Carpintera, CA) was inserted into the vessel through a small incision and advanced 
anterograde until the tip of the catheter lay approximately 1 cm proximal to the 
coalescence of two jejunal veins. A portion of the spleen was retracted and another 
silastic catheter (0.04 in ID) was inserted into a distal branch of the splenic vein and 
advanced until the tip of the catheter lay 1 cm beyond the bifurcation of the main splenic 
vein. The catheters were secured in place with 4-0 silk, filled with saline (Baxter 
Healthcare Corp, Deerfield, IL) containing 200 U/ml heparin (Abbott Laboratories, North 
Chicago, IL), knotted and placed in a subcutaneous pocket prior to closure of the skin. 
These catheters were used for intraportal infusion of pancreatic hormones (insulin and 
glucagon).   
The central and left lateral lobes of the liver were retracted cephalically and 
caudally, respectively. The left common hepatic vein and the left branch of the portal 
vein were exposed. A 14-gauge angiocath (Benton Dickinson Vascular Access, Sandy, 
UT) was inserted in the left branch of the portal vein 2 cm from the central lobe of the 
liver. A silastic catheter (0.04 in ID) for blood sampling was inserted into the hole created 
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by the angiocath, advanced retrograde about 4 cm into the portal vein so that the tip of the 
catheter lay 1 cm beyond the bifurcation of the main portal vein. It was then secured with 
three ties of 4-0 silk through the adventitia of the vessel and around the catheter. Another 
angiocath was inserted into the left common hepatic vein 2 cm from its exit from the left 
lateral lobe. A silastic sampling catheter was inserted into the hole and advanced 
antegrade 2 cm and secured into place with three ties of 4-0 silk. The sampling catheters 
were filled with heparinized saline, knotted and placed in a subcutaneous pocket, with 
excess catheter looped within the peritoneum. These catheters were used for the 
acquisition of blood samples from the hepatic portal vein and hepatic vein, respectively. 
An arterial sampling catheter was inserted into the left femoral artery following a 
cut-down in the left inguinal region. A 2 cm incision was made parallel to the vessel. The 
femoral artery was isolated and ligated distally, and a sampling catheter (0.04 in ID) was 
inserted and advanced 16 cm in order to place the tip of the catheter in the abdominal 
aorta. The arterial catheter was secured and filled with a mixture of heparin and glycerin 
(1000 U/ml in a 1:1 ratio), while its free end was knotted and placed in a subcutaneous 
pocket prior to closure of the skin. This catheter was used for the sampling of arterial 
blood.  
Sections of the portal vein and hepatic artery were exposed by retracting the 
duodenum laterally. A small section of the portal vein was exposed by blunt dissection 
taking care not to disturb the nerve bundle located on the vessel. A 6 or 8 mm ID 
ultrasonic flow probe (Transonic Systems Inc, Ithaca, NY) was placed around the vessel.  
A small portion of the common hepatic artery was also carefully exposed and a 3 mm ID 
ultrasonic flow probe was secured around the vessel. The flow probes were used to 
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determine portal vein and hepatic artery blood flow during experiments. To prevent blood 
from entering the portal vein beyond the site of the flow probe, the gastroduodenal vein 
was isolated and ligated. Blood that would normally flow through the gastroduodenal 
vein was shunted through the caudal pancreatoduodenal vein draining the tail of the 
pancreas. The ultrasonic flow probe leads were positioned in the abdominal cavity, 
secured to the abdominal wall, and placed in a subcutaneous pocket prior to closure of the 
abdominal skin.    
The subcutaneous layer was closed with a continuous suture of 3-0 Vicryl 
(Ethicon, Inc). The skin was closed with horizontal mattress sutures of 3-0 Ethilon 
(Ethicon, Inc.). Metacam (0.2 mg/kg S.C.) was administered 30 minutes prior to surgical 
recovery for actue pain relief. Animals awoke from surgery within 2 h, were active, and 
ate normally approximately 8 h after surgery.  For 3 post-operative days, dogs received 
10 mg/kg Simplicef (Pfizer Animal Health, New York City, NY) orally, once a day. 
Partial Pancreatectomy  
Prior to commencing the HFFD in Specific Aims I and II, each dog underwent a 
laparotomy in which a sham operation (Sh; n=13) or a partial pancreatectomy (Px, 
approximately 65% removal; n=11) was performed. The Px was utilized as a surgical tool 
to compromise endocrine pancreatic function in the hope that, when coupled with a 
dietary insult, a diabetic phenotype would emerge that mimicked the metabolic 
characteristics of type 2 diabetes. Briefly, the pancreatic-duodenal artery and vein were 
isolated along with isolation of the right lobe of the pancreas from its mesenteric 
connections. The right lobe was ligated and transected at the union of the right lobe 
caudal extremity and the distal duodenum while preserving the venous and arterial 
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vasculature of the duodenum. The pancreatico-duodenal artery and vein were ligated and 
transected at the distal end of the lobe and the right pancreatic lobe was removed. Next, 
the pancreatico-splenic arteries and veins were identified and isolated.  The left lobe was 
ligated and transected at the union with the pylorus in the apical portion of the pancreas.  
The mesenteric and omental connections and the arterial and venous vasculature 
supplying the left lobe were ligated and transected, and the left pancreatic lobe was 
removed. Approximately 35% of the pancreas remained in place with intact exocrine and 
biliary tree function.  
All dogs studied had: 1) leukocyte count <18,000/mm3, 2) a hematocrit >35%, 3) 
a good appetite, and 4) normal stools at the time of study.  On the morning of the clamp 
experiment, the free ends of the catheters and ultrasonic leads were removed from their 
subcutaneous pockets under local anesthesia (2% lidocaine; Abbott Laboratories, North 
Chicago, IL). The contents of each catheter were aspirated, and flushed with saline. Blunt 
needles (18 gauge; Monoject, St. Louis, MO) were inserted into the catheter ends, and 
stopcocks (Medex, Inc, Hilliard, OH) were attached to prevent the backflow of blood 
between sampling times. Twenty gauge Angiocaths (Beckton Dickson) were inserted 
percutaneously into the left and right cephalic and saphenous veins for the infusion of 
labeled (3-[3H]-glucose; left cephalic) and unlabeled (50% dextrose; right cephalic) 
glucose, para-aminohippuric acid (Specific Aims I, III, and IV; PAH; right saphenous), 
and somatostatin (SRIF; left saphenous). A continuous infusion of heparinized saline was 
started via the femoral artery at a rate to prevent blood clotting in the line. For oral 
glucose tolerance tests and hyperinsulinemic euglycemic clamp experiments (OGTTs and 
HIEGs, respectively; Specific Aim I), deep venous sampling catheters (19 ga catheter, 
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adjustable up to 18 in; MILA International Inc., Erlanger, KY) were inserted into the left 
or right saphenous vein and advanced 30 cm to reach inferior vena cava. Animals were 
allowed to rest quietly in a Pavlov harness for 30 min before commencing the 
experiment.  
 
Experimental Diets  
Table 2.1: Macronutrient compositions of experimental diets utilized in Specific Aims I-
IV.  
Percentage of Total Energy Macronutrient 
CTR HFFD HFA HFR 
Fat 26.0 52.0 52.0 26.0 
Protein 31.0 22.0 22.0 26.0 
Carbohydrate 43.0 26.0 26.0 48.0 
Starch 41.0 8.5 21.0 24.0 
Glucose <1.0 <0.1 <0.1 <0.1 
Fructose <1.0 17.0 <0.1 17.0 
Sucrose 1.3 <1.0 <1.0 <1.0 
Lactose <1.0 <1.0 <1.0 <1.0 
Mean Daily 
Energy Intake 
(kcal/day) 
2000 ± 30 3200 ± 70 2800 ± 50 2800 ± 20 
 
Dogs were fed once daily a pre-determined quantity (to match daily energy intake 
in HFFD, HFA, and HFR) of one of the following diets: 1) meat (Kal Kan, Franklin, TN) 
and laboratory chow diet (Laboratory Canine Diet 5006, chunk form; Control or CTR); 2) 
high-fat/high-fructose diet (5A4J, short cut pellet form; HFFD); 3) high-fat diet 
(modification of 5A4J with cornstarch replacing fructose, short cut pellet form; HFA); 4) 
high-fructose diet (modification of 5A4J with lower fat content, short cut pellet form; 
HFR). PMI Nutrition TestDiet in St. Louis, MO produced each diet. The feeding 
paradigms for each Specific Aim are outlined in Table 2.2.  
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Table 2.2: Experimental diet assignment, feeding duration (weeks), and sample size (n) 
for Specific Aims I-IV. 
Specific Aim Diet 
I II III IV 
CTR 13 weeks (Sh, n=4) 
8 weeks 
(n=5) 
4 weeks 
(n=15) 
4 weeks 
(n=5) 
13 weeks 
HFFD (Sh, n=4; Px, 
n=6) 
8 weeks 
(n=5) 
4 weeks 
(n=16) ------- 
HFA ------- ------- ------- 4 weeks (n=5) 
HFR ------- ------- ------- 4 weeks (n=5) 
 
 
Collection and Processing of Samples 
 
Blood Samples 
Before the start of the experiment, a blood sample was drawn and used for the 
preparation of PAH standards and hormone infusions when applicable. During the study, 
blood samples were drawn from the femoral artery and portal and hepatic veins at the 
predetermined sampling points indicated in the experimental protocols. Prior to 
acquisition of the blood sample, the respective sampling catheter was cleared of saline by 
withdrawing 5 ml of blood into a syringe. The blood sample was then drawn using a 
separate syringe, after which the cleared blood was re-infusesd into the animal, and the 
catheter was flushed with heparinized saline (1U/ml; Abbott Laboratories, North 
Chicago, IL). In addition, whenever the experimental design required a glucose clamp, 
small (~0.5 ml) arterial or deep venous blood samples were drawn every 5 min for 
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assessment of the plasma glucose concentration. When samples were taken from all three 
vessels, the arterial and portal blood samples were collected simultaneously ~30 s before 
the collection of the hepatic venous sample in an attempt to compensate for the transit 
time through the liver, and thus allow the most accurate estimates of net hepatic substrate 
balance [254]. The total volume of blood withdrawn did not exceed 20% of the animal’s 
blood volume, and two volumes of saline were given for each volume of blood 
withdrawn. No significant decrease in hematocrit occurred with this procedure. 
Immediately following sample collection, the blood was processed. A small 
artieral aliquot (20 µl) was used for the assessment of hematocrit in duplicate using 
capillary tubes (0.4 mm ID; Drumond Scientific Co., Broomall, PA). The remaining 
blood was quickly placed into tubes containing potassium ethylenediaminetetraacetate 
(EDTA, 1.6 mg EDTA/ml; Sarstedt, Newton, NC), inverted and mixed gently. One-half 
ml of whole blood was removed from the above tube and lysed with 1.5 ml of 4% 
perchloric acid (PCA; Fisher Scientific, Fair Lawn, New Jersey). The solution was 
vortexed, centrifuged, and the supernatant was stored for later determination of whole-
blood metabolites (alanine, glycerol, and lactate). For Specific Aim II, 1 ml of whole 
blood was added to a tube containing 10 µl of DPP-IV inhibitor (Linco Research, St. 
Charles, MO) to ensure the integrity of the GLP-1. This aliquot was then centrifuged, and 
the supernatant was stored on dry ice for later determination of plasma GLP-1 levels. The 
remainder of the whole blood containing EDTA was centrifuged at 3000 rpm for 6 
minutes at 4°C to obtain plasma. 
 Four to eight 10µl aliquots of plasma from each sample were immediately 
analyzed for glucose using the glucose oxidase technique in a glucose analyzer (Analox 
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Instruments, London, U.K.) A 1 ml aliquot of plasma received 50 l of 10,000 KIU/ml 
Trasylol (aprotinin; FBA Pharmaceuticals, New York, NY), a protease inhibitor, and was 
stored for analysis of immunoreactive glucagon and c-peptide. A 10µl aliquot of 
tetrahydrolipstatin (THL, Xenical; Roche Pharmaceuticals, Nutley, NJ) was added to a 
0.5 ml aliquot of plasma for the measurement of non-esterified free fatty acid (NEFA) 
concentrations. To ensure that the assessment of portal venous plasma insulin 
concentrations was on the linear range of the insulin assay standard curve, 400µl of portal 
vein plasma was mixed with 400µl of insulin assay buffer for a 1:1 dilution. The 
remainder of the plasma was used for analysis of 3-[3H]-glucose (in triplicate), total 
triglycerides, and cortisol. All samples were kept in an ice bath during the experiment and 
were then stored at -80C until the assays were performed. Plasma samples for the 
assessment of 3-[3H]-glucose were deproteinized according to the method of Somogyi-
Nelson [255-257]. Briefly, 1 ml aliquots of saline and plasma (0.5 ml saline + 0.5 ml 
plasma) were mixed with 5 ml of 0.067 N Ba(OH)2 and 5 ml of 0.067 N ZnSO2 (Sigma 
Chemical). Samples were shaken and stored at 4C for 1-3 days prior to processing.  
 
Tissue Samples 
Immediately after the final sample was attained, each animal was anesthetized 
with an I.V. injection of sodium pentobarbital (390 mg/ml Fatal-Plus; Vortech 
Pharmaceutical Inc., Dearborn, MI) at 125 mg/kg. The animal was then removed from 
the Pavlov harness while the tracers, hormones, and glucose continued to infuse. A 
midline laparotomy incision was made, the liver was exposed, and clamps cooled in 
liquid nitrogen were used to simultaneously freeze portions of the left central, left lateral, 
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and right central hepatic lobes in situ. The hepatic tissue was immediately immersed in 
liquid nitrogen, and stored at -80C. Approximately two minutes elapsed between the 
time of anesthesia and the time of tissue sampling.  All animals were then euthanized. 
 
Sample Analysis 
 
Whole Blood Metabolites 
Whole blood metabolite concentrations were determined using the methods 
developed by Lloyd et al. [258] for the Technicon Autoanalyzer (Tarrytown, NY) and 
were modified to the Packard Multi Probe Robotic Liquid Handline System (Perkin 
Elmer; Shelton, CT). Enzymes and coenzymes for metabolic analyses were obtained 
from Boehringer-Mannheim Biochemicals (Germany) and Sigma Chemicals. These 
assays rely upon a reaction in which NAD (oxidized) is reduced to NADH. In contrast to 
the oxidized form, NADH has a native fluorescence; as the reaction proceeds and NADH 
is produced, the system detects changes in fluorescence via a fluorometer incorporated in 
the system. Thus, the concentration of the metabolite in a given sample is proportional to 
the amount of NADH produced.  
Metabolites were measured in the PCA-treated blood samples as described under 
Collection and Processing of Samples. A standard curve was constructed for each 
metabolite using known concentrations of the analyte prepared in 3% PCA. The Packard 
Multi Probe Robotic Liquid Handling System pipettes the sample into one well of a 96 
well pate. For the analysis of alanine and glycerol, an initial reading is taken, after which 
the system pipettes enzyme solution into each well, shakes the plate to ensure adequate 
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mixing of the sample and enzyme, and the reaction then proceeds. After a designated 
period of time, the change in absorbance is recorded. When lactate is assayed, an 
intermediate reading is taken half way through the run, and then another reading is 
obtained at the end. Excluding glycerol kinase, all assay reactions are reversible. 
However, the NAD and enzyme are in excess compared to the substrate, thus the 
reactions are essentially taken to completion with the substrate being the rate-limiting 
component. As a result, all reactions written below are presented with a single direction 
arrow. All reactions were carried out at 23°C.  
Alanine 
The alanine assay involved the reaction: 
 
       alanine dehydrogenase  
L-alanine + NAD+ + H2O -------------------------------> Pyruvate + NADH + NH4+              (1)   
 
The enzyme buffer used was 0.05 M trizma base, 2 mM EDTA and 1 mM hydrazine 
hydrate, pH 10. To 10 ml of enzyme buffer, 4.6 mg of NAD and 3.4 Units (U) of alanine 
dehydrogenase were added. 
Glycerol 
The glycerol assay involved the following reactions: 
glycerol kinase 
glycerol + ATP --------------------------------> glycerol-l-phosphate + ADP    (2) 
 
 
     glycerol-3-phosphate dehydrogenase 
L-glycerol-l-phosphate + NAD+ -----> dihydroxyacetone phosphate + NADH + H+ (3) 
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The enzyme buffer was 0.09 M glycine, 1 mM hydrazine, and 0.01 M MgC12, pH 9.5. To 
10 ml of the enzyme buffer, 15.4 g NAD, 15.4 mg ATP, 0.3 U glycerokinase, and 0.6 U 
glycerol-3-phosphate dehydrogenase were added. 
Lactate 
The lactate assay involved the following reaction: 
                                 lactate dehydrogenase 
lactate + NAD+ ----------------------------------------> pyruvate + NADH + H+ (4) 
 
  
The enzyme buffer used was 0.24 M glycine and 0.25 M of hydrazine dihydrochloride 
and 7 mM disodium EDTA, pH 9.6. To 10 ml of enzyme buffer, 4.6 mg NAD and 0.1 U 
lactate dehydrogenase were added.  
 
Plasma Metabolites 
Plasma Glucose 
Plasma glucose concentrations were determined using the glucose oxidase method 
[259] with a glucose analyzer (Analox Instruments, Lunenburg, MA). The reaction 
sequence was as follows: 
                                       glucose oxidase 
ß-D-glucose + O2 ----------------------------------> gluconic acid and H2O2 (5) 
 
                                         catalase 
H2O2 + ethanol -------------------------------------> acetaldehyde + H2O  (6) 
 
                                        molybdate 
H2O2 + 2H+ +2I- ------------------------------------> I2 + 2 H2O (7) 
  
 
The plasma glucose concentration is proportional to the rate of oxygen consumption, and 
the glucose level in a plasma sample is determined by comparison of the oxygen 
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consumption in the samples with the rate of oxygen consumption by a standard solution.  
The second and third reactions quickly remove all hydrogen peroxide so that there is no 
end-product inhibition of the process. Glucose was measured 4 times at each sampling 
time point for each vessel and a minimum of 2 times for samples drawn to clamp glucose. 
The glucose analyzer is accurate to 450 mg/dl.  
Plasma 3-[3H]-glucose 
 For determination of plasma 3-[3H]-glucose, samples were deproteinized 
according to the method of Somogyi-Nelson [255-257]. Immediately following each 
experiment, three 1 ml aliquots of plasma + saline (1:1) from each sample were mixed 
with 5 ml of 0.067 N Ba(OH)2 and 5 ml of 0.067 N ZnSO2 (Sigma Chemical). These 
samples were kept at 4°C for 1-3 days, after which they were centrifuged at 3000 rpm for 
30 min. A 5 ml aliquot of the supernatant was pipetted into a glass scintillation vial and 
placed in a heated vacuum oven to evaporate 3H2O. The residue was reconstituted in 1 ml 
of deionized water and 10 ml liquid scintillation fluid (EcoLite (+); Research Product 
Division, Costa Mesa, CA), and placed in Beckman LS 9000 Liquid Scintillation Counter 
(Beckman Instruments Inc, Irvine, CA). The counter was programmed so that the 
processor corrected the counts per minute (cpm) for quenching of the radioactivity in the 
sample, and presented the data as disintegrations per minute (dpm). To assess for the loss 
of labeled glucose during the deproteinizaiton step, a recovery standard was creasted. The 
3-[3H]-glucose infusate was diluted 1:250 (v:v) with saturated benzoic acid. Six, 1 ml 
aliquots of this diluted 3H infusate were placed into 2 sets of glass scinitallation vials and 
were labeled as chemical standard evaporated (CSE) or chemical standard (CS). The 
diluted infusate aliquots in the CSE vials were evaporated to dryness in a heated vacuum 
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oven, reconstituted with 1 ml of deionized water plus 10 ml of scintillation fluid and 
counted. The diluted infusate aliquots in the CS vials were not evaporated, but had 
scintillation fluid added and were counted. Three additional 1 ml aliquots of diluted 3H 
infusate were treated in a manner identical to the plasma samples and labeled chemical 
recovery standard (CRS). Comparison of the CS and CSE provided an evaluation of the 
loss of 3H counts in the evaporation process. The ratio of radioactivity in the CSE 
samples compared to the CRS samples generated a recovery factor that was used to 
determine the final radioactivity by accounting for the loss during sample processing. 
Non-esterified fatty acids 
Plasma non-esterified fatty acids were determined spectrophotometrically using 
the Packard Multi probe Robotic Liquid Handling System (Perkin Elmer; Shelton, CT) 
and a kit from Wako Chemicals (Richmond, VA). The following reactions were used in 
the analysis: 
 acyl-CoA synthetase 
NEFA + ATP + CoA ----------------------------> acyl-CoA + AMP + PPi  (8)  
 
                acyl-CoA oxidase 
acyl-CoA + 02 ---------------------------> 2,3-trans-enoyl-CoA + H202 (9) 
 
                                                                                       peroxidase  
2H202 + 3 methyl-N-ethyl-N-(ß-hydroxyethyl)-aniline + 4-aminoantipyrine ---------------> 
 
purple color adduct (10)  
 
The purple colored adduct optical density was measured at 550 nm and is proportional to 
the NEFA concentration in the sample. The NEFA values were then obtained from a 
calibration curve with known amounts of oleic acid. This reaction was run at 37°C. 
 
 72 
Triglycerides 
Plasma triglyceride levels were assessed by the enzymatic measurement of 
glycerol, true triglycerides, and total triglycerides in plasma using the Spectramax Plus 
384 (Molecular Device Corp. Sunnyvale, CA) and the Serum Triglyceride Determination 
Kit (Sigma, St. Louis, MI). The assay was performed in a 96 well plate. The procedure 
involves enzymatic hydrolysis of triglycerides by lipoprotein lipase to free fatty acids 
(FFA) and glycerol. Glycerol is then phosphorylated by glycerol kinase and adenosine-
5’-triphosphoate (ATP) resulting in the production of glycerol-1-phosphate (G1P) and 
adenosine-5’-diphosphate (ADP). G1P is then oxidized by glycerol phosphate oxidase 
(GPO) to dihydroxyacetone phosphate (DAP) and hydrogen peroxide (H2O2).  H2O2 is 
then coupled with 4-aminoantipyrine(4-AAP) and sodium N-ethyl-N-(3-sulfopropyl)-
anisiden (ESPA) producing quinoneimine dye (absorbance 540 nm). The increase in 
absorbance is directly proportional to the triglyceride levels of the plasma sample. The 
assay was run at 37°C. The triglyceride concentrations were calculated using a calibration 
curve of known amounts of glycerol. The specific reactions were as follows: 
       Lipoprotein lipase 
Triglycerides ----------------------------------- > Glycerol + FFA              (11) 
 
         Glycerol kinase 
Glycerol + ATP -------------------------------- > G1P + ADP     (12) 
 
         GPO 
G1P + O2 ---------------------------------------- > DAP + H2O2    (13) 
 
 
Hormones 
 The plasma hormone levels of insulin, glucagon, cortisol, and c-peptide were 
measured using radioimmunoassay (RIA) techniques [260]. Briefly, a plasma sample 
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containing an unknown amount of hormone was incubated with an antibody specific for 
that hormone.  A known amount of radiolabeled hormone was added to the mixture to 
compete with the antibody binding sites.  A double antibody procedure (single antibody 
procedure for cortisol), which caused precipitation of the bound complex, was used to 
separate unbound hormone from the antibody-hormone complexes.  The radioactivity of 
the precipitate was measured via a Cobra II Gamma Coutner (Packard Instrument Co, 
Meriden, CT). The binding of the radiolabeled hormone was inversely proportional to the 
amount of unlabeled hormone present.  A standard curve was constructed using known 
concentrations of the unlabelled hormone.   
Insulin 
Immunoreactive plasma insulin was measured using a double-antibody RIA 
procedure [261]. Insulin antibodies and 125I tracers were obtained from Linco Research 
Inc. (St. Charles, MO). A 100 µl aliquot of the plasma sample was incubated 18h at 4°C 
with 200 µl of 125I-labeled insulin and 100 µl guinea pig specific antibody to insulin. The 
sample was then treated with 100 µl goat anti-guinea pig IgG (2nd antibody) and 100 µl 
IgG carrier and incubated for 30 min at 4°C. One ml of a wash buffer was added, and the 
tubes were centrifuged at 3000 rpm. The liquid portion of the samples was decanted and 
the remaining pellet containing the total radioactivity bound to the antibody was counted 
in a Cobra II Gamma Counter. The log of the amount of hormone in the samples was 
inversely proportional to the log (bound label/free label). The insulin concentration in 
each sample was determined by comparison to a standard curve constructed using known 
amounts of unlabeled hormone. The samples were corrected for non-specific binding. 
The sample detection range was 1-150 µU/ml. The specificity of the antibody is 100% to 
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porcine, canine, and human insulin, but cross-reacts with bovine insulin (90%), human 
proinsulin (38%), and the split proinsulin products Des 31,32 (47%) and Des 64,65 
(72%). In general, less than 15% of the basal insulin level is due to non-insulin material. 
The antibody has no cross-reactivity with glucagon, pancreatic polypeptide, C-peptide, or 
somatostatin. The recovery for the assay was between 90-100% and the interassay CV 
was approximately 7-8% for the entire range of the dose response curve.  
Glucagon 
Immunoreactive glucagon was measured using a double antibody insulin RIA 
[262]. The protocol utilized primary and secondary antibodies specific for glucagon. 
Glucagon antibodies and 125I tracers were obtained from Linco Research (St. Louis, MO). 
A 100 µl aliquot of the plasma sample was incubated for 24 hours at 4oC with 100 µl of 
guinea pig specific antibody to glucagon. Next, 100 µl of 125I-labeled glucagon was 
added to the solution and incubated for 24 h at 4°C. Afterwards, the samples were 
incubated for 2 h at 4°C with 100µl of both goat anti-guinea pig IgG (2nd antibody) and 
IgG carrier. One ml of a wash buffer was added and the tubes were centrifuged at 3000 
rpm. The samples were decanted and the portion of total radioactivity bound to the 
antibody (pellet) was counted in a Cobra II Gamma Counter. The log of the amount of 
hormone in the sample was inversely proportional to the log (bound label/free label). The 
glucagon concentration in each sample was determined by comparison to a standard 
curve constructed using known amounts of unlabeled hormone. The samples were 
corrected for non-specific binding. The sample detection range was 20-400 ng/l. The 
antibody is 100% specific to glucagon with only slight (0.01 %) cross reactivity to 
oxyntomodulin, and no cross reactivity with human insulin, human proinsulin, human C-
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peptide, glucagon-like petide-1, somatostatin or pancreatic polypeptide. However, due to 
a cross-reacting protein effect, this assay reads 15-20 pg/ml above the actual glucagon 
level, representing a stable, constant background in all samples. The recovery for the 
assay was between 80-100%, and the interassay CV was approximately 6-10% for the 
entire range of the dose response curve. 
C-peptide 
 Canine C-peptide was measured using a double antibody disequilibrium 
procedure similar to that used for glucagon [263]. Kits containing canine C-peptide 
antibody and 125I tracer were obtained from Linco Research (St. Louis, MO). A 100 µl 
aliquot of the plasma sample was incubated for 24 h at 4°C with 100 µl of guinea pig-
specific antibody to canine C-peptide. Then, 100 µl of 125I-labled canine C-peptide was 
added and incubated for 24 h at 4°C, after which the sample was incubated with 1 ml of 
precipitating agent containing anti-guinea pig IgG (2nd antibody) and IgG carrier for 30 
min at 4°C. Tubes were centrifuged, decanted, and the portion of total radioactivity 
bound to the antibody (pellet) was counted in a Cobra II Gamma Counter. The log of the 
amount of hormone in the sample was inversely proportional to the log (bound label/free 
label).  The C-peptide concentration in each sample was determined by comparison to 
standards dissolved in plasma using known amounts of unlabeled hormone. Samples 
were corrected for non-specific binding. The sample detection range was 0.1-10 ng/ml. 
The antibody is 100% specific for canine C-peptide with no cross-reactivity to rat C-
peptide, human C-peptide, human proinsulin, bovine proinsulin, porcine proinsulin, or 
glucagon. The recovery of the assay was approximately 90%. 
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Glucagon-like Peptide-1 (GLP-1) 
 For Specific Aim II, plasma GLP-1 levels were determined using an enzyme-
linked immunosorbent assay (ELISA) kit (Linco Research, Inc.) A 100 µl aliquot of 
plasma (pretreated with DPP-IV inhibitor as described in Collection and Processing of 
Samples) and 100 µl of assay buffer were manusally pipetted into a well of a 96-well 
plate, bound with monoclonal antibodies specific to the N-terminal region of active GLP-
1 molecules, and incubated at 4°C overnight. After a series of washes, 200 ml of methyl 
umbelliferyl phosphate (MUP) was added and incubated in the dark for 25 min at room 
temperature. MUP, in the presence of alkaline phosphatase, forms the fluorescent product 
umbelliferone. This reaction was stopped with 50 µl of stop buffer. Immediatley after 
stop solution was added, excitation/emission wavelength was read at 365/450 nm on a 
fluorescence plate reader (Packard Fusion, PerkinElmer, Waltham, MA). 
 All samples were pipetted in duplicate, and read by the plate reader three times. 
The amount of fluorescence generated was directly proportional to the concentration of 
active GLP-1 in the sample. Quantification of plasma GLP-1 levels was derived from a 
standard curve run on the same plate as the samples. This assay is highly specific for 
active forms of GLP-1 [GLP-1 (7-36) amide and GLP-1 (7-37)], with no cross-reactivity 
to other forms of GLP-1 (e.g., 1-36 amide, 1-37, 9-36 amide, 9-37), and is reliable in a 
range of 2-100 pM. 
 
Acetaminophen 
 For Specific Aim II, arterial plasma acetaminophen levels were measured using a 
modified protocol designed for high performace liquid chromatography (HPLC) [264]. A 
 77 
500 ml aliquot of plasma was spiked with 20 µl of 2-acetaminophenol (40 µg/ml) to 
serve as an interna standard [265]. Equal volumes of spiked plasma, 0.3 N barium 
hydroxide, and 0.3 N zinc sulfate were mixed and incubated on ice for 5 min. The sample 
was then spun at 4°C at 3000 rpm for 10 min. The dcanted supernatant was dried using 
vacuum centrifugation (Speedvac Concentrator, Savant SVC 200H, Thermo Scientific, 
Waltham, MA). The sample was then reconstituted with 200 µl of a 10% methanol/water 
solution (v:v). A 50 µl aliquot was injected for delivery into the HPLC column 
(uBondapak C18 3.9x30 w/guard), at a temperature of 45°C. The mobile phase A (5% 
methanol/water, v:v) and B (15% methanol/water, v:v) were set at a combined flow rate 
of 0.4 ml/min for the entire duration of the assay. With the profile curve indicating the 
type of transition from one setting to the next, the gradient for the mobile phae was set as 
follows: initial setting at 100% A, 0 profile curve; t=4 min at 100% A, 11 profile curve; 
t=20 min at 75% A, 25% B, 6 profile curve; t=30 min at 100% B, 7 profile curve; t=40 
min at 100% A, 11 profile curve. The total run time was 64 min, with an 18 min 
acquisition delay. Fluorescence was measured with variable wavelength UV detector 
(Waters 481, Millipore, Billerica, MA) set at 240 nm at 0.5 AUFS. 
 Peak area as identified by the ESA 500 Chromatograph and data station are 
representative of acetaminophen concentration. Peak area increases in a linear fashion, 
proportional to acetaminophen concentration. Thus, sample concentration is determined 
as a ratio of acetaminophen peak area in the sample to internal standard peak area. This 
assay has been validated up to concentrations of 40µg/ml.  
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Hepatic Blood Flow 
Total hepatic blood flow in the hepatic artery and portal vein was measured by 
use of ultrasonic flow probes (Transonic Systems Inc, Ithaca, NY) that were implanted 
during surgery, as described in Surgical Procedures. Ultrasonic flow measurements 
demonstrated instantaneous variations in velocity and provided blood flow in individual 
vessels. This method determines the mean transit time of an ultrasonic signal passed back 
and forth between two transducers within a probe that are located upstream and 
downstream of the direction of blood flow in the vessel. The transducers are made of 
piezoelectric material, which is both capable of receiving and transmitting the ultrasonic 
signal. The downstream transducer emits an ultrasonic pulse into the blood vessel that is 
received upstream by a second transducer. After the upstream transducer receives the 
ultrasonic signal, it re-emits the ultrasonic pulse signal back to the downstream 
transducer. The transit time of each ultrasonic beam, as measured by the upstream and 
downstream transducers (ΔTup and ΔTdown, respectively) is defined by the following 
relationships: 
ΔTup = D / (vo - vx)              (14) 
ΔTdown = D / (vo + vx) (15) 
where D is the distance traveled by the ultrasonic beam within the acoustic window of the 
probe, vo is the phase velocity, or the speed of sound, in blood, and vx is the component 
of fluid velocity that is parallel or antiparallel to the phase velocity. The parallel 
component augments the phase velocity when the signal is traveling in the same direction 
of blood flow, while the antiparallel component subtracts from phase velocity if the 
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ultrasonic signal is moving against the flow of blood in the vessel. Combining the two 
expressions for transit time yields the following equation: 
ΔTup - ΔTdown = [D / (vo - vx )] – [D / (vo + vx )] (16) 
Since the transit times measured by both transducers, the distance traveled by the beam, 
and the speed of sound in blood are all known quantities, this equation can be used to 
calculate vx. Once vx is attained, the transit velocity (V) of blood traveling through the 
vessel can be determined according to the following equation:  
V cos θ = vx (17) 
where θ is the angle between the centerline of the vessel and the ultrasonic beam axis.  
Finally, the product of the transit velocity and the cross-sectional area of the vessel 
determine blood flow. The cross-sectional area of the vessel is pre-determined by the size 
of the acoustic window according the probe model. Since transit time is sampled at all 
points across the diameter of the vessel, volume flow is independent of the flow velocity 
profile. 
 
Liver Tissue Analysis 
 
Liver Glycogen Content 
 Liver glycogen content was determined using a modification of the method of 
Keppler and Decker [266]. Frozen liver tissue was ground and weighed (180-200 mg) 
while kept chilled with liquid nitrogen. The tissue weight (mg) was multiplied by 5 to 
determine the volume (ml) of 0.6 N PCA to be used. The tissue was combined with the 
PCA then thoroughly homogenized. A 200µl aliquot was then combined with 100µl 
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KHCO3 to neutralize the sample.  A 500µl aliquot of amyloglucosidase in sodium acetate 
solution (2 mg amyloglucosidase / ml 0.4 M sodium acetate buffer) was incubated in a 
shaker bath at 40°C for 2 hrs.  Glycogen concentration was calculated by subtracting the 
glucose concentration in duplicate samples not treated with the enzyme from samples 
incubated with amyloglucosidase. [3H]-glycogen counts were determined in the 
supernatant after evaporation, reconstitution, and counting as discussed previously for 
determination of plasma 3-[3H]-glucose. 
 
Liver Total Triglyceride Content 
 Approximately 100 mg of tissue was homogenized in chloroform/methanol (2:1 
v/v) and the lipids were extracted using a modified method of Folch-Lees [267]. The 
homogenates were then filtered through sharkskin filter paper. 0.1 M potassium chloride 
was added to separate the chloroform and methanol layers. The chloroform phase was 
removed, dried down, and the individual classes of lipids were separated by thin layer 
chromatography using a Silica Gel 60 A plate developed in acetic acid (80:20:1), ethyl 
ether, and petroleum ether, and visualized by rhodamine 6G. Phospholipids and 
acylglycerol bands were scraped from the plates and methylated using boron 
trifluoride/methanol as described by Morrison and Smith [268]. Methylated fatty acids 
were extracted and analyzed by gas chromatography. Gas chromatographic analysis was 
carried out on an HP 5890 gas chromatograph equipped with flame ionization detectors, 
an HP 3365 Chemstation, and a capillary column (SP2380, 0.25 mm x 30 m, 0.25 µm 
film, Supelco, Bellefonte, PA). Helium was used as a carrier gas. Fatty acid methyl esters 
were identified by comparing the retention times to those of known standards. Inclusion 
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of lipid standards with odd chain fatty acids permitted quantification of the amount of 
lipid in the sample. Standards used were dipentadecanoyl phosphatidycholine (C15:0) 
and trieicosenoin (C20:1).  
 
RNA Extraction, cDNA Synthesis, and Real-Time PCR  
Total RNA was extracted by homogenizing 50 mg of canine liver in 1 mL of Tri-reagent 
(Sigma, St. Louis, MO) following the manufacturer’s instructions. The RNA pellet was 
dissolved in nuclease-free TE buffer (where from). The purity of the RNA in solution 
was verified based on A260/A280 ratios greater than 1.8, whereas the integrity of the 
RNA was verified using ethidium bromide-stained agarose gels. First strand cDNA was 
synthesized from 1 µg of total RNA using the High Capacity reverse transcription kit 
(ABI, Foster City, CA) as per manufacturer’s directions, and cDNA was stored at -80°C 
until use. Primers were designed and analyzed using Premier Biosoft International 
Beacon Designer Software (Palo Alto, CA). Real-time PCR primer specificity was 
determined by BLAST analysis. Primer efficiencies were validated to be between 91-
96%, and primer specificity was confirmed by melt curve analysis. The sequences of 
canine primer pairs were as follows: GK, 5’-CAGAGGGGACTTTGAAATG-3’ and 5’-
ATGAATCCTTACCCACAATC-3’; RPL13, 5’-GCCGGAAGGTTGTAGTCGT-3’ and 
5’-GGAGGAAGGCCAGGTAATTC-3’. Real-time PCR analysis was performed using a 
BioRad iCycler Detection System (CFX96) with iQ SYBR Green Supermix fluorophore 
(BioRad) and the following protocol: step 1, 95ºC for 3 min (1x); step 2, 95ºC for 10 s; 
step 3, 55ºC for 30 s (steps 2 and 3 were repeated 39 x). Reactions were initiated by 
adding 100 ng of cDNA template to 25 µL total reaction mix, which consisted of the 
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following: 12.5 µL iQ SYBR Green Supermix, 2 µL of 5 µM forward primer (0.4 µM 
final concentration), 2 µL of 5 µM reverse primer (0.4 µM final concentration), 6.5 µL 
nuclease free water, and 2 µL cDNA template.  Target genes were normalized to RPL13 
(reference gene) using the Livak method [269], and expressed relative to basal CTR 
animals. Melt curve analysis was performed after every run and samples were run in 
duplicate. Relative gene expression data comprise the average of 2 to 3 runs per target 
gene. In addition, gene expression analysis was performed on liver tissue from the left 
central and left lateral lobes because they represent approximately 50% of the total liver 
mass of the dog.  
 
Western Blotting 
 Frozen liver tissue (~50 mg) was combined with 1 ml of homogenizing buffer 
(pH 7.2; 20 mM Tris, 200 mM NaCL, 50 mM NaF, 1 mM EDTA, 1 mM EGTA, 10% v:v 
glycerol, 10 ul/ml buffer of phosphatase inhibitor cocktail 1 and 2, and protease inhibitor 
cocktail [Sigma; St. Louis, MO]) and thoroughly homogenized. Tissue homogenates 
were centrifuged at 12,000 g for 15 min, after which the supernatants were removed and 
soluble protein concentration was determined using the BioRad Protein Assay (BioRad; 
Hercules, CA). Aliquots of supernatant were mixed 1:1 (v:v) with freshly prepared 2X 
SDS-PAGE loading buffer (100 mM Tris-HCl pH 6.8, 4% w:v SDS, 20% v:v glycerol, 
0.2% w:v bromophenol blue, 10% v:v 2-mercaptoethanol), and denatured at ~85-90°C 
for 10 min. Samples were subjected to SDS-PAGE (4-12% resolving gel) for ~ 2 hrs at 
180 V, followed by transfer to nitrocellulose membranes for 1.5 hrs at 60 V.  
Nitrocellulose membranes, SDS-PAGE, and wet-transfer reagents were supplied by 
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Invitrogen (Carlsbad, CA). Membranes were blocked for 1 hr at room temperature in 5% 
(w:v) bovine serum albumin in Tris-buffered saline containing Tween 20 (TBS-T: 10 
mM Tris-base pH 7.0, 150 mM NaCl, 0.2% v:v Tween 20). Upon blocking, membranes 
were incubated overnight with the appropriate primary antibody at 4°C. After 3 x 5 min 
washes with TBS-T, membranes were incubated with HRP-conjugated secondary 
antibody (Promega, Madison, WI) for 1 hr at room temperature, followed by 3 x 5 min 
washes in TBS-T. Proteins were visualized using ECL Plus Western detection reagents 
(GE Healthcare, Piscataway, NJ), and the ECL signals were detected after brief (1-60 
sec) exposure to X-ray film (BioMax Light X-ray films, Kodak, Chalon-sur-Saone, 
France). Bands were quantified via densitometric analysis using ImageJ software 
(http://rsb.info.nih.gov/ij/), and the intensity of the target protein signal was normalized 
against that of β -Actin. Antibodies specific for phosphorylated Akt (Ser473), GSK3β 
(Ser9), and GS (ser641) were purchased from Cell Signaling Technology, Inc. (Danvers, 
MA), whereas the GKRP and actin antibodies were purchased from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA). The GK antibody was a gift from Dr. Masakazu 
Shiota (Vanderbilt University School of Medicine, Molecular Physiology & Biophysics 
Department). The following antibody dilutions were used: GK and GKRP, 1:10,000; Akt 
(Ser473), GSK3β (Ser9), GS (Ser 641), and Actin, 1:5000. Relative protein data comprise 
the average of 2 to 3 western blots per test protein. In addition, western blotting 
experiments were performed on liver tissue from the left central and left lateral lobes 
because they represent approximately 50% of the total liver mass of the dog. 
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Glucokinase Activity 
To assess the catalytic activity of hepatic glucokinase (GK) [270], 200 mg of 
freeze-clamped liver was homogenized in 2 ml of buffer containing 50 mmol/l HEPES, 
100 mmol/l KCl, 1 mmol/l EDTA, 5 mmol/l MgCl2, and 2.5 mmol/l dithioerythritol. 
Homogenates were centrifuged at 100,000g for 45 min to sediment the microsomal 
fraction. The post-microsomal fraction (10 µl) was assayed in 1 ml of incubation buffer 
(37°C, pH 7.4) containing 50 mmol/l HEPES, 100 mmol/l KCl, 7.5 mmol/l MgCl2, 5 
mmol/l ATP, 2.5 mmol/l dithioerythritol, 10 mg/ml albumin, 0.5, 8, and 100 mmol/l 
glucose, 0.5 mmol/l NAD+, and 4 units/ml of G-6-P dehydrogenase (Leuconostoc 
mesenteroides). The reaction was initiated by the addition of ATP, and the rate of NAD+ 
reduction was recorded at 340 nm for 30 min. Glucose phosphorylation by GK was 
determined as the absorbance change in the presence of 8 or 100 mmol/l glucose minus 
the absorbance change in the presence of 0.5 mmol/l glucose under conditions in which 
the absorbance was increasing linearly between 10 and 30 min. This assay is not 
reflective of the subcellular compartmentation of GK or its association with GK 
regulatory protein.  
 
Glycogen Synthase and Phosphorylase Activity 
 Hepatic glycogen synthase (GS) activity was determined by measuring the 
incorporation of [14C]-glucose from UDP-[14C]-glucose into glycogen in the absence or 
presence of 7.2 mM glucose-6-phosphate [271]. Glycogen phosphorylase (GP) activity 
was assayed by measuring the incorporation of [14C]-glucose from [14C]-glucose-1-
phosphate into glycogen in the absence or presence of 2 mM AMP [272]. Activity ratios 
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represent the activity measured in the absence divided by that in the presence of the 
allosteric effectors glucose-6-phosphate for GS or AMP for GP, and are indicative of the 
phosphoryaltion state of the enzyme. 
 
Calculations 
 
Net Hepatic Substrate Balance 
The net hepatic balance of a substrate (NHSB) was calculated as: 
NHSB = Loadout - Loadin (18) 
or the difference between the substrate load leaving the liver (Loadout) and the substrate 
load reaching the liver (Loadin). The Loadin was calculated according to the equation: 
Loadin = ([S]A x HABF) + ([S]PV x PVBF)     (19) 
where [S]A and [S]PV are arterial and portal venous blood substrate concentrations, 
respectively, and HABF, PVBF are hepatic artery and the portal vein blood/plasma flows, 
respectively. The Loadout was calculated according to the equation: 
Loadout = [S]HV x HBF (20) 
where [S]HV is the substrate concentration in the hepatic vein blood, and HBF is the total 
hepatic blood flow. Blood flows were used for all substrate balance calculations except 
NEFA balances, for which plasma flows were used. 
 
Net Gut Substrate Balance 
Net gut substrate balance (NGSB) was calculated as: 
NGSB = Loadoutgut - Loadingut (21) 
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or the difference between the substrate load leaving the gut (Loadoutgut) and the substrate 
load entering the gut (Loadingut). The Loadingut was calculated according to the equation: 
Loadingut = [S]A x PVBF     (22) 
Loadoutgut = [S]PV x PVBF                         (23) 
 
Net Hepatic Substrate Fractional Extraction 
Net substrate fractional extraction across the liver (NHSFE) was calculated as: 
NHSFE = NHSU / Loadin= (24) 
where NHSU is the net hepatic substrate uptake. 
 
Hepatic Sinusoidal Substrate Concentration 
 Hepatic sinusoidal substrate level (HSSL) was calculated as: 
HSSL = ([S]A x HABF/HBF) + ([H]PV x PVBF/HBF) (25) 
where [S]A and [S]PV are arterial and portal venous blood substrate concentrations, 
respectively, and HABF, PVBF, and HBF are hepatic artery, portal vein, and total hepatic 
blood flows, respectively.  
 
Glucose Mixing in the Portal Vein 
Technical issues associated with assessment of the responsiveness of the liver to 
portal glucose delivery, as well as our rationale for using a tracer-based method to 
quantify ‘committed’ unidirectional hepatic glucose uptake (HGU) for Specific Aims III 
and IV warrant discussion. When glucose is infused into the laminar flow of the hepatic 
portal vein, poor mixing of the blood with the portal glucose infusate can occur. 
 87 
Streaming of glucose in the portal vein results in random under- or over-recovery of the 
portal glucose infusate in the portal and hepatic vein blood samples, leading to variation 
in the estimate of net hepatic glucose uptake (NHGU). Historically, we have utilized the 
para-aminohippuric acid (PAH) method to assess for errors associated with poor mixing, 
given that PAH is not extracted by the liver or red blood cells and thus, should be 
quantitatively recovered in the portal and hepatic veins. Briefly, PAH is mixed with the 
portal glucose infusate such that the PAH infusion rate is 0.4 mg/kg/min. The 
concentration of PAH is then measured on whole-blood samples from arterial, portal 
venous, and hepatic venous blood [273]. The assay involves a 1:5 dilution (200 µl of 
metabolite sample + 800 µl of PAH reagent solution) of the blood sample in a reagent 
solution (10 g p-dimethyamino-benzaldehyde, 600 ml 95% ethanol, 40 ml 2N HCl, 
deionized H2O up to 1000 ml). Light absorbance of the diluted samples is then measured 
on a spectrophotometer at 465 nm, and compared with a standard curve containing 
increasing concentrations of PAH in blood drawn from the animal prior to the start of 
PAH infusion. The ratio between the recovery of PAH in portal and hepatic veins, and 
the actual intraportal PAH infusion rate is then used as an index of mixing of the 
intraportal glucose infusate with the blood entering and exiting the liver. A ratio of 1.0 
would represent perfect mixing.  
Our laboratory established criteria to define studies as “poorly mixed” if recovery 
of the infused PAH in the portal and/or hepatic veins was < 60% or > 140%. This does 
not necessarily mean that all studies that fit within those inclusion criteria were mixed; it 
just meant that we could not prove that they were not mixed. Historically, we lost 1 in 3 
studies due to poor mixing. In my experiments for Specific Aims III and IV, however, 
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mixing in the portal vein was poor such that, based on our own exclusion criteria by 
means of the PAH method, I would have lost 2 in 3 studies. Given the expense of each 
experiment, the fact that we knew we were going to have several diet groups with a 
relatively small sample size in each (n=5-6/group), and the fact that our primary endpoint 
was the calculation of ‘committed’ (because this method does not account for glucose 
cycling within the liver and thus, undestimates total HGU) unidirectional HGU, we 
wanted to develop a method that would, to the best of our ability, overcome errors in the 
assessment of HGU associated with poor mixing and thus, utilize our resources most 
effectively. Given that 3-[3H]-glucose (labeled) can be infused into a peripheral vein, it 
circulates through the heart before reaching peripheral tissues. As a result, labeled and 
unlabeled plasma glucose mix completely by the time they reach the liver. Thus, 
unidirectional HGU was calculated in Specific Aims III and IV using a tracer-based 
hepatic fractional extraction method. It should be noted that this method yields HGU 
rather than NHGU; however, values derived from either method will be equal when HGP 
is zero.   
 
Unidirectional Hepatic Glucose Uptake (Specific Aims III and IV) 
Unidirectional HGU (mg/kg/min) was calculated by multiplying the hepatic 
fractional extraction of [3H]-glucose (HFrExG*) by the hepatic glucose load (HGL; 
mg/kg/min). HFrExG* (unitless) was determined by dividing the hepatic [3H]-glucose 
balance by the hepatic [3H]-glucose load according to the following equation, 
G*H x BFH – [(G*A x BFA) + (G*P x BFP)]) / [(G*A x BFA) + (G*P x BFP)],  (26) 
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where G*A, G*P, and G*H represent [3H]-glucose values (dpm/ml) in the artery, portal, and 
hepatic veins, respectively, and BFA, BFP, and BFH represent blood flow (ml/kg/min as 
determined by the ultrasonic flow probes) in the hepatic artery, portal vein, and total 
liver, respectively. HGL was calculated according to the following equation, 
HGL = GA x BFH – GUG,         (27) 
where GA represents the unlabeled blood glucose concentration in the artery (mg/ml), 
BFH represents total hepatic blood flow (ml/kg/min), and GUG represents the uptake of 
glucose by the gut (mg/kg/min). GUG was calculated as follows, 
([G*A - G*P] / G*A) x (GA x BFP),        (28) 
where ([G*A - G*P] / G*A) represents the fractional extraction (unitless) of [3H]-glucose 
across the gut, GA represents the unlabeled blood glucose concentration (mg/ml) in the 
artery, and BFP represents blood flow (ml/kg/min) in the portal vein, respectively. 
Samples drawn for the measurement of [3H]-glucose in the arterial, portal, and hepatic 
vein plasma were assayed in triplicate to allow for precise determination of HFrExG* 
throughout the study.  
One of the assumptions of this method is that the characteristics of glucose entry 
into the erythrocyte are the same for labeled and unlabeled glucose. Based on this 
assumption, plasma [3H]-glucose was converted to blood [3H]-glucose by applying the 
same corrections factors (the mean of the ratio of the blood value to the plasma 
concentration [187, 279]) to labeled glucose as we do to unlabeled glucose (0.74 for all 
values because [3H]-glucose was infused peripherally). Nevertheless, calculation of HGU 
using plasma [3H]-glucose or whole blood-converted [3H]-glucose yielded very similar 
results.  
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Another assumption of this method is that HGU in response to portal glucose 
delivery would be similar in well mixed and poorly mixed studies. In other words, the 
rate of HGU would be similar whether all of the HGL was delivered to half the liver or to 
the whole liver. This assumption holds true as long as HGU does not become saturated in 
any one part of the liver. Given that previous studies [116] have reported NHGU rates as 
high as 12.0 mg/kg/min in the presence of intraportal fructose infusion, we believe this 
assumption is valid.  
 
Hepatic Glucose Production 
 Upon calculation of unidirectional HGU, hepatic glucose production (HGP) can 
then be determined by taking the difference between NHGB and HGU according to the 
following equation: 
HGP = NHGB – HGU,             (29) 
where NHGB and HGU represent net heptic glucose balance and tracer-determined 
unidirectional hepatic glucose uptake, respectively, as described under Net Hepatic 
Substrate Balance and Unidirectional Hepatic Glucose Uptake. One of the advantages of 
this method is that it provides an estimate of hepatic glucose production, as opposed to 
tracer-determined Ra, which provides an estimate of whole-body glucose production.  
 
Glucose Turnover 
The rates of glucose production (Ra) and glucose utilization (Rd) were calculated 
using Steele’s steady-state equation [274]. The glucose pool was initially primed with an 
injection of 3-[3H]-glucose, followed by a constant infusion of the tracer. By the 
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beginning of the control period the tracer (3-[3H]-glucose) and tracee (cold glucose) were 
in equilibrium so that the specific activity of glucose (SA = dpm glucose/mg glucose) 
was in a steady state. Ra and Rd were calculated according to the following equations:  
Ra = [I - N (dSA/dt)]/SA, and (30) 
Rd = Ra – (dN/dt) (31) 
where I is infusion rate of tracer (dpm/min), N is the pool size of glucose (mg) and t is 
time (min) [275]. In a steady state, when dSA/dt = 0, the Ra equation is simplified to: 
Ra = I/SA               (32) 
Only values obtained during the steady-state period of the clamp (during which the 
specific activities were constant) were used for the determination of glucose turnover.  In 
Specific Aim I, endogenous glucose production (endo Ra) was calculated as Ra – 
(peripheral glucose infusion rate + [portal glucose infusion rate x 1-net hepatic fractional 
glucose extraction]) [220]. Hepatic glucose uptake was estimated (est HGU) by 
subtracting NHGU from endo Ra (Specific Aim 1).  
 There are two major assumptions when using the isotope dilution method to 
determined whole-body glucose turnover: 1) labeled and unlabeled glucose molecules are 
assumed to be metabolized in the same manner, and 2) the label is assumd to be 
irreversibly lost [276]. It should also be noted that tracer-determined glucose production 
is slightly higher than hepatic glucose release, given that both the liver and the kidneys 
produce glucose. Although net kidney glucose balance in the postabsorptive state is near 
zero, the kidney has been estimated to contribute 5-15% to whole body endogenous 
glucose production [277]. 
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Net Hepatic Carbon Retention 
 Net hepatic carbon retention, an estimate of hepatic glycogen accretion, was 
calculated as the sum of the hepatic balances of glucose, lactate, alanine x 2 (to account 
for the contribution of amino acids other than alanine), and glycerol, with all factors in 
glucose equivalents as described and validated previously [222, 278-281]. It has the 
advantage of not being dependent upon an estimate of the pre-study glycogen content, 
which must be obtained from a separate set of fasted dogs.  
The direct contribution of plasma glucose to hepatic glycogen stores was 
estimated by dividing 3H-glycogen counts/g liver by the average arterial plasma 3H-
glucose specific activity present during the experimental period (dpm/g ÷ dpm/mg).  
 
Nonhepatic Glucose Uptake 
 Nonhepatic glucose uptake (Non-HGU) was calculated over time intervals by the 
following formula: 
Non-HGU = average total glucose infusion rate between T1 and T2 + (T1NHGB + 
T2NHGB)/2) - glucose mass change in the pool between T1 and T2                                (33) 
 
where T1 and T2 represent the time points for which Non-HGU is begin measured. Note 
that the ((T1NHGB + T2NHGB)/)2 term will be negative when the liver is taking up glucose 
in a net sense. The glucose mass change in the pool is calculated using the following 
equation: 
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Glucose mass change in the pool = ((([GA]T2 - [GA]T1) / 100) * ((0.22 * body wt in kg * 
1000 * 0.65) / body wt in kg)) / (T2-T1),      (34) 
where [GA] is the blood glucose concentration, T1 and T2 are the two end time points of 
the interval, 0.22 represents the volume of extracellular fluid (the volume of distribution) 
or 22% of the dog’s weight [282], and 0.65 represents the pool fraction [283]. 
 
Statistical Analysis 
All data are expressed as means ± standard error (SE). Time course data were 
analyzed with two-way repeated measures ANOVA (group x time), and one-way 
ANOVA was used for comparisons of other mean data. Post-hoc analysis was performed 
with Student-Newman-Keuls method. When only two values were compared, an 
independent student t-test was used. Statistical significance was accepted at P < 0.05. 
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CHAPTER III 
 
CHRONIC CONSUMPTION OF A HIGH-FAT/HIGH-FRUCTOSE DIET 
RENDERS THE LIVER INCAPABLE OF NET HEPATIC GLUCOSE UPTAKE 
 
(Adapted from Coate et al. Am J Physiol Endocrinol Metab 299:E887-E898, 2010) 
 
Aim 
Chronic consumption of a western diet, characterized by foods rich in sugar and 
abundant in total and saturated fat, has been suggested to play a role in the development 
of type 2 diabetes [28, 29, 143]. While the effects of high dietary fat or fructose on 
insulin’s ability to suppress hepatic glucose production have been extensively studied, 
their effects on hepatic glucose uptake and disposition have not been delineated. In 
addition, the combined effects of dietary fat and fructose, in quantities that mimic a 
western diet, on the temporal development of glucose intolerance and hepatic and/or 
peripheral insulin resistance are incompletely understood. Lastly, it is not known if high-
fat, high-fructose feeding coupled with an experimental reduction in beta cell mass 
(partial pancreatectomy) augments glucose intolerance to a larger extent than diet alone. 
Thus, the objective of Specific Aim I was to investigate how the combination of high 
dietary fat and fructose influences, 1) the temporal development of insulin resistance and 
impaired glucose tolerance in the presence or absence of a compromised endocrine 
pancreas, and 2) the ability of the liver to take up glucose under conditions that mimic the 
postprandial state (hyperinsulinemia, hyperglycemia and the portal glucose feeding 
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signal). 
 
Experimental Timeline (Figure 3.1) 
Prior to initiation of experimental diets (as described in Tables 2.1 and 2.2), baseline 
metabolic assessments of glucose tolerance and whole-body insulin sensitivity were 
attained by performing oral glucose tolerance tests (OGTTs) and hyperinsulinemic 
euglycemic (HIEG) clamps, respectively. The following week, each dog underwent a 
laparotomy in which a sham operation (Sh; n=8) or a partial pancreatectomy (Px; n=6) 
was performed, as described under Surgical Procedures in Chapter II. Post-operatively, 
dogs were randomly assigned to either the control (CTR: n=4) or high-fat, high-fructose 
diet (HFFD-Sh: n=4; HFFD-Px: n=6). OGTTs were repeated after 4 and 8 weeks of CTR 
or HFFD feeding, and HIEGs after 10 weeks of feeding. At week 11, dogs underwent a 
second laparotomy for hepatic catheterization and flow cuff placement, as described 
under Surgical Procedures in Chapter II. At week 13, hyperinsulinemic hyperglycemic 
clamps (HIHG) were performed, and net hepatic substrate balance was measured.  
 
Experimental Design 
 
Oral glucose tolerance tests (OGTTs) 
The OGTTs were conducted in 24-h-fasted dogs that had been fed 1 can of meat 
immediately prior to fasting. Following a 10 min basal control period, Polycose (0.9 g/kg 
body weight; Polycose, Abbott Nutrition; Columbus, OH) was administered orally and 
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plasma glucose, insulin, c-peptide and glucagon concentrations were monitored over the 
following 180 min.  
 
Hyperinsulinemic-euglycemic clamp (HIEG) 
The HIEGs were conducted in 18-h-fasted dogs that had been fed 1 can of meat 
just prior to initiation of the fast. The HIEGs consisted of a 90 min equilibration period (-
120 to -30 min), a 30 min basal control period (-30 to 0 min) and a 120 min experimental 
period (0 to 120 min). At time 0, a constant infusion of somatostatin (0.8 µg/kg/min; 
Bachem, Torrance, CA) was started in a peripheral vein in order to suppress endogenous 
insulin and glucagon secretion. Insulin (2.0 mU/kg/min; Lilly, Indianapolis, IN) and 
glucagon (0.7 ng/kg/min; Novo Nordisk, Princeton, NJ) were then replaced via infusion 
into a peripheral vein with a goal of increasing arterial insulin 10-fold while clamping 
glucagon at a basal value. In addition, at time 0, a variable IV infusion of 50% dextrose 
was started in a leg vein in order to maintain euglycemia (~100 mg/dl) throughout the 
study.  
 
Hyperinsulinemic-hyperglycemic clamp (HIHG) 
The HIHGs were conducted in 18-h-fasted adult male mongrel dogs that had been 
fed 1 can of meat just prior to initiation of the fast. Each experiment consisted of a 100 
min equilibration period (-120 to -20 min), a 20 min basal control period (-20 to 0 min), 
and a 180 min experimental period divided into 2 sub-periods (P1, 0 to 90 min; P2, 90 
to180 min). At -120 min, a priming dose of 3-[3H]-glucose (38 µCi) was given, followed 
by a constant infusion of 3-[3H]-glucose (0.38 µCi/min). At time 0, a constant infusion of 
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somatostatin (0.8 µg/kg/min) was started in a peripheral vein, and insulin and glucagon 
were then replaced intraportally at threefold basal (1.2 mU/kg/min) and basal (0.55 
ng/kg/min) rates, respectively. In addition, a variable infusion of 50% dextrose was 
started in a leg vein in order to double the arterial plasma glucose concentration (~220 
mg/dl) and the hepatic glucose load (HGL). In P2, 20% dextrose (4.0 mg/kg/min) was 
infused intraportally, and the peripheral glucose infusion rate was adjusted as necessary 
to clamp the HGL to that in P1. 
 
Results 
Oral glucose tolerance tests.  In the CTR group, glucose tolerance (assessed by the delta 
AUC for glucose over 180 min), insulin secretion (assessed by the delta AUC for c-
peptide over 180 min) and plasma insulin levels (assessed by the delta AUC for insulin 
over 180 min) seen in response to an oral glucose challenge were not different at 
baseline, or after 4 or 8 weeks of feeding (Figure 3.2), demonstrating the reproducibility 
of normal glucose tolerance in dogs maintained on a standard meat and chow diet. On the 
other hand, the glycemic response to an oral glucose challenge was significantly 
increased after HFFD feeding, as indicated by a 123% and 113% increase in the delta 
AUC for glucose in the HFFD-Sh and HFFD-Px groups, respectively, after 4 weeks of 
feeding, and a 106% and 147% increase in the HFFD-Sh and HFFD-Px groups, 
respectively, after 8 weeks of feeding (Figures 3.3A and 3.4A). The deterioration of 
glucose tolerance in the HFFD groups was attributable in part to a beta cell defect, given 
that a compensatory increase in insulin secretion, as indicated by c-peptide levels, failed 
to occur whether or not the pancreas was compromised (Figures 3.3B and 3.4B). As a 
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result, the delta AUC for insulin at 4 and 8 weeks was not significantly different from 
that observed in the baseline OGTT (Figures 3.3C and 3.4C) despite increased plasma 
glucose. In addition, while fasting plasma glucagon concentrations were similar between 
diet groups at BL, 4 and 8 weeks, the magnitude of the decrease in plasma glucagon 
during the 8 week OGTT was significantly less in both HFFD groups compared to CTR 
(pg/ml; HFFD-Px: 7±3 and HFFD-Sh: 13±5 vs. CTR: 29±8, P < 0.05) (Table 3.1), 
suggestive of impaired alpha cell function after HFFD feeding.  
Hyperinsulinemic-euglycemic clamps. Hyperinsulinemic-euglycemic (HIEG) clamp 
studies were performed at baseline (BL) and after 10 weeks of feeding. Plasma glucagon 
concentrations were clamped at basal levels while plasma insulin concentrations were 
elevated 10-fold from basal (Table 3.2). Plasma c-peptide levels fell to zero in each group 
secondary to somatostatin infusion. In the CTR group, the average (90-120 min) glucose 
infusion rate (GIR) required to maintain euglycemia was 19.9±3.4 and 17.6±1.3 
mg/kg/min during the BL- and 10wk-HIEGs, respectively (Figure 3.5A and C).  On the 
other hand, the average GIR (mg/kg/min) required to maintain euglycemia in the HFFD 
group was decreased by approximately 30% (BL: 18.9±0.9, 10wk: 13.9±0.7, P < 0.05 vs. 
BL) after 10 weeks of HFFD feeding (Figure 3.5B and C). Because the reduction in GIR 
after HFFD feeding was similar between the HFFD-Sh and HFFD-Px groups, the data 
from both groups were combined in Figure 3.5 (see figure legend 3.5). Despite use of the 
same insulin infusion rate (2.0 mU/kg/min), the steady-state plasma insulin concentration 
was higher in the HFFD group at week 10 compared to BL (µU/ml; BL: 112±16, 10wk: 
128±10) (Table 3.2). As a result, a 33% decrease in the GIR to insulin ratio was evident 
in the HFFD group after 10 weeks of feeding (Figure 3.5D). As expected, the elevation in 
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insulin elicited a rapid reduction in plasma NEFA levels, while plasma TGs tended to 
drift down throughout the experiment in each group at BL and 10 weeks (Table 3.2). 
There were no differences in plasma lipid levels between the CTR and HFFD groups at 
any time point.  
Hyperinsulinemic-hyperglycemic clamps.  
Hormone concentrations  
After 13 weeks of HFFD feeding, the fasting plasma arterial insulin (µU/ml; 
CTR: 8±2, HFFD: 11±1, P = 0.06) and glucagon (pg/ml; CTR: 33±4, HFFD: 48±5, P = 
0.06) concentrations tended to be elevated relative to those in the CTR group (Figure 
3.6A and C and Table 3.3). During the HIHG clamp, glucagon was maintained at a basal 
level while insulin was increased 3-4 fold (Figure 3.6 A-D).  
Plasma glucose concentrations and hepatic glucose load  
During the control period, arterial plasma glucose concentrations were 108±1 and 
106±1 mg/dl in the CTR and HFFD groups, respectively (Figure 3.7A). During P1, 
arterial plasma glucose was increased to 218±3 mg/dl in both groups in order to double 
the hepatic glucose load. The arterial plasma glucose concentrations were reduced 
slightly in both groups during P2 (mg/dl; CTR: 205±4, HFFD: 199±6) to maintain a 
doubling of the hepatic glucose load in the presence of portal glucose infusion. As a 
result, the hepatic glucose loads (mg/kg/min; CTR: 36±3, HFFD: 40±3) were similar 
throughout the experiment in both groups (Figure 3.7C).  
Net hepatic glucose balance (NHGB) 
Net hepatic glucose output in the control period (NHGO, mg/kg/min; CTR: 
1.6±0.2, HFFD: 1.8±0.3) was unaffected by diet (Figure 3.7D). Since NHGB after 13 
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weeks of HFFD feeding was similar in the HFFD-Px and HFFD-Sh groups (see figure 
legend 3.7), the data from both groups were combined in Figures 3.6 and 3.7. When 
challenged with hyperinsulinemia and hyperglycemia (P1), the CTR group switched from 
net glucose output to net glucose uptake (NHGU), reaching an average NHGU rate of -
1.8±0.8 mg/kg/min (last 30 min of P1, Figure 3.7D). The livers of dogs in the HFFD 
group, on the other hand, displayed an inability to consume glucose in the presence of 
hyperinsulinemia and hyperglycemia, as indicated by an average NHGO rate of 0.4±0.1 
mg/kg/min (last 30 min of P1, P < 0.05 vs. CTR, Figure 3.7D). When glucose was 
infused into the portal vein to activate the portal glucose signal (P2), there was a doubling 
of NHGU in the CTR group (-3.5±1.0 mg/kg/min during the last 30 min of P2, Figure 
3.7D). In contrast, portal glucose delivery in the HFFD group was unable to cause 
significant NHGU (-0.2±0.8 mg/kg/min during the last 30 min of P2, P < 0.05 vs. CTR, 
Figure 3.7D).  
Glucose turnover, glucose infusion rates, and nonhepatic glucose uptake 
In the CTR group during hyperinsulinemia and hyperglycemia (P1), the tracer-
determined rate of endogenous glucose appearance (endo Ra) decreased (mg/kg/min; 
Basal: 2.2±0.2, P1: 0.6±0.5, P < 0.05 vs. basal period) and the estimated rate of hepatic 
glucose uptake (est HGU) increased (mg/kg/min; Basal: 0.6±0.3, P1: 2.5±1.2) relative to 
the basal period (Table 3.4). In the presence of the portal glucose signal (P2), there was 
no further suppression of endo Ra (mg/kg/min; P2: 0.8±0.6), but the rate of est HGU 
significantly increased (mg/kg/min; P2: 4.3±1.3, P < 0.05 vs. basal). However, in the 
HFFD group, a significant decline in endo Ra was not observed until P2 (mg/kg/min; 
Basal: 2.4±0.2, P1: 1.7±0.2, P2: 0.4±0.2, P < 0.05 vs. basal period). Despite the presence 
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of the portal glucose signal, est HGU did not increase significantly (mg/kg/min; Basal: 
0.8±0.3, P1: 1.4±0.3, P2: 1.3±0.7, not significant [NS]) (Table 3.4). 
The GIR and the rate of nonhepatic glucose uptake (non-HGU) increased over 
time in both groups in response to hyperinsulinemia, hyperglycemia, and portal glucose 
delivery (Table 3.5 and Figure 3.7B). Given that NHGU was reduced by ≈ 3.0 mg/kg/min 
in the HFFD group compared to the CTR group, one might have expected a comparable 
decrease (≈ 30%) in the GIR in the HFFD group if peripheral insulin sensitivity was 
unchanged. However, the decrease in GIR was somewhat less than that (1.9 mg/kg/min 
or ≈ 20% reduction) indicating that a small increase occurred in the average non-HGU 
rate (mg/kg/min; CTR: 6.6±1.1, HFFD: 7.9±0.8). Furthermore, the rate of glucose 
disappearance (Rd) did not differ significantly among the CTR and HFFD groups during 
either experimental period (mg/kg/min; CTR, P1: 7.3±0.8, P2: 10±1.5; HFFD, P1: 
7.0±0.9, P2: 8.7±1.3) (Table 3.4). In fact, the difference in Rd between groups in P2 (1.3 
mg/kg/min) was similar to the difference in GIR in P2 (1.9 mg/kg/min). These data thus 
clearly indicate that the defect in glucose uptake occurred in the liver and not peripheral 
tissues. 
 Lactate, net hepatic carbon retention and glycogen metabolism 
During the control period, arterial blood lactate concentrations and net hepatic 
lactate uptake were similar in both groups (Table 3.5). However, in response to 
hyperinsulinemia, hyperglycemia and portal glucose delivery, there was a significant 
increase in the arterial blood lactate concentrations in the CTR group that resulted from a 
switch in net hepatic lactate balance from uptake to output (Table 3.5). In contrast, a 
switch from net hepatic lactate uptake to output did not occur at any time in the HFFD 
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group (Table 3.5). Likewise, net hepatic carbon retention (mg glucose 
equivalents/kg/min), an index of glycogen accretion, was lower in the HFFD group 
compared to the CTR group during P1 (CTR: 1.2±0.7; HFFD: -0.1±0.1 [net glycogen 
breakdown]). In response to portal glucose delivery, there was an increase in net hepatic 
carbon retention (mg glucose equivalents/kg/min) in the CTR group (1.9±0.3) coincident 
with a doubling in NHGU; however, this was not evident in the HFFD group (0.6±0.8), 
consistent with an inability of the portal signal to activate NHGU (Table 3.5). Although 
the terminal hepatic glycogen content was not significantly lower in the HFFD group (mg 
glycogen/g liver, CTR: 46±2; HFFD: 38±5 [data not shown]), glycogen synthesis via the 
direct pathway was (mg/kg/min; CTR: 1.5±0.4, HFFD: 0.5±0.2, P < 0.05 [data not 
shown]), consistent with a decrease in NHGU and net hepatic carbon retention in the 
HFFD group.  
Fat metabolism 
Arterial plasma free fatty acid (NEFA) and glycerol concentrations were similar 
between the HFFD and CTR groups during the basal control period (Table 3.5). In 
response to an elevation in arterial insulin (P1 and P2), an equivalent decrease in arterial 
plasma NEFA and blood glycerol concentrations was observed in the two groups. The net 
hepatic uptake rates of NEFA and glycerol were reduced in parallel to the changes in the 
levels of NEFA and glycerol in the blood (Table 3.5). 
 
Discussion 
The purpose of this study was to investigate, in a large animal model, how 
consumption of a high-fat, high-fructose diet (HFFD), coupled with a compromised 
 103 
pancreatic mass, influences the temporal development of impaired glucose tolerance, 
whole-body insulin resistance, and the ability of the liver to take up and store glucose in 
the presence of conditions that mimic the postprandial state. Utilization of the canine 
model enabled the longitudinal assessment of perturbations in glucose metabolism and 
insulin sensitivity at the whole-body and organ level, including the measurement of 
NHGU. Herein we report that 13 weeks of HFFD feeding rendered the liver incapable of 
NHGU despite the presence of hyperinsulinemia, hyperglycemia, and the portal glucose 
feeding signal.  
HFFD and the Liver 
The chow-fed control (CTR) group displayed normal glucose tolerance, as well as 
a rapid induction of NHGU in the presence of hyperinsulinemia and hyperglycemia, a 
response that was augmented even further in the presence of the portal glucose signal. 
Coincident with stimulation of NHGU, a significant increase in net hepatic carbon 
retention was observed. On the other hand, consumption of a HFFD resulted in impaired 
glucose tolerance (IGT) in a relatively short period of time (4 weeks) as indicated by 
more than a doubling in the delta AUC for glucose in response to an oral glucose 
challenge in both the HFFD-Sh and HFFD-Px groups. Given the vital role of the liver in 
the disposition of an oral glucose load [184], these data raise the possibility that a 
reduction in hepatic insulin sensitivity and/or hepatic glucose effectiveness (GE) 
contributed to the attenuation in glucose tolerance after 4 weeks of HFFD feeding. This is 
supported by our data from the hyperinsulinemic-hyperglycemic clamps which 
demonstrated that 13 wks of HFFD feeding rendered the liver incapable of switching 
from net glucose output to net glucose uptake in response to a combined increase in 
 104 
glucose and insulin. Glucose tracer kinetics indicated that this was attributable to a defect 
in both the suppression of glucose production and in the augmentation of hepatic glucose 
uptake. Consequently, net hepatic carbon retention and glycogen synthesis through the 
direct pathway were markedly diminished relative to the rates evident in the CTR group. 
Altogether, these data demonstrate that HFFD feeding elicits adverse metabolic effects 
characterized by a diminished ability of hyperinsulinemia and hyperglycemia to suppress 
hepatic glucose production, as well as an inability of the liver to consume glucose and 
synthesize glycogen under conditions that mimic the postprandial state.  
HFFD and Non-hepatic Tissues (Adipose and Skeletal Muscle) 
It was evident from the OGTTs that some degree of whole-body insulin resistance 
or reduced GE contributed to the attenuation in glucose tolerance, given that greater 
hyperglycemia existed in the HFFD group compared to the CTR group even though their 
insulin levels were virtually equivalent. Thus, hyperinsulinemic-euglycemic clamp 
(HIEG) experiments were conducted to assess changes in whole-body insulin sensitivity 
more precisely. Consistent with IGT, whole-body insulin resistance was evident in the 
HFFD group as indicated by a significant decrease (≈ 5.0 mg/kg/min) in the GIR required 
to maintain euglycemia after 10 weeks of feeding. Since tracers were not infused during 
the HIEG clamps, it is not known if the reduction in GIR was due to an impairment in the 
ability of insulin to suppress hepatic glucose production, stimulate glucose uptake in the 
liver and/or peripheral tissues (skeletal muscle and adipose tissue), or some combination 
of the two. The possibility exists that the reduction in GIR may have been accounted for 
solely by a decrease in hepatic, not peripheral, insulin sensitivity. For example, the GIR 
decreased by ≈ 5.0 mg/kg/min in the HFFD group, and by ≈ 2.0 mg/kg/min in the CTR 
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group after 10 weeks of feeding. The decrease in GIR in the CTR group was not 
statistically significant and did not impact glucose tolerance, whole-body insulin 
sensitivity or NHGU. If the decrease in GIR in the HFFD group was adjusted for the 
decrease observed in the CTR group, the signal size of the reduction in whole-body 
glucose utilization in the HFFD group would be ≈ 3.0 mg/kg/min. Given that hepatic 
glucose production under basal conditions is ≈ 2.5 mg/kg/min, and that the liver can take 
up a small amount of glucose even under euglycemic conditions (≈ 1.0 mg/kg/min), we 
think it is likely that the reduction in GIR seen after 10 weeks of HFFD feeding was 
explained primarily by a defect at the liver.  
Consistent with this notion, as stated earlier, the ability of hyperinsulinemia and 
hyperglycemia to suppress endo Ra and stimulate hepatic glucose uptake was 
significantly impaired after 13 weeks of HFFD feeding. On the other hand, the ability of 
insulin to stimulate skeletal muscle glucose uptake was normal if not improved, given 
that non-HGU was modestly elevated (20%) in the HFFD group compared to CTR during 
the HIHG clamps. The increase in non-HGU was likely related to the fact that the arterial 
insulin concentration was slightly higher in the HFFD group compared to the CTR group 
during insulin infusion. Indeed, when non-HGU was expressed relative to the arterial 
insulin concentration, the ratios were similar in the HFFD and CTR groups (HFFD: 
0.25±0.03; CTR: 0.28±0.08). Furthermore, although NHGU during P2 was decreased by 
3.3 mg/kg/min in the HFFD group compared to the CTR group, the reductions in whole-
body glucose Rd (1.3 mg/kg/min) and GIR (1.9 mg/kg/min) were nearly equivalent in 
magnitude and less than the change in NHGU, indicating that the ability of insulin and/or 
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glucose to stimulate non-HGU was enhanced despite a marked impairment in hepatic 
glucose uptake.  
Previous studies have suggested that diet-induced impairments in insulin action 
during euglycemia can be compensated for by enhanced glucose effectiveness during 
hyperglycemia. For example, Commerford et al [284] demonstrated in rodents that 
consumption of a high-fat or high-sucrose diet resulted in a decrease in insulin’s ability to 
suppress hepatic glucose production and stimulate whole-body glucose uptake during a 
hyperinsulinemic-euglycemic clamp, but during a hyperinsulinemic-hyperglycemic 
clamp, these parameters were restored to the rates observed in chow-fed controls. This 
was also demonstrated to be the case in insulin resistant, normoglycemic relatives of type 
2 diabetic patients, in which glucose disposal was increased during a hyperglycemic 
pancreatic clamp due in part to enhanced glucose effectiveness in the skeletal muscle 
[285].  Thus, it is possible that increased non-HGU in the HFFD group during the HIHG 
clamps was reflective of enhanced glucose effectiveness in the skeletal muscle in the 
presence of hyperglycemia. The absence of a defect in Non-HGU might be related to the 
fact that the dog does not develop fasting hyperglycemia or dyslipidemia when fed a 
HFFD. As a result, the dog does not develop gluco- or lipotoxicity. It is possible that 
these pathogenic processes need to be present in order to elicit a defect in skeletal muscle 
glucose uptake.    
With regard to adipose tissue, the ability of insulin to suppress lipolysis after 13 
weeks of HFFD feeding was also similar between the HFFD and CTR groups, as 
demonstrated by rapid and comparable reductions in arterial NEFA and glycerol 
concentrations in the presence of a 4-fold rise in plasma insulin. As a result, net hepatic 
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NEFA uptake was similar between groups and did not provide an explanation for the 
deficit in NHGU in the HFFD group.  
HFFD and the Endocrine Pancreas  
Consumption of a HFFD resulted in significantly augmented glycemia in response 
to an oral glucose challenge in both the HFFD-Sh and HFFD-Px groups after 4 and 8 
weeks of feeding. Based on the delta AUCs for c-peptide and insulin, it appeared as if the 
impairment in glucose tolerance was due in part to a beta cell defect given that insulin 
secretion was not enhanced relative to baseline studies despite a greater than 2-fold 
increase in glucose. To lend support to the observation that HFFD feeding impaired 
glucose tolerance due in part to a beta cell defect, a meta-analysis of all OGTTs 
performed over the last 3 years in our lab was conducted. Consistent with the findings of 
the current paper, HFFD feeding increased the delta AUC for glucose in response to an 
oral glucose challenge by 121% in sham pancreatectomized (n=5; P  < 0.05 vs. baseline 
OGTT) and 130% in pancreatectomized (n=10; P < 0.05 vs. baseline OGTT) dogs. On 
the other hand, the rise in insulin secretion (as indicated by the delta AUC for c-peptide 
following HFFD feeding vs. that observed during the baseline OGTT) was virtually 
unchanged in the either group (7% decrease in the sham group; 5% increase in 
pancreatectomized group). Although a decrease in beta cell mass and/or function could 
explain insufficient glucose-stimulated insulin secretion (GSIS) in response to an oral 
glucose challenge, the beta cell responses were similar in both HFFD groups regardless 
of partial pancreatic resection, suggesting that a defect in beta cell function, not mass, 
was associated with the lack of hyperinsulinemic compensation. In fact, it appears as 
though the surgical reduction (≈ 65%) in pancreatic mass was without significant effect, 
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which is consistent with earlier data. For example, Frey and colleagues [286] suggested 
that the development of diabetes following a partial pancreatectomy was directly related 
to the extent of pancreatic resection. In patients with otherwise normal pancreatic 
function, up to 80% of the pancreatic parenchyma could be removed without a change in 
metabolic status. On the other hand, near-total (80-95%) or total pancreatectomy resulted 
in 100% of the patients developing diabetes post-operatively [286, 287]. Studies 
conducted in rodents demonstrated that removal of 85-95% of the pancreas was required 
before hyperglycemia ensued, and even then, there was a heterogeneous hyperglycemic 
response, which correlated with the extent of pancreatic resection [288, 289]. Our hope 
was that the dietary insult might trigger a further reduction in beta cell function in HFFD-
fed dogs leading to the development of a diabetic phenotype, but that did not occur.  
Recently, Ionut et al. [290] characterized the development of IGT in a canine 
model of high-fat diet-induced obesity before and after streptozotocin [STZ]-induced beta 
cell destruction. In the absence of STZ, glucose tolerance was retained during high-fat 
feeding due to a compensatory increase in insulin secretion, whereas high-fat feeding 
coupled with an intermediate dose of STZ (18.5 mg/kg) resulted in impaired glucose 
tolerance due to a 77-93% reduction in beta cell function secondary to beta cell 
destruction [290]. In the present study, however, insulin secretion following an oral 
glucose challenge was impaired in both the HFFD-Sh and -Px groups, resulting in 
augmented glycemia. There are some key differences between the studies conducted by 
Ionut et al. [290] and those presented here. First, we utilized a surgical (partial 
pancreatectomy) rather than chemical (STZ) approach to create a pure model of 
compromised pancreatic mass so that any toxic, off-target effects of STZ could be 
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avoided (e.g. generation of highly reactive ions and DNA strand break within the beta 
cells) [291, 292]. In addition, after the initial hypercaloric phase, dogs in the present 
study consumed approximately 1600-2100 kcal/day, whereas caloric consumption by 
dogs in the study of Ionut et al. [290] exceeded 5000 kcal/day. Lastly, we utilized a high-
fat and high-fructose feeding paradigm to emulate consumption of a Western diet. High 
fructose feeding has been associated with a reduction in beta cell mass and an increase in 
the percentage of apoptotic cells, whereas high-fat feeding has been associated with a 
reduction in beta cell glucose oxidation and insufficient GSIS [293, 294]. It is possible 
that an interaction with the fructose component of the diet modified the impact of high 
dietary fat on whole-body insulin sensitivity and beta cell function in the current study. 
Just as STZ precipitated the development of impaired glucose tolerance secondary to beta 
cell destruction [290], so might an increase in dietary fructose impair beta cell function 
and glucose tolerance in the context of high-fat feeding.     
In addition, the composition of dietary fat has been shown to directly influence 
beta cell function in that unsaturated fat impairs, whereas saturated fat enhances, GSIS 
[69]. Although the composition of dietary fat was not described in the paper by Ionut et 
al. [290], it is possible that their diet contained a higher concentration of saturated fat 
and/or a lower concentration of unsaturated fat than that used in the current study (22% 
saturated / 28% unsaturated as a % of total energy), which might have altered beta cell 
responses in the presence of a glucose challenge [69]. Altogether, the phenotypic 
differences amongst our models are likely related to differences in dietary constituents 
and caloric consumption.  
In conclusion, a defect in the ability of the liver to transition from glucose 
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production to glucose uptake has been implicated in the development of IGT and 
hyperglycemia with type 2 diabetes[200-204]. Likewise, a marked reduction in 
splanchnic glucose uptake and hepatic glycogen synthesis following a meal has been 
observed in individuals with either type 1 or type 2 diabetes [203, 204]. In the present 
study, we utilized a large animal model to demonstrate that chronic consumption of a 
HFFD diminishes the sensitivity of the liver to hormonal (insulin) and glycemic 
(hyperglycemia and the portal glucose signal) cues, and results in a marked impairment in 
NHGU and glycogen synthesis. Thus, consumption of dietary fat and fructose in excess 
might play a role in the etiology of IGT, insulin resistance and diabetes through their 
hepatospecific effects.  
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Figure 3.1: Experimental timeline. Numbers below the horizontal line indicate the 
week in which an experiment or surgery was conducted relative to initiation of the 
experimental diets (CTR or HFFD). CTR, standard meat and laboratory chow diet; 
HFFD, high-fat, high-fructose diet; VU, Vanderbilt University; OGTT, oral glucose 
tolerance test; HIEG, hyperinsulinemic-euglycemic clamp; Px, partial pancreatectomy; 
HIHG, hyperinsulinemic-hyperglycemic clamp.   
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Figure 3.2: OGTTs in CTR group. OGTTs were conducted in 24-h-fasted dogs at 
baseline (BL; ○), and after 4 (□) and 8 (∆) weeks of feeding a CTR diet (n = 4). Polycose 
was administered orally (0.9 g/kg), and plasma glucose (A), c-peptide (B), and insulin 
(C) concentrations were measured over 180 min.  Insets: Delta AUCs over 180 min for 
glucose (A), c-peptide (B), and insulin (C). Data are means ± SE.  
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Figure 3.3: OGTTs in HFFD-Sh group. OGTTs were conducted in 24-h-fasted dogs at 
baseline (BL; ●), and after 4 (■) and 8 (▲) weeks of feeding a HFFD to sham-operated 
dogs (HFFD-Sh; n = 4). Polycose was administered orally (0.9 g/kg), and plasma glucose 
(A), c-peptide (B), and insulin (C) concentrations were measured over 180 min.  Insets: 
Delta AUCs over 180 min for glucose (A), c-peptide (B), and insulin (C). Data are means 
± SE. * P < 0.05 vs. baseline ∆AUC. 
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Figure 3.4: OGTTs in HFFD-Px group. OGTTs were conducted in 24-h-fasted dogs at 
baseline (BL; ●), and after 4 (■) and 8 (▲) weeks of feeding a HFFD to partially 
pancreatectomized dogs (HFFD-Px; n = 6). Polycose was administered orally (0.9 g/kg), 
and plasma glucose (A), c-peptide (B), and insulin (C) concentrations were measured 
over 180 min.  Insets: Delta AUCs over 180 min for glucose (A), c-peptide (B), and 
insulin (C). Data are means ± SE. * P < 0.05 vs. baseline ∆AUC. 
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Figure 3.5: Hyperinsulinemic euglycemic clamps in CTR and HFFD groups. Mean glucose infusion 
rates (GIR; A and B) during HIEG clamps conducted in 18-h-fasted dogs at baseline (BL; CTR, ○; HFFD, 
●) and after 10 weeks (CTR, □; HFFD, ■) of feeding a CTR (n = 4; A) or a HFFD to Sh or Px (n = 10; B) 
dogs. Average GIR (C) and GIR-to-insulin ratios (D) during 90-120 min of HIEGs conducted at BL (filled 
bars) and after 10 weeks (patterned bars) of feeding. Data from the HFFD-Sh and HFFD-Px groups were 
combined in B-D because the reduction in GIR (mg/kg/min) after 10 weeks of HFFD feeding was similar 
between groups (HFFD-Sh, BL: 18.5±1.7, 10wk: 13.9±0.7; HFFD-Px, BL: 19.2±1.3, 10wk: 14.1±1.1). 
Data are means ± SE. *P < 0.05 vs. baseline; NS, not significant. 
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Figure 3.6: Plasma hormone concentrations during hyperinsulinemic hyperglycemic clamps in CTR and HFFD groups. Arterial plasma insulin (A) and 
glucagon (C), and hepatic sinusoidal insulin (B) and glucagon (D) during the basal (-20 to 0 min) and experimental periods (0 to 180 min) of HIHG clamps 
conducted in 18-h-fasted dogs after 13 weeks of feeding a CTR diet (n = 4; □) or a HFFD (n = 8; ●). Data from the HFFD-Sh and HFFD-Px groups were 
combined in this figure because there were no differences between groups for these clamped parameters. Two dogs in the HFFD-Px group had to be dropped 
from the cohort, one because of catheter failure and one because of an infusion error. Data are means ± SE. † P < 0.05 vs. basal period (HFFD and CTR groups).    
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Figure 3.7: Hyperinsulinemic hyperglycemic clamps in CTR and HFFD groups. Arterial blood glucose (A), nonhepatic glucose uptake (B), hepatic glucose 
load (C) and net hepatic glucose balance (NHGB; D) during the basal (-20 to 0 min) and experimental periods (0 to 180 min) of HIHG clamps conducted in 18-h-
fasted dogs after 13 weeks of feeding a CTR diet (n = 4; □) or a HFFD (n = 8; ●). Negative values for NHGB indicate net hepatic uptake; positive values indicate 
net hepatic production. Data from the HFFD-Sh and HFFD-Px groups were combined for HIHG analyses because there was no difference in NHGB (mg/kg/min) 
between the two groups (average during last 30 min of the 2 subperiods; HFFD-Sh: -0.1±0.5; HFFD-Px: 0.3±0.8). Data are means ± SE. †P < 0.05 vs. basal 
period (HFFD and CTR groups); *P < 0.05 vs. CTR group.   
 118 
TABLE 3.1.  
Venous plasma glucagon concentrations during OGTTs  
 Experimental Period, min 
Group 
Basal Period,  
-10 to 0 min 30 60 90 120 150 180 
Plasma Glucagon (pg/ml) 
CTR 
 BL  38 ± 11   34 ± 9 31 ± 7 29 ± 8 29 ± 7 35 ± 6 31 ± 8 
 4wk  40 ± 4   37 ± 3 39 ± 3 33 ± 5 30 ± 4 32 ± 4 35 ± 3 
 8wk  65 ± 7   58 ± 8 55 ± 14 52 ± 8 57 ± 9 46 ± 2 50 ± 4 
HFFD-Sh 
 BL  46 ± 11   54 ± 12 43 ± 7 45 ± 12 44 ± 14 47 ± 11 43 ± 10 
 4wk  42 ± 9   41 ± 11 43 ± 9 40 ± 11 42 ± 11 47 ± 11 42 ± 10 
 8wk  46 ± 5   38 ± 4 47 ± 14 44 ± 12 47 ± 12 41 ± 12 42 ± 12 
HFFD-Px 
 BL  42 ± 9   42 ± 10 44 ± 13 41 ± 9 37 ± 9 41 ± 9 39 ± 7 
 4wk  47 ± 9   38 ± 10 44 ± 13 43 ± 8 38 ± 8 39 ± 8 40 ± 7 
 8wk  43 ± 10   45 ± 10 46 ± 9 48 ± 11 48 ± 9 46 ± 8 48 ± 11 
Values are means ± S.E.; CTR, n = 4; HFFD-Sh, n = 4; HFFD-Px, n = 6. Dogs were 24-h-fasted prior to study. BL, baseline.
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TABLE 3.2.  
Venous plasma glucose, insulin, glucagon, free fatty acid, and triglyceride concentrations 
during hyperinsulinemic euglycemic clamps   
  Experimental Period, min 
 Group 
Basal Period,  
-30 to 0 min  30 60 90 120 
Plasma glucose, mg/dl 
 CTR                
BL 102 ± 3 102 ± 1 101 ± 6 105 ± 7 104 ± 2 
    10wk 104 ± 4 93 ± 8 90 ± 5 113 ± 5 99 ± 3 
 HFFD                
 BL 108 ± 2 99 ± 4 97 ± 2 106 ± 3 104 ± 3 
    10wk 110 ± 2 104 ± 4 103 ± 2 101 ± 2 105 ± 3 
Plasma insulin, µU/ml 
 CTR                
 BL 8 ± 1 76 ± 5† 82 ± 8† 84 ± 7† 85 ± 6† 
    10wk 7 ± 1 87 ± 13† 83 ± 6† 85 ± 6† 83 ± 8† 
 HFFD                
 BL 10 ± 1 104 ± 7† 110 ± 7† 113 ± 7† 114 ± 5† 
    10wk 11 ± 1 122 ± 9† 125 ± 10† 128 ± 10† 126 ± 11† 
Plasma glucagon, pg/ml 
 CTR                
 BL 34 ± 5 42 ± 8 41 ± 3 42 ± 3 40 ± 3 
    10wk 47 ± 11 44 ± 6 45 ± 5 44 ± 3 48 ± 9 
 HFFD                
 BL 41 ± 5 49 ± 5 48 ± 6 50 ± 6 48 ± 6 
    10wk 43 ± 5 52 ± 4 49 ± 5 48 ± 6 46 ± 6 
Plasma free fatty acids, µmol/l 
CTR    
 BL 821 ± 49 
 
166 
 
± 
 
30† 
 
56 
 
± 
 
7† 
 
48 
 
± 
 
10† 
 
39 
 
± 
 
13† 
    10wk 775 ± 113 127 ± 26† 97 ± 21† 71 ± 21† 62 ± 19† 
 HFFD                
 BL 758 ± 97 168 ± 52† 105 ± 13† 71 ± 11† 54 ± 9† 
    10wk 751 ± 72 146 ± 21† 113 ± 27† 80 ± 10† 61 ± 8† 
Plasma triglycerides, µmol/l 
 CTR                
 BL 1195 ± 81 1202 ± 107 1044 ± 104 937 ± 106 841 ± 96† 
    10wk 1244 ± 239 1304 ± 188 1122 ± 142 979 ± 146 958 ± 182 
 HFFD                
 BL 870 ± 100 858 ± 105 779 ± 117 669 ± 75† 625 ± 58† 
    10wk 1021 ± 77 979 ± 89 812 ± 75† 736 ± 58† 700 ± 72† 
Values are means ± SE; CTR, n = 4; HFFD, n = 10.  Dogs were 18-h-fasted prior to 
study. †P < 0.05 vs. basal period.  
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TABLE 3.3. 
 Body weight, fasting plasma glucose, and insulin 
 Week of CTR or HFFD Feeding 
 Group BL 4 wk 8 wk 13 wk 
Body weight, kg 
 CTR 25 ± 2 24 ± 1 25 ± 2 26 ± 1 
             
 HFFD 26 ± 1 28 ± 1 29 ± 1 29 ± 1 
Plasma glucose, mg/dl 
 CTR 106 ± 5 99 ± 9 105 ± 6 108 ± 1 
              
 HFFD 106 ± 2 107 ± 3 108 ± 2 106 ± 1 
Plasma insulin, µU/ml 
 CTR 8 ± 2 8 ± 1 6 ± 1 8 ± 2 
              
 HFFD 8 ± 1 11 ± 1* 10 ± 1 11 ± 1* 
Values are means ± SE; CTR, n = 4; HFFD, n = 10.  Data from the HFFD-Sh and HFFD-
Px groups were combined because there was no difference between groups for each 
parameter. Dogs were 24-h-fasted prior to plasma collection. *P < 0.05 vs. baseline (BL; 
paired t-test).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 121 
TABLE 3.4. 
Tracer-determined rate of endogenous glucose appearance (Endo Ra), net hepatic 
glucose balance (NHGB), estimated hepatic glucose uptake (Est HGU = Endo Ra-
NHGB), and rate of glucose disappearance (Glucose Rd) during hyperinsulinemic 
hyperglycemic clamps in a subset of dogs   
   Experimental Period  
 Group Basal Period Period 1 Period 2 
Endo Ra  
 CTR 2.2 ± 0.2  0.6 ± 0.5†   0.8 ± 0.6†  
   HFFD 2.4 ± 0.2  1.7 ± 0.2   0.4 ± 0.2†  
NHGB  
 CTR 1.6 ± 0.2  -1.9 ± 0.8†   -3.5 ± 0.9†  
   HFFD 1.6 ± 0.1  0.3 ± 0.1†*   -0.9 ± 0.9†  
Est HGU  
 CTR 0.6 ± 0.3  2.5 ± 1.2   4.3 ± 1.3†  
   HFFD 0.8 ± 0.3  1.4 ± 0.3   1.3 ± 0.7  
Glucose Rd  
 CTR 2.2 ± 0.2  7.3 ± 0.8†   10.0 ± 1.5†  
   HFFD 2.4 ± 0.2  7.0 ± 0.9†   8.7 ± 1.3†  
Values are means ± SE in mg/kg/min; CTR, n = 4; HFFD, n = 4. Negative values for 
balance data indicate net hepatic uptake; positive values indicate net hepatic output. Dogs 
were 18-h-fasted prior to study. †P < 0.05 vs. basal period; *P < 0.05 vs. CTR.  
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TABLE 3.5. 
Total hepatic blood flow, total glucose infusion rate, arterial blood lactate and glycerol 
concentrations, arterial plasma NEFA concentration, net hepatic lactate, glycerol and 
NEFA balance, and net hepatic carbon retention during hyperinsulinemic hyperglycemic 
clamps  
   Experimental Period  
 Group Basal Period Period 1 Period 2 
Total hepatic blood flow,  
          ml/kg/min 
 CTR 23 ± 3  21 ± 3   22 ± 3  
 HFFD 27 ± 2  25 ± 2   26 ± 1  
Total glucose infusion rate,  
          mg/kg/min 
 CTR 0.0 ± 0.0  7.7 ± 0.9†   11.0 ± 1.2†  
 HFFD 0.0 ± 0.0  6.0 ± 0.6†   9.1 ± 1.0†  
Arterial blood lactate, 
          µmol/l 
 CTR 295 ± 10  703 ± 113†   829 ± 58†  
 HFFD 296 ± 17  469 ± 35†*   731 ± 72†  
Net hepatic lactate balance, 
          µmol/kg/min 
 CTR -6.4 ± 0.9  5.3 ± 2.8†   6.2 ± 2.3†  
 HFFD -6.9 ± 0.8  -3.6 ± 1.1†*   -4.1 ± 0.8†*  
Arterial blood glycerol,  
          µmol/l 
 CTR 81 ± 17  33 ± 5†   34 ± 7†  
 HFFD 96 ± 7  42 ± 7†   44 ± 9†  
Net hepatic glycerol balance, 
          µmol/kg/min 
 CTR -1.6 ± 0.5  -0.6 ± 0.1   -0.7 ± 0.1  
 HFFD -2.3 ± 0.3  -0.8 ± 0.1   -1.0 ± 0.2  
Arterial plasma NEFA,  
          µmol/L 
 CTR 828 ± 117  122 ± 22†   62 ± 10†  
 HFFD 813 ± 81  127 ± 34†   101 ± 38†  
Net hepatic NEFA balance,  
          µmol/kg/min 
 CTR -2.4 ± 0.9  -0.4 ± 0.1†   -0.1 ± 0.1†  
 HFFD -3.0 ± 0.4  -0.2 ± 0.1†   -0.2 ± 0.1†  
Net hepatic carbon retention, 
mg glucose equivalents/kg/min 
 CTR -1.0 ± 0.1  0.7 ± 0.7†   2.6 ± 0.9†  
 HFFD -1.2 ± 0.2  -0.1 ± 0.1†   0.5 ± 0.8†  
Values are means ± SE; CTR, n = 4; HFFD, n = 8. Negative values for balance data 
indicate net hepatic uptake; positive values indicate net hepatic production; negative 
values for carbon retention indicate net hepatic glycogen breakdown; positive values 
indicate net hepatic glycogen synthesis. Dogs were 18-h-fasted prior to study. †P < 0.05 
vs. basal period; *P < 0.05 vs. CTR.  
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CHAPTER IV 
 
A HIGH-FAT, HIGH-FRUCTOSE DIET ACCELERATES NUTRIENT 
ABSORPTION AND IMPAIRS NET HEPATIC GLUCOSE UPTAKE IN 
RESPONSE TO A MIXED MEAL IN PARTIALLY PANCREATECTOMIZED 
DOGS 
 
(Adapted from Coate et al. J Nutr 141:1-9, 2011) 
 
Aim 
The liver serves as one of the principal buffers of perturbations in postprandial 
glycemia; however, individuals with diabetes display a marked impairment not only in 
the ability of hyperinsulinemia and hyperglycemia to suppress hepatic glucose 
production, but also in the ability of those postprandial stimuli to activate splanchnic 
glucose uptake and hepatic glycogen synthesis in response to a mixed meal [200, 201, 
203, 204]. In Specific Aim I, we found that chronic consumption of a high-fat, high-
fructose diet renders the liver incapable of switching from net glucose output to net 
glucose uptake. However, this defect was identified in response to a glucose challenge, 
which lacked other meal-associated factors that can influence the gastric emptying rate, 
insulin and glucagon secretion, and net hepatic glucose uptake (NHGU) [295-304]. Thus, 
the goal of Specific Aim II was to investigate whether high-fat, high-fructose (HFFD) 
feeding impairs NHGU during a more physiological mixed meal test. Experiments were 
conducted to assess the response of the liver and extrahepatic tissues to an orally-
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administered liquid mixed meal after consumption of a HFFD or a chow control diet 
(CTR) for 8 weeks. 
 
Experimental Design 
Ten adult male mongrel dogs were randomly assigned to either a CTR diet (n = 5) or 
a HFFD (n = 5) for 8 weeks (Table 4.1). Dogs in CTR or HFFD underwent a sham or 
partial pancreatectomy (PPx; ≈ 65% resection), respectively, at wk 0, as described under 
Surgical Procedures in Chapter II. Approximately 2 weeks before the meal test (week 6 
of feeding), dogs underwent a second laparotomy for hepatic catheterization and flow 
cuff placement, as described under Surgical Procedures in Chapter II. After 8 weeks of 
feeding, dogs were challenged with a liquid mixed meal, and net gut/hepatic substrate 
balance was measured.  
Oral mixed meal tests were carried out in dogs that had been feed-deprived for 24-h.  
On the morning of the study, a liquid mixed meal was drawn up into two 60 mL syringes. 
Following the control period, it was delivered directly into the dog’s mouth over the 
course of 2 minutes in order to activate the cephalic response to a meal. Experiments 
consisted of consecutive 60 min equilibration (0 to 60 min) and control (60 to 120 min) 
periods, followed by oral administration of a defined liquid mixed meal, and then a 270 
min postprandial sampling period (120 to 390 min). The test meal consisted of 20% 
protein (26.9g Beneprotein [96 kcal]; Nestle Healthcare Nutrition, Inc., Minneapolis, 
MN), 56% carbohydrate (67.2g Polycose [255 kcal]; Abbott Nutrition, Columbus, OH) 
and 24% fat (25.3 ml Microlipid [114 kcal]; Nestle Healthcare Nutrition, Inc., 
Minneapolis, MN). Beneprotein and Polycose were dissolved in 60 mL of water along 
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with Microlipid. Each meal was spiked with acetaminophen (500 mg) in order to measure 
the gastric emptying rate during mixed meal testing [305]. Blood was drawn every 10 
min during the early postprandial period (120 to 150 min), and every 30 min thereafter 
(180 to 390 min).   
 
Results 
Glucose metabolism and hormone levels 
In CTR, arterial plasma glucose levels tended to rise in response to the meal and 
tended to remain elevated for the duration of the study, albeit not significantly greater 
than their glucose concentrations during the basal period (Figure 4.1A). A significant 
increase from basal in net gut output of glucose was evident 1 h after the meal which 
coincided with an increase in the gastric emptying rate, as indicated by a significant 
elevation from basal in arterial plasma acetaminophen concentration in CTR (Figure 4.1B 
and C). Glucose output by the gut and arterial plasma acetaminophen levels eventually 
plateaued 3 h post-meal delivery in CTR (Figure 4.1B and C). In HFFD, on the other 
hand, arterial plasma glucose levels increased more rapidly from basal following meal 
consumption, and were significantly elevated from basal and CTR for 2.5 h post-meal 
delivery (Figure 4.1A). Glucose output by the gut also increased more rapidly from basal 
in HFFD, albeit for a shorter duration, peaking 1.5 h post-meal administration (P<0.05 
vs. basal period and CTR), and then falling such that during the last hour of the 
experiment, it was significantly lower in HFFD than in CTR (Figure 4.1B). In agreement 
with their gut glucose absorption profile, arterial plasma acetaminophen levels were 
significantly increased in HFFD vs. CTR during the early postprandial period (Figure 
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4.1C).  
In response to the meal, there was a 4- and 5-fold increase from basal in arterial 
plasma c-peptide (P < 0.05) and insulin concentrations, respectively, in CTR, as well as a 
significant elevation from basal in arterial and portal vein plasma GLP-1 (active form) 
concentrations 3 h post-meal administration (Figure 4.2 A-C and Table 4.2). In 
agreement with a sustained rate of gastric emptying and delivery of nutrients to the gut, 
plasma GLP-1 levels tended to remain elevated from basal throughout the experiment in 
CTR (Figure 4.2C and Table 4.2). In contrast, there was a 5- and 7-fold increase from 
basal (P < 0.05) in arterial plasma c-peptide and insulin concentrations, respectively, in 
HFFD, which were significantly greater than those in CTR during the experiment (Figure 
4.2A and B). Likewise, arterial and portal vein plasma GLP-1 levels were significantly 
greater in HFFD vs. CTR 1 h post-meal delivery, but returned to basal levels by the end 
of the study (Figure 4.2C and Table 4.2). There were no significant changes from basal or 
between groups in arterial or hepatic sinusoidal plasma glucagon concentrations 
following meal consumption (Table 4.2).  
During the basal period, net hepatic glucose output (NHGO) was comparable 
between CTR and HFFD groups (Figure 4.3A). In response to meal consumption, the 
livers of dogs in CTR rapidly switched from net glucose output to net glucose uptake (P 
< 0.05 vs. basal period and HFFD), and remained in an uptake mode for the duration of 
the study (Figure 4.3A). In contrast, NHGU was nearly absent in HFFD, as evidenced by 
the lack of a significant change from basal in net hepatic glucose balance following meal 
consumption (Figure 4.3A). As a result, NHGU was significantly lower in HFFD vs. 
CTR during the last 2 h of the experiment (Figure 4.3A). On the other hand, non-hepatic 
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glucose uptake (non-HGU) in response to meal consumption was markedly amplified in 
HFFD compared to CTR (P < 0.05 vs. basal period and CTR) (Figure 4.3C). Given that 
the ratios of non-HGU to arterial insulin (CTR: 0.15±0.04, HFFD: 0.10±0.01) and non-
hepatic glucose clearance to arterial insulin (CTR: 0.15±0.04, HFFD: 0.09±0.01) were 
similar between groups, these data indicate that the muscle was able to compensate for 
impaired NHGU in HFFD, but at the expense of increased postprandial plasma insulin 
and glucose.    
Lactate metabolism 
In both CTR and HFFD, arterial blood lactate levels increased from basal 
following meal consumption (Figure 4.4A). In CTR, this was consistent with a robust 
switch from net hepatic lactate uptake to output, and a significant increase from basal in 
net hepatic carbon retention, an index of net hepatic glycogen synthesis (GSYN) (Figure 
4.4B and Figure 4.3B, respectively). Net hepatic lactate output and GSYN continued for 
the remainder of the study in CTR. In HFFD, on the other hand, there was only a 
transient switch from net hepatic lactate uptake to output following meal consumption, 
and the rate was significantly lower in HFFD than in CTR during the experiment (Figure 
4.4B). This was consistent with a significantly diminished rate of net hepatic carbon 
retention in HFFD compared to CTR (Figure 4.3B). These data suggest that in the 
absence of meal-associated glucose uptake, the livers of dogs in the HFFD group 
produced significantly less lactate and synthesized significantly less glycogen.    
Glycerol, non-esterified fatty acid (FFA), and triglyceride metabolism 
During the basal period, arterial blood glycerol levels were significantly elevated 
in HFFD vs. CTR (Table 4.3). Although arterial blood glycerol and plasma FFA levels 
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fell rapidly in both groups following meal consumption, glycerol concentrations 
remained significantly higher in HFFD vs. CTR for the duration of the study (Table 4.3).  
Likewise, arterial plasma FFA concentrations began to rise in HFFD 3 h post-meal 
delivery such that by the end of the study, they were similar to basal values and 
significantly greater than those in CTR (Table 4.3). Changes in net hepatic glycerol 
uptake paralleled those in arterial blood glycerol; by the end of the study, net hepatic 
glycerol uptake was significantly greater in HFFD compared to CTR (Table 4.3). Arterial 
plasma triglyceride (TG) concentrations declined in both groups over the first 3 
postprandial hours, after which they remained low in CTR but returned to basal levels in 
HFFD (Table 4.3).   
 Alanine metabolism 
Arterial blood alanine levels rose to a significantly greater extent in HFFD than in 
CTR 2 h post-meal administration (Table 4.4). This was partly attributable to a 5- vs. 3-
fold increase from basal in alanine output from the gut in HFFD vs. CTR, respectively, 1 
h post-meal delivery, coupled with a lower hepatic fractional extraction of alanine during 
the mid- to late postprandial period in HFFD vs. CTR (Table 4.4).  
 
Discussion 
 The objective of the present study was to investigate whether chronic 
consumption of a HFFD, in combination with partial (≈ 65%) pancreatic resection, alters 
the response of the liver and extrahepatic tissues to an orally-delivered, liquid mixed meal 
under non-clamped experimental conditions. A HFFD was utilized because it reflects the 
macronutrient composition of a western diet, which contains foods that are replete with 
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fat and fructose, and when consumed in increasing quantities, has been associated with a 
heightened risk for the development of type 2 diabetes [28, 306]. We report herein that 8 
weeks of HFFD feeding elicited: 1) excessive postprandial hyperglycemia due to 
accelerated gastric emptying and glucose absorption, as well as diminished NHGU, and 
2) a reduction in the ability of insulin to suppress lipolysis.   
Several factors probably contributed to postprandial hyperglycemia in HFFD-fed 
animals. For example, the rates of gastric emptying and glucose absorption can influence 
the timing and magnitude of postprandial glucose excursions in healthy and diabetic 
individuals [307, 308]. Previously, Davis et al. [309] demonstrated that glucose 
absorption (and presumably, gastric emptying) occurs very slowly in the overnight fasted 
dog when fed a test meal of the same composition as their normal diet. In the present 
study, a sustained rate of glucose output by the gut occurred in the CTR group following 
meal consumption, consistent with the observations of Davis et al. [309]. In contrast, the 
rates of gastric emptying and glucose output by the gut were significantly increased in 
HFFD vs. CTR during the early postprandial period, consistent with excessive 
postprandial hyperglycemia in the former. Furthermore, there was a tendency for alanine 
production by the gut to be greater in HFFD vs. CTR 1 h post-meal delivery, suggesting 
that accelerated nutrient absorption in HFFD was not exclusive to glucose. By the end of 
the study, however, temporal differences in gastric emptying and nutrient absorption 
between groups were reversed such that net glucose and alanine output by the gut were 
significantly greater in CTR vs. HFFD, indicative of accelerated meal macronutrient 
absorption in the latter.  
In addition, there was a doubling in arterial and portal vein plasma GLP-1 levels 
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10 min post-meal delivery in HFFD, whereas there was virtually no change 10 min post-
meal in CTR. GLP-1 is an incretin hormone secreted by the L-cells cells of the distal 
small intestine primarily in response to nutrient ingestion [310, 311]. GLP-1 is thought to 
delay gastric emptying and potentiate glucose-dependent insulin secretion, thus limiting 
postprandial hyperglycemia [312-321]. Previous studies conducted in our laboratory, 
however, have demonstrated that a physiologic rise in endogenous GLP-1 is without 
significant effect on insulin secretion, gastric emptying, and glucose utilization in dogs 
[322-324]. Thus, we believe that the temporal changes in GLP-1 levels in the current 
study are a reflection of the differential gastric emptying rates in HFFD vs. CTR. 
Previous studies conducted in individuals in the early stages of type 2 diabetes or 
those without autonomic neuropathy have also reported an accelerated gastric emptying 
rate following consumption of a glucose solution or liquid mixed meal [325-332]. 
Although the mechanisms that mediate differential gastric emptying rates in healthy and 
diabetic individuals remain poorly defined, one study [327] attributed augmented gastric 
emptying to increased phasic contractility of the proximal stomach in patients with 
asymptomatic (no autonomic neuropathy) type 2 diabetes. It is also possible that the 
HFFD induced perturbations in the gut microbiota, which might have elicited an increase 
in intestinal permeability as a consequence of endotoxemia, as reported previously [333-
338]. Future studies will need to be conducted to explore the mechanism(s) responsible 
for accelerated gastric emptying in HFFD-fed animals.  
Another factor that contributed to meal-associated glucose intolerance in HFFD 
was inadequate stimulation of NHGU. Under normal conditions, the liver is highly 
responsive to the route of glucose delivery (peripheral vs. enteral/intraportal), the hepatic 
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glucose load, and the hepatic sinusoidal insulin level [183, 196, 197]. However, NHGU 
was markedly diminished in HFFD vs. CTR despite 1.6- and 2.4-fold greater increases in 
peak plasma glucose and insulin levels, respectively. These data suggest that HFFD 
feeding rendered the liver insensitive to the stimulatory effects of glucose, insulin, and 
portal glucose delivery on NHGU in the context of a physiologic mixed meal challenge, 
consistent with our previous findings with a glucose challenge [339]. 
In agreement with impaired NHGU, net hepatic lactate production, an index of net 
glycolytic flux, and net hepatic carbon retention, an index of net GSYN, were markedly 
diminished in HFFD vs. CTR following meal consumption. Previously, Basu et al. [200, 
201] reported that decreased hepatic UDP-glucose flux in type 2 diabetic individuals 
during hyperinsulinemia and hyperglycemia is entirely accounted for by a decrease in the 
contribution of extracellular glucose to the UDP-glucose pool, suggestive of reduced 
hepatic glucokinase (HGK) activity with diabetes. Moreover, restoration of HGK 
expression in 20-week-old Zucker diabetic fatty rats, a genetic model of obese type 2 
diabetes, normalized their hepatic glucose flux and the incorporation of glucose into 
glycogen during a hyperglycemic clamp [246]. Thus, it is possible that HFFD feeding 
impaired HGK activity, which resulted in diminished NHGU and GSYN in response to a 
mixed meal challenge.  
Interestingly, Non-HGU, which is primarily reflective of glucose uptake in the 
skeletal muscle [340], was augmented in HFFD vs. CTR in response to meal ingestion. 
This was due in part to the fact that the skeletal muscle of dogs in the HFFD group was 
exposed to a much higher concentration of glucose and insulin postprandially. Thus, 
through a mass action effect of glucose as well as through the pleiotropic effects of 
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insulin on muscle glucose uptake [340-343], the skeletal muscle responded accordingly 
by increasing its consumption of glucose. Indeed, when Non-HGU or clearance was 
expressed relative to the arterial plasma insulin level in HFFD and CTR, the ratios were 
similar between groups, suggesting that augmented Non-HGU in HFFD was secondary to 
elevated insulin and glucose. These data also underscore the predominance of the defect 
in hepatic glucose uptake.  
Eight weeks of HFFD feeding was also associated with a remarkable resistance to 
insulin at the level of triglyceride hydrolysis within the adipose tissue. This was evident 
from the fact that postprandial blood glycerol concentrations were significantly elevated 
in HFFD vs. CTR despite peak arterial plasma insulin concentrations that were 100% 
greater in HFFD. Conversely, plasma FFA concentrations were similar between groups, 
indicative of a selective impairment in the ability of insulin to suppress lipolysis, whereas 
the ability of hyperinsulinemia and hyperglycemia to stimulate re-esterification of FFA 
into TG remains intact. The latter is exemplified by the fact that plasma FFA 
concentrations began to increase in HFFD towards the end of the study as plasma insulin 
and glucose concentrations waned.   
We cannot ascertain from these data whether relative beta cell failure contributed 
to meal-associated glucose intolerance in HFFD because we do not know how much 
insulin would have been secreted in CTR had their plasma glucose concentrations been 
matched to those of HFFD. What we now know that was not evident at the time in which 
we designed these experiments is that resection of 65% of the pancreas is insufficient to 
exacerbate the glucose intolerance induced by HFFD feeding [339]. This is consistent 
with previous studies conducted in rodents in which removal of 85-95% of the pancreas 
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was required before diabetes ensued, and even then, there was a heterogeneous 
hyperglycemic response, which correlated with the extent of pancreatic resection [288, 
289]. Nevertheless, the possibility cannot be excluded that in the context of a mixed 
meal, factors associated with a PPx might have influenced the results in the present study.  
This study revealed novel metabolic consequences of a HFFD on the function of 
the gastrointestinal tract, liver, and adipose tissue in response to a mixed meal. These data 
highlight the need for additional studies aimed at elucidating the mechanism(s) by which 
a HFFD per se perturbs the coordinated response of the aforementioned tissues in the 
postprandial state.  
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Figure 4.1: Arterial plasma glucose (A), net gut glucose balance (B), and arterial plasma 
acetaminophen (C) concentrations during the basal (60 to 120 min) and experimental 
(120 to 390 min) periods following oral administration of a liquid mixed meal to 24-h-
fasted dogs that had been fed a CTR (n = 5; ●) or HFFD (n = 5; ○) for 8 weeks. Data are 
means ± SE. † P < 0.05 vs. basal period; * P < 0.05 vs. CTR group.  
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Figure 4.2: Arterial plasma insulin (A), c-peptide (B), and glucagon like peptide-1 (GLP-
1, active) (C) concentrations during the basal (60 to 120 min) and experimental (120 to 
390 min) periods following oral administration of a liquid mixed meal to 24-h-fasted 
dogs that had been fed a CTR (n = 5; ●) or HFFD (n = 5; ○) for 8 weeks. Data are means 
± SE. † P < 0.05 vs. basal period; * P < 0.05 vs. CTR group.  
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Figure 4.3: Net hepatic glucose balance (NHGB) (A), net hepatic carbon retention 
(NHCR; mg of glucose equivalents) (B), and nonhepatic glucose uptake (C) during the 
basal (60 to 120 min) and experimental (120 to 390 min) periods following oral 
administration of a liquid mixed meal to 24-h-fasted dogs that had been fed a CTR (n = 5; 
●) or HFFD (n = 5; ○) for 8 weeks. Negative values for NHGB or NHCR indicate net 
hepatic glucose uptake or glycogen synthesis, respectively; positive values indicate net 
hepatic glucose output or glycogen breakdown, respectively. Data are means ± SE. † P < 
0.05 vs. basal period; * P < 0.05 vs. CTR group.  
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Figure 4.4: Arterial blood lactate (A) and net hepatic lactate balance (B) during the basal 
(60 to 120 min) and experimental (120 to 390 min) periods following oral administration 
of a liquid mixed meal to 24-h-fasted dogs that had been fed a CTR (n = 5; ●) or HFFD 
(n = 5; ○) for 8 weeks. Negative values for net hepatic lactate balance indicate net hepatic 
lactate uptake; positive values indicate net hepatic lactate output. Data are means ± SE. † 
P < 0.05 vs. basal period; * P < 0.05 vs. CTR group.  
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TABLE 4.1. 
Composition of the experimental diets 
Nutrient 
High-Fat, High-Fructose 
Diet (HFFD) 
Composition 
Meat + Chow Control 
Diet (CTR) Composition 
 g/kg diet g/kg diet 
Protein1 247 289 
Fat2 252 98 
Saturated Fat 110.9 36.63 
Monounsaturated Fat 104.2 34.03 
Polyunsaturated Fat 34.2 13.33 
Total Carbohydrate 298 355 
Starch4 95.9 335 
Glucose 0.1 2.3 
Fructose 189.3 2.3 
Sucrose 7.4 10.8 
Lactose 5.6 4.6 
Crude Fiber5 22 28 
Moisture 100 100 
Vitamins6 1.7 1.7 
Minerals7 73 73 
Percentage of Energy: % % 
Protein 21.8 30.7 
Fat 52.0 25.8 
Total Carbohydrate 26.2 43.5 
Starch 8.5 41.0 
Glucose <0.01 0.3 
Fructose 16.7 0.3 
Sucrose 0.6 1.3 
Lactose 0.5 0.6 
Energy Density  18.9 kJ/g 17.3 kJ/g 
1Protein sources include porcine meat meal, dehulled soybean meal, corn gluten meal, wheat 
middlings, and dried whey 
2Fat sources include lard, porcine animal fat, vegetable shortening, and/or unsalted butter 
3Corresponds to saturated, mono- and polyunsaturated fat content of non-purified diet only; these 
data are not provided by the manufacturer for the can of meat  
4Starch sources include wheat germ and middlings 
5Fiber sources include wheat, beat pulp, and corn 
6Vitamin mix, mg/kg prepared diet: provitamin A carotenoids, 1.0; retinol, 12.0; cholecalciferol, 
0.11; α-tocopherol, 29.4; menadione, 0.3; thiamin hydrocholoride, 8.9; riboflavin, 4.5; niacin, 78; 
pantothenic acid, 20; folic acid, 2.8; pyridoxine, 13; biotin, 0.2; vitamin B-12, 27; choline chloride, 
1492 
7Mineral mix, g/kg (unless otherwise specified) prepared diet: calcium, 19.2; phosphorus, 10.6; 
phosphorus (available), 9.1; potassium, 7.0; magnesium, 1.7; sulfur, 2.0; sodium, 4.5; chloride, 7.1; 
fluorine, 48 mg/kg; iron, 390 mg/kg; zinc, 160 mg/kg; manganese, 55 mg/kg; copper, 14 mg/kg; 
cobalt, 0.5 mg/kg; iodine, 1.7 mg/kg; chromium, 2.3 mg/kg; selenium, 0.36 mg/kg 
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TABLE 4.2.  
Portal vein plasma glucagon like peptide-1 (GLP-1), arterial plasma glucagon, and hepatic sinusoidal plasma glucagon 
concentrations during the basal (60 to 120 min) and experimental (120 to 390 min) periods following oral administration of a liquid 
mixed meal to 24-h-fasted dogs that had been fed a control diet (CTR) or a high-fat, high-fructose diet (HFFD) for 8 weeks  
 Basal Period 
min 
Experimental Period 
min 
 60 to 120 180 240 300 360 390 
Portal vein plasma GLP-1, pmol/l 
CTR 3.9 ± 0.5 5.6 ± 0.7 12.7 ± 1.8 15.6 ± 2.8† 13.5 ± 1.4 9.6 ± 1.1 
                   
HFFD 3.1 ± 0.3 14.4 ± 4.7†* 9.8 ± 1.4 9.4 ± 2.8 9.7 ± 3.8 6.5 ± 3.0 
Arterial plasma glucagon, ng/l 
CTR 47.4 ± 6.4 40.6 ± 4.3 40.9 ± 4.2 43.2 ± 4.5 45.2 ± 5.2 43.8 ± 3.4 
                   
HFFD 31.9 ± 6.0 34.4 ± 4.1 36.2 ± 6.0 35.5 ± 6.4 36.1 ± 4.0 36.4 ± 4.2 
Hepatic sinusoidal plasma glucagon, ng/l 
CTR 51.0 ± 7.7 43.5 ± 6.8 45.2 ± 4.6 49.1 ± 10.9 47.3 ± 8.6 49.1 ± 7.5 
                   
HFFD 40.1 ± 6.1 43.4 ± 4.0 40.6 ± 3.3 41.2 ± 5.2 41.2 ± 4.0 42.2 ± 6.4 
Values are means ± SE; CTR, n = 5; HFFD, n = 5. †P < 0.05 vs. basal period; *P < 0.05 vs. CTR.  
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TABLE 4.3. 
Arterial blood glycerol, net hepatic glycerol uptake, and arterial plasma FFA and TG concentrations during the basal (60 to 120 min) 
and experimental (120 to 390 min) periods following oral administration of a liquid mixed meal to 24-h-fasted dogs that had been fed 
a control diet (CTR) or a high-fat, high-fructose diet (HFFD) for 8 weeks 
 Basal Period min 
Experimental Period 
min 
 60 to 120 180 240 300 360 390 
Arterial blood glycerol, µmol/l 
CTR 87 ± 7 29 ± 4† 27 ± 3† 31 ± 3† 29 ± 3† 32 ± 3† 
                   
HFFD 113 ± 10* 55 ± 14†* 56 ± 13†* 60 ± 15†* 83 ± 9†* 80 ± 6†* 
Net hepatic glycerol uptake, µmol/kg/min 
CTR 1.9 ± 0.2 0.7 ± 0.1† 0.6 ± 0.1† 0.6 ± 0.1† 0.5 ± 0.1† 0.5 ± 0.1† 
                   
HFFD 1.9 ± 0.3 1.3 ± 0.4† 1.2 ± 0.4† 1.4 ± 0.5* 1.6 ± 0.2* 1.6 ± 0.2* 
Arterial plasma FFA, µmol/l 
CTR 926 ± 122 144 ± 7† 123 ± 5† 104 ± 12† 81 ± 4† 92 ± 8† 
                   
HFFD 914 ± 43 137 ± 34† 92 ± 21† 137 ± 59† 280 ± 104†* 402 ± 110†* 
Arterial plasma TG, mmol/l 
CTR 0.22 ± 0.03 0.20 ± 0.03 0.18 ± 0.11 0.16 ± 0.03 0.14 ± 0.02† 0.16 ± 0.03† 
                   
HFFD 0.20 ± 0.02 0.19 ± 0.02 0.16 ± 0.01 0.15 ± 0.01 0.18 ± 0.01 0.19 ± 0.03 
Values are means ± SE; CTR, n = 5; HFFD, n = 5. †P < 0.05 vs. basal period; *P < 0.05 vs. CTR.  
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TABLE 4.4.  
Arterial blood alanine, gut production of alanine, net hepatic alanine uptake, and hepatic fractional extraction of alanine during the 
basal (60 to 120 min) and experimental (120 to 390 min) periods following oral administration of a liquid mixed meal to 24-h-fasted 
dogs that had been fed a control diet (CTR) or a high-fat, high-fructose diet (HFFD) for 8 weeks  
 Basal Period min 
Experimental Period 
min 
 60 to 120 180 240 300 360 390 
Arterial blood alanine, µmol/l 
CTR 284 ± 46 350 ± 20 321 ± 9 313 ± 17 307 ± 20 311 ± 19 
                   
HFFD 318 ± 35 442 ± 25† 452 ± 29†* 452 ± 46†* 409 ± 46† 374 ± 63† 
Gut production of alanine, µmol/kg/min 
CTR 1.1 ± 0.2 3.5 ± 0.4† 3.6 ± 0.5† 3.7 ± 0.3† 3.9 ± 0.4† 3.8 ± 0.6† 
                   
HFFD 0.9 ± 0.1 4.4 ± 0.5† 3.7 ± 0.4† 2.8 ± 0.4† 3.4 ± 1.0† 1.1 ± 0.4* 
Net hepatic alanine uptake, µmol/kg/min 
CTR 3.0 ± 0.1 5.8 ± 0.6† 5.4 ± 0.6† 6.5 ± 0.1† 5.8 ± 0.6† 5.3 ± 0.6† 
                   
HFFD 1.9 ± 0.3 4.9 ± 0.7† 4.5 ± 0.6† 4.6 ± 0.5†* 3.9 ± 0.5†* 2.5 ± 0.5* 
Hepatic fractional extraction of alanine 
CTR 0.29 ± 0.04 0.32 ± 0.02 0.33 ± 0.02 0.41 ± 0.02† 0.37 ± 0.03# 0.35 ± 0.03 
                   
HFFD 0.22 ± 0.02 0.25 ± 0.02 0.27 ± 0.03 0.32 ± 0.04†* 0.32 ± 0.04† 0.25 ± 0.03* 
Values are means ± SE; CTR, n = 5; HFFD, n = 5. †P < 0.05 vs. basal period; *P < 0.05 vs. CTR.  
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CHAPTER V 
 
PORTAL VEIN GLUCOSE ENTRY TRIGGERS A COORDINATED 
MOLECULAR RESPONSE THAT ACTIVATES HEPATIC GLUCOSE UPTAKE 
AND GLYCOGEN SYNTHESIS IN NORMAL, BUT NOT HIGH-FAT, HIGH-
FRUCTOSE-FED, DOGS 
 
(Manuscript in preparation) 
 
Aim 
Neither hyperinsulinemia (physiologic) nor hyperglycemia alone is sufficient to 
stimulate hepatic glucose uptake (HGU) [182, 190, 205-207]. Likewise, a physiologic 
elevation in plasma insulin concomitant with hyperglycemia resulting from the infusion 
of glucose into a peripheral vein is insufficient to elicit the peak rates of HGU and 
glycogen synthesis (GSYN) that occur in response to oral glucose ingestion [27, 182, 
183, 185, 190, 192, 198, 206, 344]. On the other hand, hyperinsulinemia and 
hyperglycemia in the presence of hepatic portal venous glucose delivery (by means of 
oral glucose ingestion or intraduodenal/portal vein glucose infusion), markedly amplifies 
HGU and GSYN in the rat [180, 181], dog [181-189], and human [190, 191]. The 
augmentation of HGU elicited by the intraportal route of glucose delivery has been 
attributed to a unique, neurally-mediated signal generated in the presence of a negative 
arterial-portal venous glucose gradient, termed the “portal glucose signal” [26, 182-184, 
193-199]. In response to ingestion of a glucose-containing meal, the portal signal works 
 143 
in concert with increased plasma glucose and insulin to orchestrate a coordinated 
response favoring enhanced HGU and GSYN [26, 198]. Although the metabolic effects 
of intraportal glucose delivery have been studied in experimental animal models and in 
the human, the molecular events linking the pleiotropic actions of the portal glucose 
signal to increased HGU and GSYN in vivo have not clearly defined. Thus, the first 
objective of Specific Aim III was to identify the molecular “signature” of the portal 
glucose signal per se in the presence of a physiologic rise in glucose and insulin.    
Postprandial hyperglycemia is one of the sequelae of diabetes that contributes to 
the elevation of hemoglobin A1c associated with the disease [24, 25]. It is due in part to 
inappropriate suppression of hepatic glucose production coupled with inadequate 
stimulation of HGU, highlighting the key role of the liver in regulating postprandial 
glucose metabolism [200, 202-204, 239-243]. Indeed, splanchnic glucose uptake (SGU) 
and hepatic GSYN through the direct pathway were markedly diminished in type 2 
diabetic subjects compared to non-diabetic controls despite equivalent elevations in 
plasma insulin and glucose during a clamp experiment [200, 201, 244]. Furthermore, 
delivery of glucose into the portal venous circulation (by way of enteral glucose infusion) 
in the presence of hyperinsulinemia was ineffective in normalizing the diminished rates 
of SGU and GSYN in diabetic subjects [200]. The authors [200, 201] conjectured that a 
defect in glucokinase was linked to the aberrant hepatic response in type 2 diabetic 
individuals, but cellular evidence supporting their supposition was not provided. In 
Specific Aims I and II, we demonstrated that HFFD feeding is also associated with a 
significant impairment in NHGU and GSYN in response to a glucose challenge or a 
mixed-meal challenge, but the cellular events associated with a diminished hepatic 
 144 
response to hyperinsulinemia, hyperglycemia, and portal glucose delivery were not 
identified. Thus, the second objective of Specific Aim III was to elucidate the molecular 
explanation for the defect in HGU caused by HFFD feeding, and whether it persists in the 
presence of the portal glucose signal. 
  
Experimental Design (Figure 5.1) 
Adult male mongrel dogs were randomly assigned to either a standard meat and 
laboratory chow diet (CTR, n=15), or to a high-fat, high-fructose diet (HFFD, n=16) for 4 
weeks. The specific macronutrient compositions of the CTR and HFFD diets are listed in 
Table 2.2 under Experimental Diets, and also in more detail in Table 4.1. After 4 weeks 
of feeding, a subset of dogs (CTR, n = 5; HFFD, n = 5) was euthanized following an 18-h 
fast for the acquisition of liver biopsies under basal conditions. In the remaining dogs, 
hyperinsulinemic hyperglycemic (HIHG) clamp experiments with (+) or without (-) 
portal vein glucose (PoG) infusion were conducted following an 18-h-fasted dogs. Just 
prior to the fast, each dog was fed a can of meat as their meal to ensure equivalent energy 
and macronutrient consumption among groups the day before the study. There were four 
groups total: HIHG-PoG CTR, n = 5; HIHG-PoG HFFD, n = 5; HIHG +PoG CTR, n = 5; 
and HIHG+PoG HFFD, n = 6. As described in Figure 5.1, each experiment consisted of a 
100 min equilibration period (-120 to -20 min), a 20 min basal control period (-20 to 0 
min), and a 180 min experimental period divided into 2 sub-periods (P1, 0 to 90 min; P2, 
90 to180 min). At -120 min, a priming dose of [3-3H] glucose (38 µCi) was given, 
followed by a constant infusion of [3-3H] glucose (0.38 µCi/min). At time 0, a constant 
infusion of somatostatin (0.8 µg/kg/min) was started in a peripheral vein, and insulin and 
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glucagon were then replaced intraportally at 3-fold basal (1.2 mU/kg/min) and basal (0.55 
ng/kg/min) rates, respectively. In addition, a variable infusion of 50% dextrose was 
started in a leg vein in order to double the hepatic glucose load (HGL). In P2, normal 
saline (HIHG-PoG) or 20% dextrose (HIHG+PoG; 4.0 mg/kg/min) was infused 
intraportally. In the HIHG+PoG groups, the peripheral glucose infusion rate was adjusted 
as necessary to clamp the HGL to that in P1. For this study, unidirectional hepatic 
glucose uptake was calculated using a tracer-determined hepatic fractional extraction 
method, as described in detail under Calculations in Chapter II. At the end of the study, 
each animal was anaesthetized with sodium pentobarbital and a laparotomy was 
performed. The hormone, cold glucose, and [3-3H] glucose infusions were continued 
while liver sections from the left central, left lateral, and right central lobes were freeze-
clamped in situ and stored at -80oC until tissue analysis. Glucokinase relative expression 
(mRNA and protein) and activity, glucokinase regulatory protein content, 
phosphorylation of Akt, GSK3β, and glycogen synthase, glycogen synthase and 
phosphorylase activity ratios, and terminal liver glycogen levels were determined in liver 
biopsies obtained at the end of the clamp experiment in all four groups (as described in 
detail under Liver Tissue Analysis in Chapter II). These values were compared to values 
from liver biopsies obtained under basal conditions (see above) in dogs that had been fed 
the CTR or HFFD 4 weeks, but were not clamped. 
 
Results 
Plasma hormone concentrations and hepatic blood flow 
HFFD feeding was associated with 43% and 47% increases in fasting arterial 
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plasma insulin (µU/ml; CTR: 6.9±0.9, HFFD: 9.8±1.1, P = 0.05) and c-peptide (ng/ml; 
CTR: 0.30±0.05, HFFD: 0.45±0.07, P = 0.13) concentrations, respectively, during the 
basal period, but there was no effect of diet on arterial plasma glucagon levels. During 
the HIHG clamp, arterial and hepatic sinusoidal insulin concentrations (µU/ml; HIHG-
PoG CTR: 22±1 and 68±6, HIHG-PoG HFFD: 23±1 and 67±3, HIHG+PoG CTR: 23±4 
and 78±10, HIHG+PoG HFFD: 27±1 and 81±11; P < 0.05 vs. basal period) were 
increased to similar levels in all 4 groups, whereas arterial and hepatic sinusoidal 
glucagon concentrations were kept at a basal level throughout the study (Figure 5.2 A-D). 
Total hepatic blood flow was similar among the 4 groups under basal conditions and 
throughout the HIHG clamp (Table 5.1). 
Blood glucose, hepatic glucose load, and total glucose infusion rate 
Fasting blood glucose concentrations did not differ between groups during the 
basal period. During P1, arterial blood glucose concentrations were increased to a similar 
level in all 4 groups (mg/dl; HIHG-PoG CTR: 159±3, HIHG-PoG HFFD: 161±3, 
HIHG+PoG CTR: 161±4, HIHG+PoG HFFD: 166±2; P < 0.05 vs. basal period) in order 
to double the hepatic glucose load (mg/kg/min; HIHG-PoG CTR: 37±3, HIHG-PoG 
HFFD: 36±3, HIHG+PoG CTR: 37±2, HIHG+PoG HFFD: 37±4; P < 0.05 vs. basal 
period) (Figure 5.3A and B). During P2, arterial blood glucose concentrations were 
clamped at a slightly reduced concentration in the HIHG+PoG groups (mg/dl; CTR: 
147±3, HFFD: 152±2) to maintain a doubling of the hepatic glucose load in the presence 
of intraportal glucose infusion (Figure 5.3A). The total glucose infusion rates (GIR) 
required to maintain hyperglycemia in CTR and HFFD groups did not differ significantly 
from one another throughout the HIHG clamp (Table 5.1).  
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Hepatic glucose uptake, hepatic glucose production, and net hepatic glucose balance  
Hepatic glucose uptake (HGU) and hepatic glucose production (HGP) 
(mg/kg/min; HIHG-PoG CTR: 0.30.1 and 1.40.1, HIHG-PoG HFFD: 0.30.1 and 
1.80.3, HIHG+PoG CTR: 0.40.1 and 2.10.4, and HIHG+PoG HFFD: 0.40.1 and 
1.90.3, respectively) were similar among all 4 groups during the basal period (Figure 
5.3C and D and Table 5.2). In response to hyperinsulinemia and hyperglycemia, HGU 
increased to a similar rate in both CTR groups during P1, reaching a peak of 1.5±0.3 and 
1.8±0.3 mg/kg/min in the HIHG-PoG CTR and HIHG+PoG CTR groups, respectively (P 
< 0.05 vs. basal period) (Figure 5.3C and D and Table 5.2). When coupled with near 
complete suppression of HGP during P1, a robust switch from net hepatic glucose output 
(NHGO) to uptake (NHGU) occurred in both CTR groups (Table 5.2). In the absence of 
portal glucose delivery during P2 in the HIHG-PoG CTR group, mean rates of HGU and 
NHGU (1.60.1 and 1.50.2 mg/kg/min, respectively) were similar to that in P1 (Figure 
5.3C and Table 5.2). On the other hand, delivery of glucose into the portal vein in the 
presence of a sustained rise in glucose and insulin rapidly augmented HGU in the 
HIHG+PoG CTR group, with a significant increase occurring 15 min after the start of 
intraportal glucose infusion (HGU, mg/kg/min; HIHG-PoG CTR: 1.40.2 vs. 
HIHG+PoG CTR: 2.20.3, P<0.05), and eventually reaching a peak of 3.0±0.3 
mg/kg/min (Figure 5.3D and Table 5.2). Given that HGP was already suppressed, the 
significant increase in NHGU in response to portal glucose delivery in the HIHG+PoG 
CTR group was accounted for by an increase in HGU (Table 5.2).  
In contrast to the response observed in CTR animals, 4 weeks of HFFD feeding 
rendered the liver resistant to the stimulatory effects of hyperinsulinemia, hyperglycemia, 
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and portal glucose delivery on HGU. As a result, mean rates of HGU in HFFD-fed 
animals during P1 and P2 (mg/kg/min; 0.4±0.1 and 0.60.2 in HIHG-PoG HFFD, and 
0.5±0.1 and 0.6±0.2 in HIHG+PoG HFFD, respectively) changed minimally from those 
observed during the basal period, and were significantly diminished relative to rates 
observed in the corresponding CTR groups (Figure 5.3C and D and Table 5.2). 
Furthermore, HGP was incompletely suppressed in both HFFD groups during P1, 
resulting in sustained NHGO despite the presence of hyperinsulinemia and 
hyperglycemia (Table 5.2). In the absence of portal glucose delivery during P2, there was 
no further suppression of HGP in the HIHG-PoG HFFD group. Thus, mean rates of HGU 
and HGP remained similar to those in P1, and as a result, the liver failed to take up 
glucose in net sense for the duration of the experiment (Figure 5.3C and D and Table 
5.2). In contrast, portal glucose delivery suppressed HGP further in the HIHG+PoG 
HFFD group (P < 0.05, P2 vs. P1), although it did not augment HGU (Table 5.2). As a 
result, NHGB fell to a value not significantly different from zero (Table 5.2).  
Lactate metabolism  
All groups exhibited net hepatic lactate uptake under basal conditions (Table 5.3). 
Coincident with the increase in HGU during P1, there was a significant increase in 
arterial blood lactate concentrations in both CTR groups that resulted from a switch from 
net hepatic lactate uptake to output in the presence of hyperinsulinemia and 
hyperglycemia (Table 5.3). Net hepatic lactate output waned during P2 in the absence of 
portal vein glucose infusion, while in its presence, it was sustained at an elevated rate, 
consistent with augmented HGU in response to the portal glucose signal (Table 5.3). On 
the other hand, both HFFD groups exhibited net hepatic lactate uptake for the duration of 
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the study, although it was somewhat reduced during both P1 and P2 (Table 5.3).  
Glycerol, nonesterified fatty acid, and triglyceride metabolism 
During the basal period, arterial blood glycerol and plasma NEFA concentrations 
were similar among the 4 groups. During P1 and P2, their levels declined in response to 
hyperinsulinemia, but the steady state values were slightly lower in the two CTR groups 
(Table 5.3). The net hepatic uptake rates of glycerol and NEFA decreased in parallel to 
the changes in their circulating concentrations, and were not different between groups 
(Table 5.3). Fasting plasma total triglyceride concentrations also did not differ between 
groups (µmol/l; 904±116, 1084±65, 1156±220, and 1089±163 in HIHG-PoG CTR, 
HIHG-PoG HFFD, HIHG+PoG CTR, and HIHG+PoG HFFD, respectively; data not 
shown).  
Hepatic glucokinase and glucokinase regulatory protein 
Under basal conditions, GK mRNA levels were similar between CTR and HFFD 
groups (Figure 5.4A). Hyperinsulinemia in the presence of hyperglycemia stimulated a 6- 
and 7-fold increase in GK expression in HIHG-PoG CTR and HFFD groups, respectively 
(P < 0.05 vs. basal CTR) (Figure 5.4A). Strikingly, delivery of glucose into the portal 
vein in the presence of hyperinsulinemia and hyperglycemia stimulated a significantly 
greater increase in GK expression in the HIHG+PoG CTR and HFFD groups (26- and 
24-fold increase above basal CTR animals, respectively; P < 0.05 vs. basal CTR and 
corresponding HIHG-PoG group) (Figure 5.4A). Likewise, portal glucose delivery was 
associated with a significant increase in the amount of GK protein and its activity in the 
HIHG+PoG CTR group relative to the HIHG-PoG CTR group (Figure 5.4B and C). In 
contrast, hepatic GK protein levels and its catalytic activity were markedly reduced in 
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HFFD-fed animals under basal conditions and during the HIHG clamp (P < 0.05 vs. 
corresponding CTR group), in agreement with impaired stimulation of HGU (Figure 5.4B 
and C). Further, portal glucose delivery failed to augment GK protein or activity. 
Interestingly, glucokinase regulatory protein (GKRP) levels were also significantly 
reduced in HFFD-fed animals under basal conditions and during the HIHG clamp (Figure 
5.4D).     
Hepatic insulin signaling and glycogen metabolism 
Under basal conditions, the phosphorylation of Akt (P-Akt on Ser473) and 
GSK3β (P- GSK3β on Ser9) did not differ significantly between groups (Figure 5.5A and 
B). In CTR liver biopsies obtained at the end of the HIHG clamp, P-Akt on Ser473 was 
significantly increased from basal in both the absence and presence of portal glucose 
infusion (34% and 50% in HIHG-PoG and HIHG+PoG CTR, respectively; NS between 
the two groups) (Figure 5.5A). In contrast, P-Akt on Ser473 in the livers of HFFD-fed 
animals was significantly lower than in the corresponding CTR group under both 
experimental conditions, and did not change from basal in response to hyperinsulinemia 
and hyperglycemia (Figure 5.5A). P-GSK3β on Ser9 did not change from basal in any of 
the groups, but tended to be reduced in HFFD-fed animals relative to CTR (Figure 5.5B).  
Under basal conditions, the phosphorylation of GS (P-GS on Ser641) and the 
activity ratios of GS and GP were not different between CTR and HFFD groups (Figure 
5.6 A-D). Likewise, total GS activity was similar between groups under basal conditions 
(data not shown). In the HIHG-PoG CTR group, hyperinsulinemia in the presence of 
hyperglycemia produced a significant decrease (35%) in P-GS on Ser641, consistent with 
stimulation of Akt phosphorylation (Figure 5.6A). Likewise, the activity ratio of GS 
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increased approximately 5-fold (P < 0.05 vs. basal), whereas that of GP was reduced by 
40% (Figure 5.6B and C). Thus, when GS and GP were themselves expressed as a ratio 
(GS/GP), there was an 8-fold increase from basal (P < 0.05) concomitant with an increase 
in liver glycogen levels (Figure 5.6D and E). In the HIHG+PoG CTR group, delivery of 
glucose into the portal vein in the presence of hyperinsulinemia and hyperglycemia did 
not produce a further decrement in P-GS on Ser641, but did stimulate a further increase 
in the GS activity ratio (approximately 40%, P < 0.05 vs. HIHG-PoG CTR), and an 
additional small decrease in that of GP (Figure 5.6 A-C). As a result, the GS/GP activity 
ratio was elevated 12-fold in the presence of intraportal glucose infusion (P < 0.05 vs. 
HIHG-PoG CTR), and liver glycogen levels were increased significantly more than in the 
HIHG-PoG CTR group (Figure 5.6D and E).  
In the HIHG-PoG HFFD group, on the other hand, hyperinsulinemia in the 
presence of hyperglycemia did not produce a decrease in P-GS on Ser641, consistent with 
lack of stimulation of Akt phosphorylation (Figure 5.6A). Although the activity ratio of 
GS increased approximately 3-fold (P<0.05 vs. basal), it was significantly reduced 
relative to the corresponding CTR group, whereas the activity ratio of GP changed 
minimally from basal (Figure 5.6B and C). As a result, the GS/GP activity ratio and the 
change in liver glycogen were significantly lower in the HIHG-PoG HFFD group relative 
to the corresponding CTR group (Figure 5.6D and E). Portal glucose delivery in the 
presence of hyperinsulinemia and hyperglycemia produced no further change in P-GS on 
Ser641, or in the GS, GP, or GS/GP activity ratios (Figure 5.6 A-E). Total GS activity did 
not differ between groups during the HIHG clamp (data not shown). Although liver 
glycogen levels were slightly increased in the HIHG+PoG HFFD group, the change in 
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glycogen induced by portal glucose delivery was markedly less in HFFD-fed dogs than in 
CTR-fed dogs (Figure 5.6E). Lastly, HFFD-feeding was associated with a significant 
decrease (approximately 70% in HIHG-PoG and HIHG+PoG HFFD groups vs. the 
corresponding CTR group; P < 0.05) in the incorporation of glucose into glycogen 
through the direct synthetic pathway (glucose  glucose 6-phosphate glucose 1-
phosphate  UDP-glucose  glycogen), in agreement with diminished HGU and GK 
activity, and impaired activation of GS in response to hyperinsulinemia, hyperglycemia, 
and intraportal glucose infusion (Figure 5.6F). 
Total Liver Triglyceride 
There was no effect of diet or experimental condition on total liver triglyceride 
levels (µg/mg liver; Basal CTR: 2.5±0.4, Basal HFFD: 1.6±0.1, HIHG-PoG CTR: 
1.3±0.2, HIHG-PoG HFFD: 1.8±0.4, HIHG+PoG CTR: 1.4±0.2; HIHG+PoG HFFD: 
1.1±0.2; data not shown). 
 
Discussion 
The first aim of this study was to identify the molecular “signature” of the portal 
glucose signal per se in the presence of a physiologic rise in glucose and insulin - 
experimental conditions that mimic the postprandial state. The second aim of this study 
was to elucidate the molecular explanation for the defect in HGU caused by HFFD 
feeding, and whether it persists in the presence of the portal glucose signal. To this end, 
we performed hyperinsulinemic hyperglycemic (HIHG) clamp experiments in the 
absence or presence (HIHG-PoG or HIHG+PoG, respectively) of portal vein glucose 
infusion in dogs that were fed a CTR or HFFD for 4 weeks. Liver biopsies were obtained 
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under basal conditions and at the end of the experiment for biochemical analyses. To 
date, the molecular events linking the pleiotropic actions of the portal glucose signal to 
increased HGU and GSYN have not been clearly defined. Likewise, the molecular 
changes associated with a diminished response of the liver to hyperinsulinemia, 
hyperglycemia, and portal glucose delivery in the insulin resistant individual are 
incompletely understood. Herein we demonstrated that delivery of glucose into the portal 
vein in the presence of a physiologic rise in glucose and insulin triggered a coordinated 
cellular response involving an increase in the activity of hepatic GK and GS, which 
occurred in association with further augmentation in HGU and GSYN. In contrast, 4 
weeks of HFFD feeding impaired HGU and GSYN in association with a marked decrease 
in GK activity, and impaired activation of Akt and GS in the presence of 
hyperinsulinemia and hyperglycemia. Furthermore, intraportal glucose infusion was 
ineffective in stimulating GK and GS activity in HFFD-fed animals, and these defects 
were associated with a loss of the stimulatory effects of the portal glucose signal. 
Altogether, these data provide novel mechanistic insight into the molecular physiology of 
the portal glucose signal under normal conditions, and to the pathophysiology of aberrant 
postprandial hepatic glucose disposition evident under an insulin resistant condition.   
Metabolic and cellular response of the liver to hyperglycemia and hyperinsulinemia in 
CTR-fed animals.  
Consistent with previous observations [182, 183, 188], a physiologic rise in 
glucose (2x basal) and insulin (3x basal) in the absence of intraportal glucose infusion 
resulted in a dynamic switch from net hepatic glucose output to uptake (1.1 to -1.5 
mg/kg/min, respectively). This was due to near complete suppression of HGP 
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concomitant with significant stimulation of HGU (mean rate of 1.6 mg/kg/min during the 
last 30 min of the study). A 6-fold increase in hepatic GK expression accompanied 
hyperinsulinemia in the HIHG-PoG CTR group, but this did not result in an increase in 
the functional amount of hepatic GK protein or its enzymatic activity within the 3-hour 
observation period. Previously, Ramnanan et al. [214] reported a 12-fold increase in 
hepatic GK expression after 2 hours of hyperinsulinemia (8-fold basal) and euglycemia, 
which was associated with an approximate 2-fold increase in GK protein. In the present 
study, insulin levels were increased only 3-fold basal, resulting in hepatic sinusoidal 
insulin concentrations of approximately 70 µU/ml vs. 160 µU/ml in the study of 
Ramnanan et al. [214]. Given that insulin is a potent inducer of hepatic GK expression 
[345-347], differences in GK mRNA levels and protein content between the two studies 
are most likely related to widely differing insulin concentrations during both experiments. 
In addition, Iynedjian and colleagues [238, 345] demonstrated that there is substantial lag 
in the time course of GK protein accumulation relative to induction of GK mRNA 
expression, which was attributed to the fairly long half-life of liver GK (approximately 30 
h in the rat). Thus, it is possible that a similar lag in GK protein accumulation existed in 
the present study under conditions of acute physiologic hyperinsulinemia, but in the 
absence of portal glucose delivery. Nevertheless, a substrate-mediated increase in GK 
flux can occur in the absence of an increase in GK activity. Indeed, Rossetti and 
colleagues [210] reported that hyperglycemia per se suppressed HGP in rats by 
decreasing glycogen phosphorylase a activity and increasing GK flux, while GK activity 
was unaffected. Given the sigmoidal kinetic properties of liver GK and its high Km for 
glucose relative to other hexokinases [122, 348], a 2-fold increase in the arterial plasma 
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glucose concentration (from 6 to 12 mM), as occurred in the present study, increased 
HGU and undoubtedly increased GK flux in the HIHG-PoG CTR group.   
Hyperinsulinemia in the presence of hyperglycemia resulted in a significant 
decrease in P-GS on Ser 641, consistent with activation of insulin signal transduction to 
Akt. Likewise, the activity ratio of GS, a reflection of its phosphorylation state in vivo, 
increased approximately 5-fold, whereas that of GP was reduced by 40%. This resulted in 
an 8-fold increase in the GS/GP activity ratio. Thus, in addition to activation of HGU, 
hyperglycemia and hyperinsulinemia stimulated the dephosphorylation and activation of 
GS, while triggering the dephosphorylation and inactivation of GP, which culminated 
with an increase in the deposition of carbon as glycogen within the liver. These data are 
in agreement with previous observations by Pagliassotti et al. [198] in dogs, and Petersen 
et al. [213] in humans.  
Activation of the PI3-kinase/Akt arm of the insulin signaling pathway usually 
stimulates the phosphorylation and inactivation of GSK3β (Ser9), a negative regulator of 
GS activity [349]. Ser641 is one of four residues on GS that is phosphorylated by GSK3β 
[349, 350]. In the present study, hyperinsulinemia in the presence of hyperglycemia 
stimulated the phosphorylation of Akt on Ser473, the dephosphorylation of GS on 
Ser641, and an increase in GS activity, in the absence of an increase in GSK3β 
phosphorylation on Ser9. Although the explanation for this finding is not clear, it is 
possible that other kinases sensitive to inhibition by hyperinsulinemia and/or 
hyperglycemia are capable of phosphorylating GS on Ser641. In addition, Patel and 
colleagues [351] demonstrated previously that the dephosphorylation of hepatic GS on 
Ser641, and the increase in GS activity in response to insulin, glucose, or a meal, was not 
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enhanced in mice with a liver-specific deletion of GSK3β. These data suggest that factors 
independent of hepatic GSK3β are also involved in the regulation of GS activity by 
insulin and glucose. In addition, loss of Akt activation in IRS 1/2 null mice had no impact 
on the ability of insulin to stimulate the phosphorylation of GSK3β on Ser9 [352], 
indicating that factors independent of Akt can regulate the phosphorylation state of 
GSK3β.  
Metabolic and cellular response of the liver to portal glucose delivery in CTR-fed 
animals.  
Delivery of glucose into the portal vein in the presence of equivalent (see above) 
hyperinsulinemia and hyperglycemia at the liver triggered a significantly greater increase 
in net hepatic glucose uptake, which was solely attributable to further augmentation of 
HGU (peak rate of 3.0 mg/kg/min), given that HGP was already suppressed. Intriguingly, 
portal glucose delivery also resulted in a dramatic induction of hepatic GK mRNA 
expression over that of the HIHG-PoG group, despite the fact that insulin concentrations 
were equivalent between the two. Previously, Iynedjian and colleagues [346] reported 
that there was no effect of hyperglycemia (up to 40 mM glucose) on the induction of GK 
expression by insulin in cultured liver cells. However, the response of the liver to portal 
vein glucose delivery is thought to be neurally-mediated [26, 184, 193, 195, 219, 353]. 
Thus, it is possible that the ability of the portal glucose signal to augment hepatic GK 
expression is also under neural control. In such a case, its effect would only be detected 
in the intact organism. Afferent fibers in the hepatic branch of the vagus nerve can detect 
the glucose concentration in the portal vein [195, 215, 228, 354], and delivery of glucose 
into the portal vein results in a decrease in the firing rate of these afferent fibers [195, 
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355, 356]. Thus, changes in parasympathetic tone to the liver, or changes in the 
abundance of other biological mediators of NHGU (e.g. nitric oxide or serotonin [5-HT]) 
might be involved in the induction of GK expression by portal glucose delivery. 
Recently, Ramnanan et al. [357] demonstrated that a selective rise in insulin in the brain 
under euglycemic conditions induces a 3-fold increase in hepatic GK expression, whereas 
icv delivery of a PI3-kinase inhibitor (LY294002) ablates the effect. These data raise the 
possibility that the induction of hepatic GK expression by insulin and/or the portal 
glucose signal is in part, neurally-mediated.  
Interestingly, hyperinsulinemia and hyperglycemia in the absence of portal 
glucose infusion produced a 6-fold increase in GK mRNA without an increase in GK 
protein over a 3-hour observation period. In contrast, portal glucose delivery during the 
last 90 min of the study produced a further 4-fold increase in GK mRNA concomitant 
with a significant increase GK protein and activity relative to the HIHG-PoG CTR group. 
One possibility for this observation is that the portal glucose signal might reduce the lag 
time for GK protein accumulation (see previous section) by stimulating more efficient 
coupling between GK transcription and GK translation, thereby ensuring the appropriate 
amount of glucose uptake and storage by the liver in response to a meal. Another 
possibility is that the portal glucose signal prevents the degradation of GK protein in 
addition to stimulating its expression. Indeed, previous studies [358-360] have suggested 
that binding of GK in the cytosol by the bifunctional enzyme, 6-phosphofructo-2-kinase 
(PFK-2) / fructose-2,6-bisphosphatase (BIF), protects GK from degradation and increases 
its catalytic activity. Furthermore, Wu and colleagues [360, 361] demonstrated that 
increasing the levels of hepatic fructose-2,6-bisphosphate, a metabolite synthesized by 
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PFK-2 secondary to an increase in glycolytic flux, increases the gene expression and 
protein content of GK. In the present study, net hepatic lactate output during P2 was 
significantly lower in the absence than in the presence of intraportal glucose infusion, 
suggesting that net hepatic glycolysis was increased in the latter. Thus, it is possible that 
the portal glucose signal increased the activity of PFK-2 and the abundance of fructose-
2,6-bisphosphate, thereby preventing the degradation of GK protein and facilitating an 
increase in GK expression and activity. Given that phosphorylation of glucose by GK is 
thought to be rate-limiting for HGU [231, 232], our data suggest that activation of GK by 
intraportal glucose delivery is one of the mechanisms through which the portal glucose 
signal stimulates a further increase in HGU over that observed in the presence of 
hyperglycemia and hyperinsulinemia alone. The present data do not shed light on the 
issue of whether portal glucose delivery stimulates the translocation of hepatic GK in 
vivo, as we have conjectured previously [26, 180, 233], but they clearly demonstrate that 
at least one additional regulatory mechanism exists through which the portal glucose 
signal per se can augment GK expression and activity. Altogether, our findings indicate 
that the portal glucose signal regulates hepatic GK acutely by increasing its activity, and 
chronically by inducing its expression, thus priming the liver for increased glucose 
uptake and storage at a subsequent meal.  
In agreement with the findings of Pagliassotti et al [198], portal glucose delivery 
triggered a significantly greater increase GS activity than the same hyperglycemia and 
hyperinsulinemia alone. Although this was not associated with further diminution in the 
phosphorylation of GS on Ser641, GS contains several other phosphorylation sites that 
regulate its activity [349, 350, 362]. Thus, the effect of the portal glucose signal on the 
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phosphorylation state of liver GS could have been mediated by dephosphorylation of sites 
distinct from that of Ser 641. In addition, it is possible that there was an increase in 
hepatocellular glucose-6-phosphate levels in response to the portal signal-induced 
increase in GK activity and HGU, which made GS a better substrate for 
dephosphorylation by protein phosphatase-1 [363, 364]. Lastly, it is also possible that 
there was neural modulation of liver GS activity in the presence of intraportal glucose 
infusion, as postulated earlier for GK mRNA. Indeed, previous studies have demonstrated 
that electrical stimulation of the efferent limb of the vagus nerve activates liver GS [215, 
228-230]. The coupling of an increase in GS activity and a smaller decrease in GP 
activity resulted in a 12-fold increase from basal in the GS/GP activity ratio in the 
presence of the portal glucose signal, and a robust increase in liver glycogen levels 
relative to that observed in the absence of the portal glucose signal.  
Collectively, these data suggest that the portal glucose signal triggers a 
significantly greater increase in HGU and GSYN by augmenting the activity of hepatic 
GK and GS. In addition, they support the concept that the intraportal route of glucose 
delivery generates a unique signal that serves as one of the primary determinants of HGU 
and GSYN in vivo [182, 183, 188, 189, 365]. 
Metabolic and cellular response of the liver to hyperglycemia and hyperinsulinemia in 
HFFD-fed animals.  
Previously [366], we demonstrated that 4 weeks of HFFD feeding was associated 
with significantly impaired glucose tolerance. Given that the contribution of the liver to 
the disposition of a moderately-sized oral glucose load is at least as great as that of 
skeletal muscle [27, 184], that observation prompted us to assess whether 4 weeks of 
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HFFD feeding was associated with a decrease in HGU in the presence of a physiologic 
rise in glucose and insulin, and in the presence of portal glucose delivery. In addition, we 
wanted to compare the molecular changes associated with hyperinsulinemia, 
hyperglycemia, and portal glucose delivery in CTR and HFFD-fed animals in an attempt 
to shed light on the early cellular defects associated with impaired regulation of hepatic 
glucose flux in an insulin resistant model.  
In stark contrast to the response observed in CTR-fed dogs, the combination of 
hyperinsulinemia and hyperglycemia was associated with impaired suppression of HGP, 
and virtually no stimulation of HGU in HFFD-fed dogs. In accord with this finding, livers 
of dogs in the HFFD group continued in net hepatic lactate uptake for the duration of the 
study, despite the presence of hyperglycemia and hyperinsulinemia. Although a 7-fold 
increase in hepatic GK expression accompanied hyperinsulinemia in the HIHG-PoG 
HFFD group, this did not result in an increase in the functional amount of GK protein. In 
fact, hepatic GK protein content and activity were markedly reduced in HFFD-fed dogs 
under basal conditions and during the HIHG clamp, consistent with impaired activation 
of HGU. Furthermore, the phosphorylation of Akt on Ser473 was significantly lower in 
HFFD-fed animals, indicative of biochemical insulin resistance after 4 weeks of HFFD 
feeding. As a result, the phosphorylation of GS on Ser641 was not reduced from basal, 
and the activity ratio of GS in the presence of hyperinsulinemia and hyperglycemia was 
only modestly increased, and was significantly lower in HFFD-fed dogs relative to the 
corresponding CTR group. When coupled with attenuated suppression of GP activity, 
there was a 4-fold increase in the GS/GP activity ratio in HFFD-fed dogs compared to an 
8-fold increase in CTR-fed dogs under the same experimental conditions. Consequently, 
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the change in liver glycogen levels in response to hyperinsulinemia and hyperglycemia 
was barely detectible, consistent with a marked decrease in direct glycogen synthesis 
compared to the corresponding CTR group. Thus, impaired activation of HGU in HFFD-
fed dogs in the presence of hyperinsulinemia and hyperglycemia was associated with 
decreased GK protein content and activity, impaired activation of Akt and glycogen 
synthase activity, and reduced suppression of glycogen phosphorylase activity.  
Metabolic and cellular response of the liver to portal glucose delivery in HFFD-fed 
animals.  
Interestingly, delivery of glucose into the portal vein in the presence of 
hyperinsulinemia and hyperglycemia triggered suppression of residual HGP in the 
HIHG+PoG HFFD group, but did not stimulate HGU. As a result, net hepatic glucose 
balance decreased to a rate not significantly different from zero, so that in a net sense, the 
liver did not take up any glucose. Although the mechanism by which portal glucose 
delivery suppressed HGP in HFFD-fed dogs is not clear, studies conducted by Newgard 
et al. [367] and Mithieux et al. [368] have suggested that inhibition of G6Pase activity 
plays a role in the suppression of HGP and in liver glycogen repletion after refeeding in 
rodents. Thus, a similar mechanism might be involved in the present study. Nevertheless, 
portal glucose delivery had no impact on net hepatic lactate balance in HFFD-fed dogs, 
consistent with lack of stimulation of HGU. These data are in agreement with those of 
Basu and colleagues [200], who demonstrated that impaired splanchnic glucose uptake 
(SGU) in type 2 diabetic individuals is not dependent on the route of glucose delivery, 
given that intraduodenal glucose infusion was incapable of restoring their diminished 
rates of SGU during an HIHG clamp.  
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There are several possibilities for why the livers of dogs fed a HFFD did not 
switch from net lactate uptake to net lactate output, despite the presence of 
hyperinsulinemia, hyperglycemia, and portal glucose delivery. One possibility is that 
HFFD-feeding produced hepatic insulin resistance and thus, might have led to impaired 
insulin-mediated activation of rate-limiting enzymes involved in the glycolytic pathway 
(phosphofructokinase-1/2 and pyruvate kinase). It is also possible that a decrease in the 
amount of substrate available for catabolism through the glycolytic pathway secondary to 
impaired HGU might have limited net hepatic lactate output during the clamp 
experiment. Another possibility relates to the difference in suppression of lipolysis in 
CTR and HFFD groups. Chu and colleagues [369] demonstrated previously that elevation 
of plasma NEFA levels brought about using intralipid and heparin infusion completely 
eliminated the ability of hyperglycemia per se to cause net hepatic lactate output. This 
was attributed to stimulation of hepatic gluconeogenic flux and inhibition of glycolysis 
[177, 369]. In the present study, there was a tendency for arterial plasma NEFA and 
glycerol concentrations to be higher in HFFD-fed dogs than in CTR-fed dogs throughout 
the experiment, which might have contributed to aberrant net hepatic lactate balance in 
the former. These data also suggest that insulin resistance was present in adipose tissue 
after only 4 weeks of HFFD feeding. This raises the possibility that endocrine factors 
(adipokines) and/or inflammatory cytokines secreted from insulin resistant adipose tissue 
might have played a role in reducing hepatic GK activity and HGU.   
Portal glucose delivery also stimulated a dramatic increase in hepatic GK mRNA 
expression in the HIHG+PoG HFFD group as it did in the CTR group, suggesting that the 
mechanism(s) through which hyperglycemia, hyperinsulinemia, and portal glucose 
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delivery bring about an increase in GK expression are intact in HFFD-fed animals. In 
contrast, the increase in GK protein content and activity seen in CTR animals in response 
to the portal glucose signal was abolished in HFFD-fed animals, as their GK protein 
levels were reduced by more than 50% relative to the corresponding CTR group. 
Likewise, there was no effect of intraportal glucose infusion on GS and GP activity ratios 
in the HIHG+PoG HFFD group, which was associated with a minimal increase in their 
liver glycogen levels. Thus, 4 weeks of HFFD feeding abrogated the stimulatory effects 
of hyperglycemia, hyperinsulinemia, and portal glucose delivery on GK and GS activity, 
which manifested as diminished HGU and GSYN.  
Normal GK mRNA expression concomitant with significantly diminished GK 
protein content suggests that the HFFD-induced decrease in GK protein occurred post-
transcriptionally. Studies conducted in GKRP-deficient mice demonstrated that they also 
have significantly reduced GK immunoreactive protein despite normal basal and insulin-
stimulated GK mRNA expression, suggesting that GKRP exerts a permissive effect on 
the level of GK protein through a post-transcriptional mechanism [370, 371]. 
Interestingly, GKRP protein levels were significantly reduced in the HFFD group under 
basal conditions and during the HIHG clamp, suggesting that reduced levels of hepatic 
GKRP in HFFD-fed animals may have contributed to the post-transcriptional decline in 
GK protein. However, the mechanism(s) through which HFFD feeding elicits a decrease 
in hepatic GKRP and GK protein content is currently unknown.  
In obese rodent models of insulin resistance and type 2 diabetes, activation of the 
unfolded protein response and induction of endoplasmic reticulum (ER) stress have been 
shown to halt the translation of proteins by phosphorylating and inactivating eIF2α 
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{Thomas,  #4940}; however, there was no difference between diet groups in the 
phosphorylation of PERK on Thr980, its downstream target, eIF2α on Ser51, or in the 
protein level of the ER chaperone, Bip, in the present study (data not shown). Likewise, 
there was no difference between diet groups in the hepatic expression of genes involved 
in the production of reactive oxygen and nitrogen species (NADPH oxidase [Nox2 and 
Nox4] and iNOS, respectively; data not shown). Furthermore, HFFD feeding induced a 
marked impairment in HGU and GSYN in the absence of an increase in liver triglyceride 
levels. In agreement with this finding, long-chain acyl Co-A, diacylglycerol, and 
ceramide levels were also not different between CTR and HFFD-fed animals in a smaller 
cohort of dogs (data not shown). These data suggest that diet-induced impairments in GK 
and hepatic glucose flux can occur independently of liver lipid accumulation. Future 
studies will need to be conducted to elucidate the mechanism(s) through which a HFFD 
impairs the regulation of hepatic GK in a post-transcriptional fashion.  
In conclusion, we demonstrated that delivery of glucose into the hepatic portal 
vein in the presence of hyperinsulinemia and hyperglycemia triggered a coordinated 
molecular response involving an increase in the catalytic activity of hepatic GK, and 
stimulation of GS activity, which collectively augmented HGU and GSYN in vivo. In 
contrast, HFFD-feeding abrogated the stimulatory effects of hyperinsulinemia, 
hyperglycemia, and portal glucose delivery on GK, Akt, and GS activation, and as a 
result, HGU and GSYN were impaired. These data provide novel mechanistic insight into 
the molecular physiology of the portal signaling mechanism under normal conditions, and 
suggest that impaired regulation of hepatic GK under insulin resistant conditions is one of 
the early molecular defects that contribute to the deterioration of glucose tolerance and 
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development of postprandial hyperglycemia secondary to diminished HGU.  
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Figure 5.1: Schematic representation of the hyperinsulinemic hyperglycemic clamp protocol. The protocol consisted of basal (-
20 to 0 min) and experimental periods (1: 0-90 min; 2: 90-180 min). Somatostatin and 3-[3H] glucose were infused peripherally, 
insulin (3-fold basal) and glucagon (basal) were infused intraportally, and glucose was infused peripherally at a variable rate to 
increase the hepatic glucose load 2-fold basal during periods 1 and 2. During period 2, glucose was also infused intraportally to 
activate the portal glucose signal. 
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Figure 5.2: Plasma hormone concentrations during hyperinsulinemic hyperglycemic clamps in CTR and HFFD groups. 
Arterial plasma insulin (A) and glucagon (C), and hepatic sinusoidal insulin (B) and glucagon (D) during basal (-20 to 0 min) and 
experimental periods (0 to 180 min) of HIHG clamps conducted in 18-h-fasted dogs after 4 weeks of feeding a CTR (HIHG-PoG 
CTR, n = 5; HIHG+PoG CTR, n = 5; □) or HFFD (HIHG-PoG HFFD, n = 5; HIHG+PoG HFFD, n = 6; ●).  Data are means ± SE. † P 
< 0.05 vs. basal period.  
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Figure 5.3: Arterial blood glucose, hepatic glucose load, and hepatic glucose uptake during hyperinsulinemic hyperglycemic 
clamps in CTR and HFFD groups. Arterial blood glucose (A), hepatic glucose load (B), and hepatic glucose uptake in the portal 
saline (C) and portal glucose (D) groups during the basal (-20 to 0 min) and experimental periods (0 to 180 min) of HIHG clamps 
conducted in 18-h-fasted dogs after 4 weeks of feeding a CTR (HIHG-PoG CTR, n = 5; HIHG+PoG CTR, n = 5; □) or HFFD (HIHG-
PoG HFFD, n = 5; HIHG+PoG HFFD, n = 6; ●). Data are means ± SE. † P < 0.05 vs. basal period; *P < 0.05 vs. corresponding CTR 
group; § P < 0.05, HIHG-PoG HFFD vs. CTR; # P < 0.05, HIHG+PoG HFFD vs. CTR. 
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Figure 5.4: Hepatic glucokinase (GK) and glucokinase regulatory protein (GKRP) 
in CTR and HFFD groups. Levels of GK mRNA (A) and protein (B), GK activity (C), 
and levels of GKRP protein (D). A, B, and D are expressed relative to levels observed in 
basal CTR animals. Data are means ± SE; n = 5-6 per group. ‡P < 0.05, basal HFFD vs. 
CTR; †P < 0.05 vs. basal CTR; *P < 0.05 vs. corresponding CTR group; §P < 0.05, 
HIHG - PoG HFFD vs. CTR; #P < 0.05, HIHG + PoG HFFD vs. CTR.   
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Figure 5.5: Markers of hepatic insulin signaling in CTR and HFFD groups. 
Phosphorylation of Akt on Ser473 (A) and GSK3β on Ser9 (B) relative to levels observed 
in basal CTR animals. Data are means ± SE; n = 5-6 per group. †P < 0.05 vs. basal CTR; 
§P < 0.05, HIHG - PoG HFFD vs. CTR; # P < 0.05, HIHG + PoG HFFD vs. CTR.   
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Figure 5.6: Markers of hepatic glycogen metabolism in CTR and HFFD groups. Phosphorylation of glycogen synthase (GS) on 
Ser641 (A) relative to levels observed in basal CTR animals. Activity ratios of GS (B), glycogen phosphorylase (GP) (C), and GS/GP 
(D). Calculated increment in liver glycogen from basal (E). Glycogen synthesized through the direct pathway (F). Data are means ± 
SE; n = 5-6 per group. †P < 0.05 vs. basal CTR; *P < 0.05 vs. corresponding CTR group; §P < 0.05, HIHG - PoG HFFD vs. CTR; #P 
< 0.05, HIHG + PoG HFFD vs. CTR. 
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TABLE 5.1. 
Mean values for total hepatic blood flow and glucose infusion rate during the basal (-20 
to 0 min) and experimental periods (P1, 60 to 90 min; P2, 150-180 min) of a 
hyperinsulinemic hyperglycemic clamp   
   Experimental Period  
 Group Basal Period Period 1 Period 2 
Total hepatic blood flow,  
          ml/kg/min 
 CTR - PoG 29 ± 5  23 ± 2   26 ± 2  
 HFFD - PoG 25 ± 1  22 ± 1   25 ± 2  
 CTR + PoG 25 ± 3  21 ± 2   23 ± 3  
 HFFD + PoG 25 ± 3  22 ± 3   24 ± 2  
Total glucose infusion rate, 
          mg/kg/min 
 CTR - PoG 0.0 ± 0.0  7.3 ± 0.8A   10.4 ± 1.3A  
 HFFD - PoG 0.0 ± 0.0  8.4 ± 1.6A   12.7 ± 1.6A  
 CTR + PoG 0.0 ± 0.0  9.0 ± 3.0A   10.2 ± 2.4A  
 HFFD + PoG 0.0 ± 0.0  5.8 ± 0.7A   7.6 ± 1.1A  
Values are means ± SE; CTR-PoG, n = 5; HFFD-PoG, n = 5; CTR+PoG, n = 5; HFFD+PoG, n = 
6. Dogs were 18h-fasted prior to study. A, P < 0.05 vs. basal period.  
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Table 5.2. 
Mean values for unidirectional hepatic glucose uptake, hepatic glucose production, and 
net hepatic glucose balance during the basal (-20 to 0 min)  and experimental 
(P1, 30 to 90 min; P2, 120 to 180 min) periods of a hyperinsulinemic hyperglycemic clamp 
in the CTR - PoG, HFFD - PoG, CTR + PoG, and HFFD + PoG groups
Basal Period 
Hepatic glucose uptake, mg/kg/min
CTR - PoG -0.27 ± 0.12 -1.31 ± 0.17A -1.64 ± 0.13AB
HFFD - PoG -0.32 ± 0.11 -0.35 ± 0.07D -0.58 ± 0.21D
CTR + PoG -0.44 ± 0.11 -1.67 ± 0.29A -2.73 ± 0.22ACF
HFFD + PoG -0.38 ± 0.10 -0.53 ± 0.05E -0.61 ± 0.17E
Hepatic glucose production, mg/kg/min
CTR - PoG 1.35 ± 0.14 0.04 ± 0.36A 0.10 ± 0.22A
HFFD - PoG 1.78 ± 0.29 0.90 ± 0.21A 0.79 ± 0.39A
CTR + PoG 2.11 ± 0.36 0.21 ± 0.26A 0.31 ± 0.29A
HFFD + PoG 1.94 ± 0.30 1.33 ± 0.18AE 0.47 ± 0.42AC
Net hepatic glucose balance, mg/kg/min
CTR - PoG 1.09 ± 0.06 -1.27 ± 0.21A -1.54 ± 0.17A
HFFD - PoG 1.46 ± 0.23 0.55 ± 0.24AD 0.21 ± 0.24AD
CTR + PoG 1.66 ± 0.26 -1.47 ± 0.14A -2.42 ± 0.36ACF
HFFD + PoG 1.57 ± 0.25 0.80 ± 0.16AE -0.14 ± 0.38ACE
Values are means ± SE; CTR-PoG, n  = 5; HFFD-PoG, n  = 5; CTR+PoG, n  = 5; HFFD+PoG, n  = 6. 
Dogs were 18-h-fasted prior to study. A, P < 0.05 vs. basal period; B, P  < 0.05, P1 vs. P2; C, P  < 0.01, P1 vs. P2; 
D, P  < 0.05, HFFD-PoG vs. CTR-PoG; E, P < 0.05, HFFD+PoG vs. CTR+PoG; F, P  < 0.05 vs. corresponding -PoG
group. Negative values for balance data indicate net hepatic uptake; positive values indicate net hepatic production.
Group Period 2Period 1 
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Table 5.3.  
Mean values for lactate, glycerol, and NEFA concentrations, and their net hepatic balance during the basal (-20 to 0 min) 
and experimental (P1, 60 to 90 min; P2, 150-180 min) periods of the hyperinsulinemic hyperglycemia clamp in the CTR - PoG, HFFD - PoG, CTR + PoG, and HFFD + PoG groups.   
Basal Period, min Period 1, min Period 2, min
Arterial blood lactate, µmol/l
CTR - PoG 325 ± 43 1000 ± 71A 972 ± 22A 970 ± 39A 850 ± 45A 873 ± 79A 853 ± 66A
HFFD - PoG 472 ± 154 504 ± 54C 579 ± 65C 658 ± 87 811 ± 132C 762 ± 83C 783 ± 85C
CTR + PoG 397 ± 111 663 ± 87A 628 ± 74AB 642 ± 88A 643 ± 78A 689 ± 87A 693 ± 121A
HFFD + PoG 318 ± 42 422 ± 44 386 ± 45 394 ± 50 444 ± 57B 452 ± 59BD 466 ± 45B
Net hepatic lactate balance, µmol/kg/min
CTR - PoG -6.6 ± 0.6 7.2 ± 1.6A 6.9 ± 1.9A 3.8 ± 2.3A 2.7 ± 0.9A 1.9 ± 1.0A 1.2 ± 1.0A
HFFD - PoG -7.3 ± 2.0 -4.1 ± 1.4AC -3.4 ± 1.3AC -3.8 ± 1.4AC -4.0 ± 1.0AC -4.6 ± 0.3C -4.7 ± 0.3C
CTR + PoG -5.3 ± 0.3 8.3 ± 1.9A 7.0 ± 1.7A 6.3 ± 1.3A 5.1 ± 0.6AB 4.4 ± 0.8AB 5.0 ± 0.8AB
HFFD + PoG -6.3 ± 1.1 -3.6 ± 0.9D -2.8 ± 0.9AD -2.5 ± 0.9AD -3.3 ± 0.7AD -3.6 ± 1.0D -3.6 ± 0.7D
Arterial blood glycerol, µmol/l
CTR - PoG 81 ± 12 27 ± 6A 31 ± 11A 27 ± 6A 23 ± 10A 31 ± 12A 29 ± 10A
HFFD - PoG 92 ± 15 62 ± 18A 62 ± 15A 57 ± 15A 68 ± 19AC 51 ± 17A 53 ± 18A
CTR + PoG 72 ± 6 32 ± 4A 27 ± 3A 23 ± 1A 29 ± 3A 29 ± 5A 29 ± 3A
HFFD + PoG 98 ± 12 56 ± 6A 51 ± 7A 45 ± 4A 55 ± 6A 49 ± 6A 50 ± 7A
Net hepatic glycerol balance, µmol/kg/min
CTR - PoG -1.7 ± 0.4 -0.5 ± 0.2A -0.4 ± 0.1A -0.4 ± 0.1A -0.3 ± 0.1A -0.6 ± 0.2A -0.6 ± 0.2A
HFFD - PoG -1.7 ± 0.4 -1.0 ± 0.4A -1.1 ± 0.3A -1.0 ± 0.4A -1.2 ± 0.4A -1.0 ± 0.3A -0.9 ± 0.5A
CTR + PoG -1.7 ± 0.1 -0.7 ± 0.2A -0.5 ± 0.1A -0.5 ± 0.1A -0.7 ± 0.1A -0.6 ± 0.1A -0.8 ± 0.1A
HFFD + PoG -2.0 ± 0.4 -1.0 ± 0.2A -1.0 ± 0.3A -0.8 ± 0.2A -1.0 ± 0.3A -0.8 ± 0.2A -0.9 ± 0.2A
Arterial plasma NEFA, µmol/l
CTR - PoG 924 ± 127 99 ± 25A 116 ± 26A 114 ± 42A 63 ± 10A 103 ± 33A 89 ± 28A
HFFD - PoG 791 ± 119 212 ± 61A 203 ± 64A 152 ± 44A 146 ± 56A 117 ± 38A 107 ± 33A
CTR + PoG 831 ± 73 154 ± 30A 136 ± 27A 118 ± 33A 84 ± 17A 109 ± 30A 102 ± 20A
HFFD + PoG 852 ± 115 261 ± 51A 207 ± 46A 168 ± 31A 169 ± 43A 139 ± 25A 174 ± 39A
Net hepatic NEFA balance, µmol/kg/min
CTR - PoG -2.7 ± 0.5 -0.1 ± 0.1A -0.2 ± 0.1A -0.2 ± 0.1A -0.1 ± 0.1A -0.3 ± 0.2A -0.2 ± 0.1A
HFFD - PoG -2.3 ± 0.3 0.0 ± 0.3A -0.5 ± 0.3A -0.3 ± 0.1A -0.5 ± 0.4A -0.3 ± 0.1A -0.3 ± 0.1A
CTR + PoG -2.5 ± 0.2 -0.2 ± 0.2A -0.1 ± 0.1A -0.2 ± 0.1A -0.2 ± 0.1A -0.3 ± 0.1A -0.3 ± 0.1A
HFFD + PoG -2.9 ± 0.5 -0.9 ± 0.2A -0.7 ± 0.1A -0.5 ± 0.2A -0.7 ± 0.2A -0.3 ± 0.1A -0.5 ± 0.2A
Values are means ± SE; CTR-PoG, n  = 5; HFFD-PoG, n  = 5; CTR+PoG, n  = 5; HFFD+PoG, n  = 6. Dogs were 18-h-fasted prior to study. A, P  < 0.05 vs. basal period; 
B, P  < 0.05 vs. corresponding HIHG-PoG group; C, P  < 0.05, HIHG-PoG HFFD vs. CTR; D, P  < 0.05, HIHG+PoG HFFD vs. CTR. Negative values for balance data indicate 
net hepatic uptake; positive values indicate net hepatic production. 
Group -20 to 0 165 18060 75 90 150
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CHAPTER VI 
 
THE EFFECT OF SHORT-TERM HIGH-FAT VS. HIGH-FRUCTOSE FEEDING 
ON HEPATIC GLUCOSE UPTAKE AND DISPOSITION 
 
(Manuscript in Preparation) 
 
Aim 
 In Specific Aim III, we demonstrated that 4 weeks of high-fat, high-fructose 
feeding is associated with diminished hepatic glucokinase (GK) and glycogen synthase 
(GS) activity, decreased insulin-mediated activation of Akt, and impaired hepatic glucose 
uptake (HGU) and glycogen synthesis (GSYN) when a dog is challenged with 
physiologic hyperinsulinemia (approximately 3-fold basal), hyperglycemia (hepatic 
glucose load that is 2-fold basal), and portal glucose delivery. However, we cannot 
ascertain from these data whether excess dietary fat, fructose, or both are required to 
elicit aberrant hepatic glucose flux under conditions that mimic the postprandial state. 
Thus, the objective of Specific Aim IV was to elucidate which macronutrient (fat or 
fructose) is driving metabolic dysfunction at the liver after 4 weeks of feeding. 
 
Experimental Design 
 Adult male mongrel dogs were fed once daily a pre-determined quantity of a 
meat/laboratory chow diet (control or CTR; n=5), a high-fat diet (HFA; n=5), or a high-
fructose diet (HFR; n=5) for 4 weeks. The specific macronutrient compositions of the 
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experimental diets utilized in Specific Aim IV are described in Chapter II under 
Experimental Diets, Table 2.2. Energy consumption of dogs in HFA and HFR was 
matched, but both groups were hypercaloric relative to CTR (mean daily energy intake 
[kcal/d] over 4 weeks: CTR, 1982±94; HFA, 2695±232; HFR, 2790±219) (Figure 6.1). 
After 4 weeks of experimental diet feeding, hyperinsulinemic hyperglycemic 
(HIHG) clamp experiments with portal vein glucose infusion were conducted on 18-h-
fasted, conscious dogs. Just prior to the fast, each dog was fed a can of meat as their meal 
to ensure equivalent energy and macronutrient consumption among groups the day before 
the study. Each experiment consisted of a 100 min equilibration period (-120 to -20 min), 
a 20 min basal control period (-20 to 0 min), and a 180 min experimental period divided 
into 2 sub-periods (P1, 0 to 90 min; P2, 90 to180 min). At -120 min, a priming dose of 
[3-3H]- glucose (38 µCi) was injected, followed by a constant infusion of [3-3H]-glucose 
(0.38 µCi/min). At time 0, a constant infusion of somatostatin (0.8 µg/kg/min) was 
initiated in the left saphenous vein, and insulin and glucagon were replaced intraportally 
at 3-fold basal (1.2 mU/kg/min) and basal (0.55 ng/kg/min) rates, respectively. In 
addition, a variable infusion of 50% dextrose was started in the right cephalic vein in 
order to double the hepatic glucose load (HGL). In P2, 20% dextrose (4.0 mg/kg/min) 
was infused intraportally, and the peripheral glucose infusion rate was adjusted as 
necessary to clamp the HGL to that in P1. For this study, unidirectional hepatic glucose 
uptake was calculated using a tracer-determined hepatic fractional extraction method, as 
described in detail under Calculations in Chapter II. At the end of the study, each animal 
was anaesthetized with sodium pentobarbital and a laparotomy was performed. The 
hormone, 3-[3H]-glucose, and unlabeled glucose infusions were continued while liver 
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sections from the left central, left lateral, and right central lobes were freeze-clamped in 
situ and stored at -80oC for tissue analysis. 
 
Results 
Plasma hormone concentrations and hepatic blood flow  
Fasting arterial plasma insulin levels were increased 45% and 70% in HFA and 
HFR, respectively, relative to CTR (µU/ml; CTR: 8.0±1.6, HFA: 11.6±1.2, HFR: 
13.6±1.2; P < 0.05 CTR vs. HFR), whereas arterial plasma c-peptide concentrations (data 
not shown) were elevated 79% and 50% in HFA and HFR, respectively, relative to CTR 
(ng/ml; CTR: 0.24±0.03, HFA: 0.43±0.08, HFR: 0.36±0.0; NS between groups). There 
was no effect of diet on fasting arterial plasma glucagon levels. During the HIHG clamp, 
arterial and hepatic sinusoidal insulin concentrations (µU/ml; CTR: 23±4 and 78±10, 
HFA: 26±2 and 89±6, HFR: 25±2 and 90±7, respectively; P < 0.05 vs. basal period) were 
increased to similar levels in all 3 groups, whereas arterial and hepatic sinusoidal 
glucagon concentrations were kept at a basal level throughout the study (Figure 6.2 A-D). 
Total hepatic blood flow was similar among groups under basal conditions and 
throughout the HIHG clamp (Table 6.1). 
Blood glucose, hepatic glucose load, and hepatic glucose uptake 
Fasting blood glucose concentrations did not differ between groups during the 
basal period. During P1, arterial blood glucose concentrations were increased to a similar 
level in all 3 groups (mg/dl; CTR: 161±4, HFA: 164±1, HFR: 163±1; P<0.05 vs. basal 
period) in order to double the hepatic glucose load (mg/kg/min; CTR: 37±2, HFA: 39±2, 
HFR: 38±3; P<0.05 vs. basal period) (Figure 6.3A and B). During P2, arterial blood 
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glucose levels were clamped at a slightly reduced concentration (mg/dl; CTR: 147±3, 
HFA: 150±2, HFR: 149±2) to maintain a doubling of the hepatic glucose load in the 
presence of intraportal glucose infusion (Figure 6.3A and B).  
 Hepatic glucose uptake (HGU) was similar among groups during the basal period 
(mg/kg/min; CTR: 0.4±0.1, HFA: 0.5±0.3, HFR: 0.4±0.2) (Figure 6.3C and D). During 
P1, hyperinsulinemia and hyperglycemia stimulated an increase in HGU in CTR, 
reaching a peak of 1.8±0.3 mg/kg/min (P<0.05 vs. basal period). Delivery of glucose into 
the portal vein during P2 in the presence of a sustained rise in glucose and insulin 
augmented HGU even further in CTR, eventually reaching a peak of 3.0±0.3 mg/kg/min 
(Figure 6.3C or D). In contrast, both high-fat and high-fructose feeding for 4 weeks 
rendered the liver resistant to the stimulatory effects of hyperinsulinemia, hyperglycemia, 
and portal glucose delivery on HGU. Thus, mean rates of HGU in HFA and HFR during 
P1 (1.0±0.4 and 0.60.2 mg/kg/min, respectively) and P2 (0.90.3 and 0.70.1 
mg/kg/min, respectively) were not significantly increased from their corresponding rates 
during the basal period (Figure 6.3C and D). However, the mean rate of HGU in high-fat-
fed dogs during P1 (average during the last 30 min of P1) did not differ significantly from 
that of CTR, whereas it did in the high-fructose-fed dogs (Figure 6.3C and D). In the 
presence of portal glucose delivery (P2), on the other hand, both groups displayed 
significantly lower rates of HGU relative to CTR. This was due to further stimulation of 
HGU during P2 in CTR, and the lack of such an effect in both HFA and HFR (Figure 
6.3C and D).  
Although the total glucose infusion rate (GIR) required to maintain 
hyperglycemia did not significantly differ among groups, it tended to be lower in HFA 
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and HFR vs. CTR throughout the entire HIHG clamp (Table 6.1).  
Lactate metabolism 
All groups exhibited net hepatic lactate uptake (NHLU) under basal conditions 
(Table 6.2). In CTR and HFA, hyperinsulinemia and hyperglycemia elicited an increase 
in arterial blood lactate levels coincident with a switch from NHLU to output (NHLO), 
although NHLO was significantly reduced in HFA vs. CTR (Table 6.2). In contrast, 
arterial blood lactate levels were not significantly elevated from basal during either test 
period in HFR, and these animals exhibited NHLU for the duration of the study (P < 0.05 
vs. CTR and HFA) (Table 6.2).    
Glycerol, nonesterified fatty acid, and triglyceride metabolism  
During the basal period, arterial blood glycerol concentrations were significantly 
elevated in HFA and HFR vs. CTR, whereas net hepatic glycerol uptake was significantly 
higher only in HFR (Table 6.2). Fasting arterial plasma NEFA concentrations were 
similar among the 3 groups. During P1 and P2, their levels declined in response to 
hyperinsulinemia, but the steady state values were slightly lower in CTR than in HFA or 
HFR (Table 6.2). The net hepatic uptake rates of glycerol and NEFA decreased in parallel 
to the changes in their circulating concentrations (Table 6.2).  
Fasting plasma total triglyceride concentrations (data not shown) did not differ 
between diet groups (1139±137, 1148±28, and 1156±284 µmol/l in HFA, HFR, and 
CTR, respectively). Likewise, terminal liver triglyceride levels (data not shown) were not 
significantly different among groups (µg/mg liver; HFA: 2.0±0.3, HFR: 1.7±0.2, CTR: 
1.4±0.2). 
 
 180 
Hepatic glucokinase (GK) and glucokinase regulatory protein (GKRP) 
Molecular parameters (n=5/group) in liver biopsies obtained at the end of the 
HIHG clamp experiment were compared amongst CTR, HFA, and HFR groups.  
Although relative hepatic GK mRNA expression was similar among groups (Figure 
6.4A), GK protein content and its catalytic activity were reduced by 35% and 56%, 
respectively, in HFA vs. CTR (P < 0.05) (Figure 6.4B and C). In HFR, on the other hand, 
GK protein content and activity were reduced even further (53% and 74%, respectively; 
P < 0.05 vs. CTR and HFA), and there was a significant decrease, albeit not to the same 
extent, in GKRP content (Figure 6.4 B-D).  
Hepatic insulin signaling and glycogen metabolism 
The phosphorylation of Akt was significantly lower (21%) in HFA compared to 
CTR, whereas there was only a minor (9%) and nonsignificant decline in HFR (Figure 
6.5A). There was no difference between groups in GSK3β phosphorylation. In support of 
impaired activation of Akt, the activity ratio of glycogen synthase (GS) was reduced by 
50% in HFA vs. CTR (P<0.05), whereas that of glycogen phosphorylase (GP) tended to 
be elevated (Figure 6.6A and B). When the activity ratios of GS and GP were themselves 
expressed as a ratio (GS/GP), they were significantly lower in both HFA and HFR vs. 
CTR (Figure 6.6C). Total GS activity was similar among groups (Figure 6.6D). In 
agreement with diminished GK activity and impaired regulation of enzymes involved in 
glycogen metabolism, terminal liver glycogen levels were significantly lower in HFR vs. 
CTR, and tended to be lower in HFA (Figure 6.6E). Likewise, the incorporation of 
glucose into glycogen through the direct synthetic pathway (glucose  glucose 6-
phosphate glucose 1-phosphate  UDP-glucose  glycogen) was markedly decreased 
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in both HFR and HFA (78% and 62%, respectively; P<0.05 vs. CTR) compared to CTR, 
but the reduction was significantly greater in HFR than in HFA (Figure 6.5F). 
 
Discussion 
Excess consumption of dietary fat and fructose in what has been commonly 
referred to as a “Western” diet, has been suggested to play a role in the obesity and 
diabetes epidemic within the U.S. [12, 28, 29]. Our previous studies (Specific Aims I and 
III) demonstrated that 4 weeks of high-fat, high-fructose (52%, 17% of total energy) 
feeding impairs glucose tolerance and renders the liver resistant to the stimulatory effects 
of hyperinsulinemia, hyperglycemia, and portal glucose delivery on HGU and GSYN 
[339]. The molecular correlates to these phenotypic observations included diminished 
hepatic GK and GS activity, impaired activation of Akt, and a decrease in GKRP protein 
content (Specific Aim III). The objective of the present study was to delineate the relative 
contribution of high dietary fat (52% of total energy) vs. fructose (17% of total energy) to 
impaired HGU and GSYN. Herein we demonstrate that both a high-fat (HFA) and a high-
fructose (HFR) diet significantly impair HGU, direct GSYN, and GK activity in the 
presence of hyperinsulinemia, hyperglycemia, and portal glucose delivery; however, the 
magnitude of the decrease in GK activity was significantly greater in HFR than in HFA. 
In addition, the sum of their individual effects on HGU, GSYN, and GK activity 
exceeded those observed previously in response to consumption of a combination high-
fat/high-fructose diet (HFFD; Specific Aim III). These data indicate that the relative 
contributions of fat and fructose to aberrant hepatic glucose metabolism in vivo are not 
additive, and suggest that either the HFA and HFR diets utilize the same pathway to 
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impair HGU, or they signal through separate pathways which converge at the same rate-
limiting, saturable step.   
Numerous studies have described the adverse metabolic effects of high dietary fat 
[16, 17, 23, 95] or fructose [18, 19, 150] on whole-body insulin action and hepatic 
glucose metabolism; however, most of those studies were conducted under 
hyperinsulinemic euglycemic conditions. Under euglycemic conditions, however, the 
liver is only a minor contributor to whole-body glucose disposal. Thus, the effects of a 
HFA or HFR diet on HGU and disposition under conditions that mimic the postprandial 
state are poorly understood. In view of this consideration, we performed 
hyperinsulinemic, hyperglycemic clamps with portal glucose delivery after 4 weeks of 
HFA or HFR feeding. In the presence of hyperinsulinemia and hyperglycemia, there was 
a tendency for HGU to be reduced in HFA vs. CTR during P1, but mean rates of HGU 
did not differ significantly between the two groups. When glucose was infused 
intraportally in the presence of elevated insulin and glucose, HGU was augmented even 
further in CTR, but not HFA. As a result, HGU was significantly lower in HFA than in 
CTR throughout P2. On the other hand, HGU was markedly reduced in HFR vs. CTR 
throughout the entire clamp study, suggesting that a selective increase in dietary fructose 
has a greater impact on HGU than that caused by an isocalorically-equivalent increase in 
dietary fat. Given that rates of HGU under the same experimental conditions in dogs fed a 
combination HFFD (Specific Aim III) were similar to those observed in the present 
study, these data suggest that the adverse effects of high dietary fat or fructose on the 
response of the liver to hyperinsulinemia, hyperglycemia, and portal glucose delivery are 
not additive.  
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Although HGU only statistically differed between the HFR and HFA diet groups 
at 2 time points, it tended to be lower in HFR than in HFA throughout the entire HIHG 
clamp. In support of this observation, the livers of dogs in the HFR group remained in 
NHLU for the duration of the experiment, despite the presence of hyperinsulinemia, 
hyperglycemia, and intraportal glucose infusion. On the other hand, livers of dogs in the 
HFA group rapidly switched from NHLU to NHLO upon initiation of hyperinsulinemia 
and hyperglycemia, although the rate was significantly reduced relative to CTR. 
Nevertheless, these data suggest that net hepatic glycolytic flux was increased in HFA in 
response to a physiologic rise in glucose and insulin, but it is not clear whether the source 
of carbon for the increase NHLO was glycogenolytically-derived or derived from 
extracellular glucose. In our previous study [339], and in Specific Aim III, dogs fed the 
combination HFFD did not switch from NHLU to NHLO under identical experimental 
conditions. In light of that observation and the present results, it would appear that a 
selective and physiologic increase in dietary fructose elicits greater impairment in net 
hepatic glycolytic flux than a selective increase in dietary fat. However, net hepatic 
lactate balance was significantly reduced in both groups relative to CTR. This might be 
due to impaired insulin-mediated activation of rate-limiting enzymes involved in the 
glycolytic pathway (phosphofructokinase-1/2 and pyruvate kinase), or a decrease in the 
amount of substrate available for catabolism through the glycolytic pathway secondary to 
impaired HGU. Previously, Chu and colleagues [369] demonstrated that elevation of 
plasma NEFA levels brought about by using intralipid and heparin infusion completely 
eliminated the ability of hyperglycemia per se to cause NHLO. This was attributed to 
stimulation of hepatic gluconeogenic flux and presumably, inhibition of glycolysis [177, 
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369]. In the present study, there was a tendency for arterial plasma NEFA and glycerol 
concentrations to be higher in HFA and HFR than in CTR, which might have contributed 
to aberrant net hepatic lactate balance in response to hyperinsulinemia and 
hyperglycemia.  
In support of the notion that hepatic GK is rate limiting for glucose utilization by 
the liver [231], there was a significant post-transcriptional decrease in GK protein content 
and activity in both the HFA and HFR groups vs. CTR. However, GK activity was 
significantly lower in HFR-fed than in HFA-fed animals. In fact, the decrease in GK 
activity in HFR was equivalent in magnitude to the decrease observed previously in dogs 
fed the combination HFFD (Specific Aim III). Thus, in accord with HGU, the effects of 
high dietary fat and fructose per se on hepatic GK activity are also not additive, and 
appear to be saturable in the presence of a selective increase in dietary fructose. 
Furthermore, the differences in GK protein between HFA, HFR, and CTR correlated with 
the differences in HGU and net hepatic lactate balance between groups, indicating that 
GK serves a critical function in facilitating the normal response of the liver to elevated 
glucose and insulin.  
A significant decline in GK protein content and activity in HFA and HFR vs. 
CTR in the absence of a difference between groups in relative GK expression suggests 
that either the translation of GK mRNA was impaired, or that the turnover (degradation) 
of GK protein was enhanced after 4 weeks of HFA or HFR feeding. The inhibitory effect 
of a high-fat diet on hepatic GK activity has been shown previously in rodents. For 
example, Oakes and colleagues [22] reported that three weeks of high-fat feeding (59% 
of energy from fat) in rats resulted in a significant impairment in the ability of insulin to 
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suppress hepatic glucose production during a hyperinsulinemic-euglycemic clamp, which 
was associated with elevated glucose-6-phosphatase activity, and significantly reduced 
glucokinase activity. Likewise, Collier et al. [20] reported that 3 weeks of high-fat 
feeding (66% of energy from fat) resulted in a more pronounced impairment of oral than 
intravenous glucose tolerance in rats, which was associated with a marked decrease (> 
50% reduction compared to low-fat-fed rats) in hepatic GK activity. Given the vital role 
of the liver in the disposition of an oral glucose load [26, 190, 215], these data suggest 
that impaired oral glucose tolerance was linked to a decrease in HGU secondary to a 
reduction in GK activity, as speculated by the authors [20]. In agreement with these 
findings, Minassian et al. [373] reported a greater than 50% decrease in GK activity after 
3 weeks of high-fat feeding in rats. Thus, it is clear from the literature that HFA feeding 
is associated with a decline in GK activity, and our findings in the present study in the 
HFA group are in accord with previous observations.  
The effect of high-fructose or high-sucrose feeding on hepatic GK activity is less 
clear. For example, Bizeau and colleagues [14] demonstrated a significant decrease in 
GK activity in primary cultures of periportal hepatocytes isolated from rats that were fed 
a high-sucrose diet (in which 35% of the energy was derived from fructose) for 1 week as 
opposed to a high-starch diet. On the other hand, liver GK activity was increased in rats 
that were administered 10% fructose in their drinking water for 3 weeks [374, 375], 
despite the fact that they had impaired glucose tolerance. However, fasting 
hyperglycemia, hyperinsulinemia, hypertriglyceridemia, and increased liver triglyceride 
content accompanied the impaired glucose tolerance associated with 3 weeks of fructose 
consumption. Thus, it is difficult to isolate the effect of excess fructose per se on liver 
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GK activity in the presence of all the other metabolic changes that occurred. In the 
present study, excess consumption of dietary fat or fructose per se induced a significant 
decrease in GK activity in the dog in the absence of coincident gluco- or lipotoxicity 
when fed a HFA or HFR diet for 4 weeks. These data are intriguing when considering 
that the dog only eats one meal per day, and the absorption of that meal is very slow such 
that the dog does not experience significant postprandial hyperglycemia [309]. In 
contrast, humans spend most of their day in the fed (postprandial) state. Thus, chronic 
consumption of a Western diet, replete with foods high in fat and fructose, might have an 
even greater detrimental impact on hepatic glucose flux and glucose tolerance in humans, 
and might precipitate the development of type 2 diabetes in susceptible individuals.  
In our previous study (Specific Aim III), there was also a marked decrease in the 
amount of hepatic GKRP content in response to HFFD feeding. Given that GKRP is 
thought to exert a permissive effect on GK protein expression by protecting it from 
degradation [370, 371], reduced levels of hepatic GKRP in HFFD-fed animals may have 
contributed to the post-transcriptional decline in GK protein. In the present study, GKRP 
was significantly reduced only in high-fructose-fed dogs, albeit not to the same extent as 
in our previous study (Specific Aim III). Although it raises the possibility that the 
combination of fat and fructose might synergize to drive a decline in GKRP when 
consumed in excess quantities, the implication of this decline with regard to GK protein 
levels is not clear, given that GK was equivalently reduced in high-fructose-fed and high-
fat, high-fructose fed (Specific Aim III) dogs.   
Hepatic GK expression is hormonally and nutritionally regulated by insulin and 
fasting-refeeding, respectively [345-347]. This is exemplified by the fact that hepatic GK 
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activity falls during fasting, and is restored by refeeding in association with robust 
induction of GK expression [376-380]. In addition, 90% pancreatectomy [210] or 
streptozotocin administration [175] in rats results in a significant decrease in hepatic GK 
mRNA and activity, whereas insulin treatment is accompanied by a prompt overshoot of 
GK mRNA levels [238, 345]. Given the putative role of insulin in the regulation of 
hepatic GK expression, one might expect a decrease in GK mRNA with hepatic insulin 
resistance. Indeed, rats fed a HFA diet for 8 weeks displayed a significant decrease in GK 
mRNA and activity relative to chow-fed CTR rats, despite the fact that their fasting 
insulin levels were increased by 74%. On the other hand, hepatic GK activity was 
significantly elevated in insulin-resistant, hyperinsulinemic Zucker fa/fa rats [381], which 
are homozygous for a mutation in the leptin receptor gene. Thus, the impact of insulin 
resistance on hepatic GK expression and activity appears to be dependent upon the 
manner in which insulin resistance was induced (e.g. by high-fat diet or by single gene 
mutations).   
Interestingly, there was dissociation among diet groups in the present study with 
regard to biochemical insulin resistance, with HFA-feeding resulting in a significant 
decrease in insulin-stimulated phosphorylation of Akt during the HIHG clamp. In 
agreement with this finding, the activity ratio of glycogen synthase, a reflection of its 
phosphorylation state in vivo, was also significantly reduced in HFA vs. CTR, whereas 
that of GP tended to be increased. In HFR, on the other hand, Akt phosphorylation, and 
the individual GS and GP activity ratios did not differ significantly from CTR, although 
there was a tendency for GS and GP to be aberrantly regulated. Thus, when GS and GP 
were themselves expressed as a ratio, there was a significant decrease in both HFA and 
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HFR vs. CTR, although it was greater in HFA. Conversely, terminal liver glycogen levels 
were reduced in both HFA and HFR vs. CTR, but the reduction was significantly greater 
in HFR, as was the decrease in direct glycogen synthesis. Thus, high-fat feeding was 
associated with greater impairment in Akt phosphorylation and in the covalent regulation 
of GS and GP, whereas high-fructose feeding was associated with greater impairment in 
GK activity and hepatic GSYN. This was perhaps due to insufficient provision of 
substrate required for the synthesis of liver glycogen secondary to markedly impaired 
HGU. Nevertheless, the combination of fat and fructose in Specific Aim III under similar 
experimental conditions did not result in a further decline in the activity ratio of GS, a 
further increase in the activity ratio of GP, or a greater impairment in hepatic GSYN. 
Thus, the relative contributions of fat and fructose to aberrant hepatic GSYN are also not 
additive.  
Furthermore, the presence or absence of biochemical insulin resistance did not 
appear to have an impact on relative GK expression in HFA and HFR vs. CTR at the end 
of the clamp. Thus, mechanisms in addition to insulin action must be involved in the 
regulation of hepatic GK expression in HFA and HFR. Given the dramatic effect of 
portal glucose delivery on GK expression in Specific Aim III, it is possible that the portal 
signal also induced an equivalent increase in GK expression in the present study, but was 
insufficient to drive an increase in GK protein in HFA and HFR.  
At this time, the mechanism by which HFA or HFR diets decrease HGK activity 
and HGU is unclear. Previous studies have implicated liver lipid accumulation in the 
pathogenesis of hepatic insulin resistance induced by HFA or HFR feeding, in which 
HFA diets increase the delivery of dietary fat to the liver, whereas HFR diets activate de 
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novo lipogenesis within the liver [23, 146, 171]. In the present study, however, total liver 
TG levels did not significantly differ among groups, suggesting that the mechanism 
linking HFA and HFR feeding to impaired regulation of HGK and HGU was independent 
of liver lipid accumulation. Asterholm and Scherer [382] demonstrated previously that 
dynamic changes in liver lipid levels occur upon exposure to a HFD, with peak 
concentrations appearing after only 48 hours of HFD feeding. This is followed by a 
significant and rapid decline in liver lipid levels, referred to as an “adaptation phase”, and 
then a gradual increase thereafter [382]. Thus, it is possible that the HFA or HFR diets 
augmented liver lipid levels within the first few days of feeding, after which the liver 
underwent an adaptation phase to cope with the dietary challenge. Nevertheless, the 
defect in HGK and HGU was sustained after 4 weeks of feeding, suggesting that 
processes other than hepatic lipid accumulation were associated with aberrant hepatic 
glucose flux in the presence of a hyperinsulinemic, hyperglycemic challenge. Future 
studies would need to be conducted to assess the early metabolic and hepatocellular 
changes that occur upon exposure to a HFA or HFR diet. 
In summary, both HFA and HFR diets significantly impair hepatic GK activity, 
HGU, and direct GSYN after 4 weeks of feeding, but the magnitude of the decrease in 
GK activity was significantly greater in HFR than in HFA. Whereas removal of the 
fructose component of the diet in the presence of high dietary fat ameliorated the severity 
of the defect in GK activity, HGU, and hepatic glucose disposition, removal of excess fat 
in the presence of high dietary fructose attenuated the severity in biochemical insulin 
resistance. Nevertheless, the sum of their individual effects on HGU, GK, and GSYN 
exceeded those observed after consumption of a combination high-fat/high-fructose diet, 
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suggesting that their relative contributions to aberrant hepatic glucose disposition are not 
additive. 
 
 
    
 
 
 
 
 
 
 
 
 
 191 
Mean Daily Energy Intake
Week 1 Week 2 Week 3 Week 4
kc
al
/d
ay
0
1000
2000
3000
4000
CTR 
HFA 
HFR 
 
 
 
Figure 6.1: Mean daily energy intake. Mean daily energy intake was recorded in dogs 
fed control diet (CTR, n = 5), a high-fat diet (HFA, n = 5), or a high-fructose diet (HFR, 
n = 5) for 4 weeks. Dogs fed the HFA or HFR diet were provided isoenergetic quantities 
of their respective diets over the course of 4 weeks, but both were hypercalorically-fed 
relative to CTR dogs.   
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Figure 6.2: Plasma hormone concentrations during hyperinsulinemic hyperglycemic clamps in CTR, HFA, and HFR groups. 
Arterial plasma insulin (A) and glucagon (C), and hepatic sinusoidal insulin (B) and glucagon (D) during basal (-20 to 0 min) and 
experimental periods (0 to 180 min) of HIHG clamps conducted in 18-h-fasted dogs after 4 weeks of feeding a CTR (HIHG+PoG, n = 
5; □), HFA (HIHG+PoG, n = 5; ▲), or HFR (HIHG+PoG HFR, n = 5; ● ) diet. Data are means ± SE. † P < 0.05 vs. basal period.   
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Figure 6.3: Arterial blood glucose, hepatic glucose load, and hepatic glucose uptake during hyperinsulinemic hyperglycemic 
clamps in CTR, HFA, and HFR groups. Arterial blood glucose (A), hepatic glucose load (B), and hepatic glucose uptake in the 
portal saline (C) and portal glucose (D) groups during the basal (-20 to 0 min) and experimental periods (0 to 180 min) of HIHG 
clamps conducted in 18-h-fasted dogs after 4 weeks of feeding a CTR (HIHG+PoG, n = 5; □), HFA (HIHG+PoG, n = 5; ▲), or HFR 
(HIHG+PoG HFR, n = 5; ● ) diet. Data are means ± SE. † P < 0.05 vs. basal period; *P < 0.05 vs. CTR; # P < 0.05, HFR vs. HFA. 
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Figure 6.4: Hepatic glucokinase (GK) and glucokinase regulatory protein (GKRP) 
in CTR, HFA, and HFR groups. Levels of GK mRNA (A) and protein (B), GK activity 
(C), and levels of GKRP protein (D). A, B, and D are expressed relative to levels 
observed in CTR animals. Data are means ± SE; n = 5 per group. *P < 0.05 vs. CTR; #P 
< 0.05, HFR vs. HFA.    
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Figure 6.5: Markers of hepatic insulin signaling in CTR, HFA, and HFR groups. 
Phosphorylation of Akt on Ser473 (A) and GSK3β on Ser9 (B) relative to levels observed 
in CTR animals. Data are means ± SE; n = 5 per group. *P < 0.05 vs. CTR.   
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Figure 6.6: Markers of hepatic glycogen metabolism in CTR, HFA, and HFR groups. Activity ratios of glycogen synthase (GS) 
(A), glycogen phosphorylase (GP) (B), GS/GP (C), and total GS activity (D). Terminal liver glycogen levels (E), and glycogen 
synthesized through the direct pathway (F). Data are means ± SE; n = 5 per group. *P < 0.05 vs. CTR; #P < 0.05, HFR vs. HFA.   
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TABLE 6.1.  
Mean values for hepatic arterial and portal venous blood flow, as well as total glucose 
infusion rate during the basal (-20 to 0 min) and experimental periods (P1, 60 to 90 min; 
P2, 150 to 180 min) of a hyperinsulinemic hyperglycemic clamp   
   Experimental Period  
 Group Basal Period Period 1 – PoG Period 2 + PoG 
Hepatic artery blood flow,  
            ml/kg/min 
 CTR   4.2 ± 0.5  5.4 ± 0.4   5.8 ± 0.8  
 HFA   4.7 ± 0.7  5.3 ± 0.8   6.0 ± 1.0  
 HFR   3.9 ± 0.2  4.2 ± 0.2   4.4 ± 0.3  
Portal vein blood flow,  
            ml/kg/min  
 CTR   22.2 ± 1.3  17.4 ± 1.0   19.1 ± 0.9  
 HFA   21.6 ± 1.4  18.0 ± 1.2   19.3 ± 2.3  
 HFR   23.1 ± 2.0  18.4 ± 1.3   19.9 ± 1.6  
Total glucose infusion rate,  
            mg/kg/min 
 CTR   0.0 ± 0.0  9.0 ± 3.0A   10.2 ± 2.4A  
 HFA   0.0 ± 0.0  5.7 ± 0.8A   8.4 ± 1.2A  
 HFR   0.0 ± 0.0  4.9 ± 0.6A   8.5 ± 1.2A  
Values are means ± SE; n = 5 per group. Dogs were 18h-fasted prior to study. A, P < 
0.05 vs. basal period. CTR, chow control diet; HFA, high-fat diet; HFR, high-fructose 
diet; - PoG, no portal glucose; + PoG, portal glucose infusion. 
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Table 6.2. 
Mean values for lactate, glycerol, and NEFA concentrations, and their net hepatic balance during the basal (-20 to 0 min)  
and experimental (P1, 60 to 90 min; P2, 150-180 min) periods of the hyperinsulinemic hyperglycemic clamp in CTR, HFA, and HFR groups   
Basal Period, min Period 1 - PoG, min Period 2 + PoG, min
Arterial blood lactate, µmol/l
CTR 397 ± 111 663 ± 86A 628 ± 73A 642 ± 88A 643 ± 78A 688 ± 87A 693 ± 121A
HFA 373 ± 30 523 ± 27AC 548 ± 54AC 565 ± 64AC 681 ± 53AC 702 ± 72AC 653 ± 83AC
HFR 308 ± 29 295 ± 24B 284 ± 25B 325 ± 38B 371 ± 67B 400 ± 77B 442 ± 52B
Net hepatic lactate balance, µmol/kg/min
CTR -5.3 ± 0.3 8.3 ± 1.9A 7.0 ± 1.7A 6.3 ± 1.3A 5.1 ± 0.6A 4.4 ± 0.8A 5.0 ± 0.8A
HFA -7.4 ± 0.7 3.3 ± 0.6ABC 3.1 ± 0.2ABC 2.6 ± 0.3ABC 1.7 ± 0.9ABC 1.1 ± 1.2ABC 1.2 ± 1.0ABC
HFR -5.9 ± 0.7 -4.3 ± 1.0B -3.8 ± 1.0B -3.4 ± 0.9B -2.9 ± 0.9B -3.3 ± 0.9B -3.9 ± 0.9B
Arterial blood glycerol, µmol/l
CTR 72 ± 6 32 ± 4A 27 ± 3A 23 ± 1A 29 ± 3A 29 ± 5A 29 ± 3A
HFA 112 ± 11B 48 ± 16A 41 ± 10A 51 ± 10A 49 ± 10A 49 ± 6A 51 ± 15A
HFR 110 ± 9B 59 ± 15A 52 ± 10A 49 ± 8A 52 ± 16A 52 ± 10A 58 ± 14A
Net hepatic glycerol balance, µmol/kg/min
CTR -1.7 ± 0.1 -0.7 ± 0.2A -0.5 ± 0.1A -0.5 ± 0.1A -0.7 ± 0.1A -0.6 ± 0.1A -0.8 ± 0.1A
HFA -2.1 ± 0.2 -1.0 ± 0.6A -0.7 ± 0.2A -1.0 ± 0.2A -1.1 ± 0.3A -1.0 ± 0.2A -1.2 ± 0.5A
HFR -2.9 ± 0.4B -1.3 ± 0.4A -1.0 ± 0.1A -1.0 ± 0.2A -1.5 ± 0.5A -1.2 ± 0.3A -1.5 ± 0.4A
Arterial plasma NEFA,  µmol/l
CTR 831 ± 73 154 ± 30A 136 ± 27A 118 ± 33A 84 ± 17A 109 ± 30A 102 ± 20A
HFA 902 ± 111 142 ± 26A 146 ± 35A 135 ± 25A 136 ± 49A 119 ± 30A 115 ± 30A
HFR 938 ± 112 258 ± 46A 216 ± 42A 170 ± 36A 179 ± 79A 156 ± 40A 215 ± 81A
Net hepatic NEFA balance  µmol/kg/min
CTR -2.5 ± 0.2 -0.2 ± 0.2A -0.1 ± 0.1A -0.2 ± 0.1A -0.2 ± 0.1A -0.3 ± 0.1A -0.3 ± 0.1A
HFA -3.1 ± 0.4 -0.5 ± 0.2A -0.4 ± 0.2A -0.3 ± 0.1A -0.4 ± 0.2A -0.3 ± 0.1A -0.4 ± 0.2A
HFR -2.4 ± 0.4 -0.8 ± 0.2A -0.7 ± 0.1A 0.0 ± 0.1A -0.5 ± 0.5A -0.6 ± 0.3A -1.0 ± 0.6A
Values are mean ± SE; n  = 5 per group. Dogs were 18h-fasted prior to study. A, P < 0.05 vs. basal period; B, P < 0.05 vs. CTR; C, P  < 0.05,  HFA vs. HFR. 
Negative values for balance data indicate net hepatic uptake, whereas positive values indicate net hepatic output.    
CTR, chow control diet; HFA, high-fat diet; HFR, high-fructose diet; PoG, portal glucose infusion.
Group -20 to 0 165 18060 75 90 150
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CHAPTER VII 
 
SUMMARY AND CONCLUSIONS 
 
The incidence of obesity and diabetes has been increasing at a staggering rate 
within the United States (U.S.) and around the globe, with type 2 diabetes accounting for 
the majority of new diagnoses. Insulin resistance, defined as a decrease in the sensitivity 
of insulin target tissues (liver, skeletal muscle, and adipose tissue) to a physiologic rise in 
the hormone, is a common pathogenic factor underlying both obesity and type 2 diabetes. 
The causes of insulin resistance comprise genetic and acquired components, and obesity 
is one of the most common acquired factors associated with the development of insulin 
resistance in Western cultures [383]. Indeed, there have been dramatic lifestyle changes 
in recent decades, including increased caloric availability, excess energy consumption, 
and decreased energy expenditure (or physical activity), all of which might be causally 
linked to the increased prevalence of obesity and type 2 diabetes [4]. Given that high-fat 
and high-sugar-containing, energy dense and nutrient deficient foods have become 
increasingly available and preferentially consumed in Westernized cultures [6-12], 
considerable emphasis has been placed on their respective contributions to the 
development of obesity and insulin resistance. Excessive consumption of dietary fat and 
fructose has been associated with adipose tissue accretion, ectopic lipid deposition, 
whole-body insulin resistance, and perturbations in the regulation of glucose metabolism 
in laboratory animals and in humans. Thus, studies aimed at investigating the pathogenic 
links between diet and metabolic diseases are warranted. The overall objective of this 
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body of work was to elucidate the metabolic and hepatocellular consequences associated 
with chronic consumption of a high-fat and/or high-fructose diet, focusing on 
perturbations in the regulation of hepatic glucose uptake (HGU) and disposition by 
hyperglycemia, hyperinsulinemia, and portal vein glucose delivery – the primary 
determinants of HGU in vivo [26].  
The liver acts as a dynamic regulator of glucose homeostasis during fasting and 
refeeding by virtue of its dynamic ability to switch from net glucose output to net glucose 
uptake, respectively. Previous studies have indicated that the liver is particularly 
vulnerable to nutritional insults induced by excess consumption of dietary fat or fructose 
[13-23]. In fact, several have suggested that hepatic insulin resistance, manifested as a 
diminished ability of insulin to suppress hepatic glucose production (HGP), is the first 
metabolic consequence to emerge upon initiation of a high-fat or high-fructose diet in 
laboratory animals [16-18, 23]. While the effects of high dietary fat or fructose on 
insulin’s ability to suppress HGP have been extensively studied, their effects on HGU 
and disposition have not been clearly defined. This is due to both the complexity of its 
regulatory signals, and because it cannot be measured directly in humans or small 
animals. On the other hand, HGU can be measured directly in the dog. In fact, the 
accessibility of both the hepatic and portal veins, allowing repeated direct measurements 
of HGU in the basal state and in the course of experimental perturbations, is a major 
strength of the dog model.  
Although impaired splanchnic (comprising the gut and liver tissues) glucose 
uptake is one of the metabolic sequelae associated with overt type 2 diabetes [200, 201, 
204, 384], its temporal manifestation along the continuum of worsening insulin action 
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during the development of type 2 diabetes is poorly understood. Likewise, the combined 
effects of dietary fat and fructose, in quantities that mimic a Western diet, on the 
temporal development of glucose intolerance and impaired HGU are not known. Thus, in 
Specific Aim I, we explored how consumption of a high-fat, high-fructose diet (HFFD), 
coupled with a compromised pancreatic mass (via partial [65%] pancreatectomy), 
influenced the temporal development of impaired glucose tolerance, whole-body insulin 
resistance, and the ability of the liver to take up and store glucose in the presence of 
conditions that mimic the postprandial state. Our findings demonstrated that consumption 
of a HFFD results in impaired glucose tolerance in a relatively short period of time (4 
weeks), which was due to both a beta cell defect and whole-body insulin resistance [339]. 
In addition, 13 weeks of HFFD feeding rendered the liver incapable of switching from 
net glucose output to net glucose uptake despite the presence of hyperinsulinemia, 
hyperglycemia, and intraportal glucose delivery [339]. Thus, the functional consequences 
of a HFFD on hepatic glucose metabolism were similar to those observed in type 2 
diabetic individuals [200, 201], and suggest that impaired HGU may be an early 
manifestation of the disease.  
The metabolic consequences associated with HFFD feeding in Specific Aim I 
were detected in response to a glucose challenge [339], which lacked other meal-
associated factors that can influence the gastric emptying rate, insulin and glucagon 
secretion, and net hepatic glucose uptake (NHGU) [295-304]. In addition, any active 
involvement of the gut or endocrine pancreas in the response of the liver to a glucose 
challenge was eliminated because we had infused somatostatin to perform a pancreatic 
clamp. Thus, in Specific Aim II we wanted to investigate whether HFFD feeding impairs 
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NHGU during a more physiological mixed meal test, as it does in individuals with 
diabetes [203, 204]. Our findings demonstrated that 8 weeks of HFFD feeding elicited 
excessive postprandial hyperglycemia due to accelerated gastric emptying and glucose 
absorption, and markedly diminished NHGU [385]. Thus, the defect in NHGU seen in 
Specific Aim I in response to a glucose challenge and under clamped experimental 
conditions also existed in a mixed meal setting after chronic consumption of a HFFD. In 
addition, the mixed meal studies exposed a second metabolic defect as indicated by an 
enhanced rate of meal macronutrient absorption [385]. Additional studies aimed at 
exploring the mechanism(s) responsible for accelerated gastric emptying and glucose 
absorption in HFFD-fed animals are needed, as this too influences the timing and 
magnitude of postprandial glucose excursions in healthy and diabetic individuals [307, 
308]. 
It is well known that the hepatic sinusoidal insulin level, the hepatic glucose load, 
and the route of glucose delivery (peripheral vs. intraportal) are the primary determinants 
of glucose uptake by the liver [26, 215]. The augmentation of HGU elicited by the 
intraportal route of glucose delivery has been attributed to a unique, neurally-mediated 
signal generated in the presence of a negative arterial-portal venous glucose gradient, 
termed the “portal glucose signal” [180, 182, 184, 193-195, 365, 386-389]. In response to 
ingestion of a glucose-containing meal, the portal signal works in concert with increased 
plasma glucose and insulin to orchestrate a coordinated response favoring enhanced HGU 
and glycogen synthesis (GSYN). Although the metabolic effects of intraportal glucose 
delivery have been studied in normal dogs and in the human, the molecular events linking 
the pleiotropic actions of the portal glucose signal to increased HGU and GSYN in vivo 
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have not been clearly defined. In addition, our findings in Specific Aim I suggested that 
HFFD feeding was associated with the loss of an intact portal glucose signal, but the 
molecular correlates to this phenotypic observation were not known. Thus, the objective 
of Specific Aim III was to identify the molecular “signature” associated with 
hyperinsulinemia, hyperglycemia, and portal glucose delivery in the livers of normal 
dogs, and to elucidate the mechanism(s) associated with impaired HGU under identical 
experimental conditions in insulin resistant dogs that had been fed a HFFD. Our findings 
demonstrated that delivery of glucose into the portal vein in the presence of 
hyperinsulinemia and hyperglycemia triggered a coordinated molecular response 
involving an increase in the catalytic activity of hepatic GK, and stimulation of hepatic 
GS activity, which collectively augmented HGU and GSYN in vivo. In contrast, HFFD 
feeding was associated with biochemical insulin resistance, a marked decline in hepatic 
GK protein content and activity, and loss of the stimulatory effects of portal glucose 
delivery on GK and GS activity. These mechanistic defects correlated with diminished 
HGU and GSYN (Figure 7.1). 
Previously, Pagliassotti et al. [198] demonstrated rapid activation of liver GS in 
response to portal glucose delivery; however, the magnitude of the increase in NHGU 
suggested that additional mechanisms might also be involved. Our findings in Specific 
Aim III extend those made by Pagliassotti et al. [198], and indicate that the portal glucose 
signal also stimulates robust induction of hepatic GK expression and activity, in addition 
to activation of GS. These data provide novel mechanistic insight into the molecular 
physiology of the portal signaling mechanism under normal conditions, and suggest that 
impaired regulation of hepatic GK under insulin resistant conditions may be one of the 
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early molecular defects that contribute to the deterioration of glucose tolerance and 
development of postprandial hyperglycemia secondary to diminished HGU.  
Follow-up studies in Specific Aim IV indicated that both a high-fat (HFA) and a 
high-fructose (HFR) diet impair HGU, GSYN, and GK activity in the presence of 
hyperinsulinemia, hyperglycemia, and portal glucose delivery. Nevertheless, the sum of 
their individual defects on HGU, GSYN, and GK exceeded those observed in Specific 
Aim III in response to consumption of a combination HFFD, suggesting that the relative 
contributions of fat and fructose to aberrant hepatic glucose disposition are not additive. 
Thus, high dietary fat and fructose either utilize the same pathway to impair HGU, or 
they signal through separate pathways which converge at the same rate-limiting, saturable 
step. The implications of these data when extended to the human population suggest that 
increased consumption of either nutrient might have a detrimental impact on glucose 
tolerance and risk of diabetes. 
Previous studies have implicated liver lipid accumulation in the pathogenesis of 
hepatic insulin resistance induced by high-fat or high-fructose feeding [23, 146, 171]. In 
the present study, however, total liver triglyceride levels, and levels of other lipid 
metabolites (data not shown), did not significantly differ among groups. Likewise, dogs 
did not develop dyslipidemia or hyperglycemia when fed diets high in fat and/or fructose, 
yet their GK activity levels and HGU were markedly impaired. Thus, the mechanism(s) 
linking dietary insults to impaired regulation of GK and hepatic glucose disposition in 
vivo may be independent of liver lipid accumulation and glucolipotoxicity. These data 
are intriguing when considering that the dog only eats one meal per day, and the 
absorption of glucose in that meal is very slow such that the dog does not experience 
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significant postprandial hyperglycemia [309]. In contrast, humans consume at least 3 
meals per day, and spend most of their day in the postprandial state. Thus, the adverse 
effects of a Western diet on glucose tolerance and hepatic glucose disposition might be 
magnified in humans.  
The clinical significance of the findings presented herein is underscored by the 
fact that individuals with diabetes display a marked impairment not only in the ability of 
hyperinsulinemia and hyperglycemia to suppress HGP, but also in the ability of those 
postprandial stimuli to activate splanchnic glucose uptake and hepatic glycogen synthesis 
[200, 201, 203, 204]. As a result, they experience frequent bouts of postprandial 
hyperglycemia, one of the sequelae of diabetes that contributes to the elevation of their 
hemoglobin A1c and many of the complications associated with the disease [24, 25]. By 
diminishing the ability of the liver to buffer perturbations in blood glucose levels, high 
dietary fat and fructose consumption might promote the development of postprandial 
hyperglycemia, increase the load of glucose that must be disposed of by peripheral tissues 
and perhaps, precipitate a defect in the beta cell or muscle in a chronic setting. 
Altogether, the findings presented in this dissertation suggest that impaired HGU might 
be one of the early metabolic consequences associated with glucose intolerance induced 
by consumption of a Western diet. In addition, nutritional modulation of hepatic GK 
might be a causally linked to the impaired regulation of HGU by insulin, glucose, and 
portal glucose delivery (Figure 7.2).  
These studies raise a number of additional questions which could be further 
investigated. For example, what is the mechanism mediating the post-transcriptional 
decline in GK protein in response to high dietary fat and/or fructose consumption? 
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Processes such as oxidative stress [390, 391], nitrosative stress [392-394] ER stress 
[395], and inflammation [396, 397] have all been implicated in the development of 
insulin resistance in association with diet-induced obesity. However, a superficial 
assessment of markers of oxidative/nitrosative stress (gene expression of NADPH 
oxidase [Nox 2 and 4] and iNOS) and ER stress (phosphorylation of PERK on Thr980, 
eIF2α on Ser51, and Bip protein levels) in the livers of HFFD-fed and CTR-fed dogs 
failed to show a difference between groups. The potential contribution of these processes 
to impaired regulation of hepatic GK in response to dietary insults needs to be addressed 
in more detail. Given that 4 weeks was the earliest time point in which we assessed 
glucose tolerance or HGU, it is possible that the liver had already undergone substantial 
adaptation at that time point. Thus, it would be interesting to go back in time, perhaps 
after 3 days or 1 week of HFFD (similar to some of the rodent studies discussed in 
Chapter I), and measure HGU with liver biopsy acquisition at the end of the study. This 
might enable us to capture the early molecular changes associated with HFFD feeding, 
and identify the pathogenic process leading to decreased GK activity and HGU after 4 
weeks of feeding.   
Another interesting question is whether the defect in HGU after 4 or more weeks 
of HFFD feeding is reversible if dogs are then switched back to their normal chow diet. 
We already know based on the findings presented in this dissertation that it is not 
reversible within 24 hours, given that all dogs received the same can of meat the day 
prior to the study, yet the defect in HGU was still manifest in HFA-, HFR-, and HFFD-
fed animals during the clamp experiment. Initial assessments of HGU and GK activity 
could begin 3 days after switching from the HFFD to the CTR diet. If HGU and GK 
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activity are still impaired 3 days after switching to a normal chow diet, then one could 
reassess HGU and GK activity after 5 or 7 days. Furthermore, several different 
permutations of this experiment could be conducted. For example, we could switch dogs 
from the HFFD to a eucaloric or hypercaloric chow diet to investigate the impact of 
excess calories and/or body weight loss on the rapidity of the reversal of impaired HGU. 
These types of studies would provide insight into the effectiveness of lifestyle 
modification on improvements in hepatic glucose flux after short- or long-term 
consumption of a Western diet.  
Another question to follow-up on would be whether pharmacologic activation of 
hepatic GK (GK activator or GKA) in HFFD-fed dogs could rescue their defect in HGU. 
Hyperinsulinemic hyperglycemic clamp studies could be conducted, but this time a GKA 
could be infused intraportally with and without portal glucose infusion. Use of 
somatostatin to perform the pancreatic clamp would enable us to isolate the liver-specific 
effects of the GKA. If the impairment in HGU is restored with intraportal GKA infusion, 
these data would suggest that the reduction in GK activity is causally linked to 
diminished HGU in HFFD-fed animals. In addition, intraportal glucose plus GKA 
infusion might shed light on whether activation of hepatic GK restores the ability of the 
portal glucose signal to augment HGU and GSYN. Conversely, would intraportal 
infusion of glucosamine, an inhibitor of GK, block the ability of hyperglycemia, 
hyperinsulinemia, and/or portal glucose delivery to augment HGU in normal dogs? This 
approach would shed light on whether the activation of GK is causally-linked to 
induction of HGU in response to the portal glucose signal.  
Questions addressing the neural mediation of the portal glucose signal could also 
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be investigated. For example, would hepatic denervation or a selective hepatic vagotomy 
ablate the effect of portal glucose delivery on the induction of hepatic GK expression? If 
non-adrenergic, non-cholinergic nerves are involved in the induction of GK expression 
by portal glucose delivery, then activators and/or inhibitors of nitric oxide synthase or 
serotonin receptors, for example, could be infused intraportally in the absence and 
presence of portal glucose delivery. These experiments might shed light on the role of the 
nervous system in mediating the effects of portal glucose delivery on hepatic GK mRNA 
and activity. 
Alternatively, would portal glucose delivery in the presence of basal insulin levels 
augment GK expression and activity? Hyperglycemic pancreatic clamps could be 
performed in which the hepatic sinusoidal insulin and glucagon concentrations are kept at 
a basal level, while the hepatic glucose load is doubled in the absence and presence of 
portal glucose delivery. These experiments would enable us to ascertain whether the 
portal glucose signal potentiates the ability of insulin to induce GK expression, or if it is 
acting independently of insulin through a neurally-mediated pathway. Furthermore, the 
same experiment could be conducted in the absence of basal insulin replacement to 
mimic insulin-dependent diabetes. Although the metabolic response of the liver to portal 
glucose delivery is lost after acute (somatostatin) or chronic (pancreatectomy) removal of 
insulin, it is possible that its effect on GK expression does not require insulin.  
Finally, what is the response of the liver to a selective and physiologic increase in 
insulin or glucose alone after chronic consumption of a HFFD? In all of the 
aforementioned studies, glucose and insulin were concomitantly increased, so the relative 
contributions of hepatic insulin resistance and/or impaired glucose effectiveness to 
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diminished HGU and GSYN could not be delineated. Hyperinsulinemic euglycemic (4x 
basal insulin) and hyperglycemic euinsulinemic (2x basal hepatic glucose load) clamp 
studies could be performed to delineate between hepatic insulin resistance and impaired 
hepatic glucose effectiveness. In addition, the deuterated water technique could be 
utilized in the hyperinsulinemic clamps to see if impaired suppression of hepatic glucose 
production is due to impaired suppression of gluconeogenesis or glycogenolysis. 
In contrast to dietary fat, there are currently no nutritional recommendations 
regarding the consumption of dietary fructose in the U.S. The findings presented in this 
dissertation demonstrate the need for additional studies aimed at elucidating the 
mechanisms through which chronic consumption of a HFFD impairs HGU and hepatic 
insulin sensitivity, and increases the risk for type 2 diabetes. 
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Figure 7.1:  Altered hepatic glucose flux by high-fat, high-fructose diet (HFFD) feeding in the presence of hyperglycemia and 
hyperinsulinemia. A physiologic rise in glucose and insulin in normal, chow-fed control (CTR) dogs (A) suppresses net hepatic 
glucose output (NHGO) and stimulates an increase in hepatic glucose uptake (HGU) and net hepatic glycogen synthesis, glycolysis, 
and lactate output. These metabolic changes are associated with an increase in hepatic glucokinase (GK) and glycogen synthase (GS) 
activity, and a decrease in glycogen phosphorylase (GP) activity. On the other hand, HFFD feeding (B) significantly reduces hepatic 
GK protein content. As a result, a physiologic rise in glucose and insulin in HFFD-fed dogs is associated with impaired suppression of 
NHGO, and diminished HGU, net hepatic glycogen synthesis, and glycolysis in comparison to CTR. Furthermore, net hepatic lactate 
uptake persists in the presence of hyperinsulinemia and hyperglycemia, which contributes to inappropriately elevated net hepatic 
gluconeogenesis relative to CTR. These metabolic changes are associated with decreased GK and GS activity, and inappropriately 
increased GP activity relative to CTR.
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Figure 7.2: Summary schematic of the metabolic staging of type 2 diabetes in the 
context of western diet-induced insulin resistance. The findings presented in this 
dissertation suggest that in the context of diet-induced insulin resistance, impaired hepatic 
glucose uptake (HGU) is manifest in the early stages of diabetes development, and 
contributes to the worsening of glucose tolerance and insulin action that occurs along the 
continuum of disease progression. Furthermore, our findings raise the possibility that 
impaired regulation of hepatic glucokinase (GK) is central to the defect in HGU and 
glucose tolerance in the early stages of the disease. Lastly, chronic consumption of a 
high-fat/high-fructose diet produces modest obesity and whole-body insulin resistance, 
and impairs glucose tolerance, HGU, and beta cell function. Each of these metabolic 
defects are associated with the development of type 2 diabetes. This raises the possibility 
that lifestyle intervention in the form of modifying the type of dietary constituents 
consumed in Westernized cultures might prove to be an effective approach in preventing 
or delaying the onset of type 2 diabetes in susceptible individuals. In addition, it is 
intriguing to speculate that a hepatoselective GK activator might have therapeutic 
potential in terms of preventing further impairment or even rescuing the defect in glucose 
tolerance and HGU in the early stages of type 2 diabetes. 
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